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I Theory
1 Introduction and objectives
Natural products are secondary metabolites that are not directly involved in primary
metabolic processes. They play important biological roles in the interactions between
organisms.
The relationship between biological activity and toxicity of natural products isolated
from marine organisms long been a question of study due to phenomena like the red
tides and human seafood poisonings. For example, saxitoxin and tetrodotoxin, which
are important tools used to investigate cell biochemistry, are responsible for severe
seafood poisoning[1].
While chemical investigations of terrestrial plants and insects started in the beginning
of the 19 th century, the first reports of marine natural products chemistry did not
appear until early in the 20 th century, with the isolation of sterols from marine
sponges by Henze[2] and Doree[3] followed by the isolation and characterisation of the
ancient Egyptian dye tyrian purple from molluscs[4]. In 1943, Bergmann isolated
gorgosterol from a gorgonian[5], but only in 1969, when Weinheimer and Spraggins
discovered prostaglandins in the octocoral Plexaura homomalla[6], did the
pharmaceutical industry become interested in the discovery of new natural products
from marine origin.
The retarded development of marine compared to "terrestrial" natural product
chemistry was mainly due to the difficulties involved in the collection of marine
organisms. Only with the development of the SCUBA diving technology in the 1960’s
were scientists finally able to explore the seas to look for new compounds with
interesting biological and pharmacological activities. Over the past 30 years, marine
natural products have been isolated from many types of marine organisms, including
algae, invertebrates, and micro-organisms [7]. Since many of the organisms are
unique to the marine environment, many novel secondary metabolites have been
discovered.
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Among the bioactive compounds isolated from marine organisms, those currently
under intense investigation as potential anticancer agents include ecteinascidin 743
(1), halichondrin B ( 2), dehydrodidemnin B (aplidine) ( 3), bryostatin 1 ( 4), and
dolastatin 10 ( 5) (Figure 1). Presently, the most promising anticancer agent is
ecteinascidin 743 ( 1), a tetrahydroisoquinoline alkaloid isolated from the marine
tunicate Ecteinascidia turbinata [8] which is in phase II clinical trials. A total of 381
patients have been already treated with 1 in phase I and all toxicities observed were
manageable[9]. The phase II studies of ecteinascidin 743 ( 1) are very promising [9d].
Ecteinascidin 743 has recently become available by total synthesis and fro
aquaculture[10, 11].
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Figure 1: Bioactive marine derived compounds under intense investigation as
anticancer agents.
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Halichondrin B (2), a polyether macrolide originally isolated from the marine sponge
Halichondria okada [12], is a potent anticancer agent in preclinical development at the
NCI (National Cancer Institute) and is expected to start phase I trials soon. The
limited supply of 2 from marine sources was circumvented by its total synthesis [13],
allowing for the preparation and subsequent evaluation of more than 180 macrocyclic
analogues. It was concluded that the biological activity of halichondrin B is related to
its macrocyclic lactone ring[14, 15].
Didemnin B , a cyclic depsipeptide isolated from the tunicate Tridemnum solidum[16],
was the first marine metabolite to enter phase I and II clinical trials, but was later
found to be cardiotoxic during phase II studies[17]. Dehydrodidemnin B (aplidine) (3) is
a close structural analogue of didemnin B, differing in the presence of a pyruvyl
instead of a lactyl side chain (highlighted in Figure 1) [18]. 3 lacks cardiotoxicity and
has reached phase I clinical trials as a potent anticancer agent made by the company
Pharmamar[17d].
Bryostatin 1 (4) is a marine-derived macrolactone isolated from the bryozoan Bugula
neritina[19]
 which possesses antineoplastic activity. Dolastatin 10 ( 5) is a novel
pentapeptide anticancer agent originally isolated from the marine mollusc Dolabella
auricularia[20]. Both 4 and 5 are currently in phase II clinical trials. Bryostatin 1 (4) has
been administrated to patients with relapsed multiple myeloma [21], soft tissue
sarcoma[22], and head and neck cancer [22] while dolastatin 10 ( 5) was used to treat
patients with advanced melanoma[23]. Unfortunately, preliminary studies revealed no
objective response to these administrated drugs.
Anti-inflammatory agents such as the tricyclic diterpene glycosides pseudopterosins
A (6) and E (7)[24] (Figure 2) have been isolated from the sea fan Pseudopterogorgia
elisabethae[24]. 6 and 7 have shown potent anti-inflammatory activity[25] and are in
preclinical trials. The partially purified extract of this sea fan, containing a mixture of
pseudopterosins, is used in the Estée Lauder cosmetic product Resiliance.
Contignasterol ( 8, figure 2) is a highly oxygenated steroid with the unnatural 14 β
configuration from the marine sponge Petrosia contignata [26]. 8 is in phase II clinical
trials conducted by the company Inflazyme as an anti-asthma agent. It is also in
preclinical development to treat respiratory disease and psoriasis because of its
topical anti-inflammatory effect in tracheobronchial airways[27].
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Figure 2: Structures of the anti-inflammatory agents pseudopterosins A ( 6) and E (7)
and of the anti-asthma agent contignasterol (8).
Many other marine derived secondary metabolites possess interesting biological
activities. Their limited availability from natural sources, however, limits further
investigation about their activities making them attractive targets for studies toward
their total synthesis. Beyond the investigation of selected marine natural products
exhibiting important biological activities, basic research must take the opportunity to
identify and explore the underlying principles of its biological function. Diaryl ether
linkages constitute an important structural element of peptoid secondary
metabolites[28]. Among them, the antibiotic vancomycin is used clinically as the "last
resort" in the case of resistance to  β-lactam antibiotics.
The bastadins are a family of highly modified bromotyrosine tetrapeptides isolated
from the marine sponge Ianthella basta [29]. Most of them are macrocyclic and exhibit
antibacterial[29c, 29f], cytotoxic [29f] or anti-inflammatory activities[30]. Among these
tetrapeptides, bastadin 5 (9, figure 3) is of special interest due to its capacity to inhibit
Ca+2 uptake into the sarcoplasmatic reticulum, being antagonised by the important
immunosuppressant natural product FK506 (10, figure 3)[30].
The total synthesis of bastadin 5 ( 9) is essential for availability of the required
quantities needed for further tests. Three total syntheses of selected bastadins
(bastadins 1-3, 6 and 12) have been reported[31] but produce in low yields because of
the employed methods of diaryl ether coupling.
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Figure 3: Structure of bastadin 5 (9) and FK506 (10).
The usage of nucleophilic attack by phenolates to [RuCp] +-complexed chloroarenes
offers unique advantages (Scheme 1) [32, 33]. Ruthenium sandwich complexes are
readily formed, even from electron-poor arenes and give stable [RuCp] +-complexed
diaryl ether products under mild reaction conditions in high yields. Furthermore,
[RuCp]+-complexes can be used for the labelling of unprotected amino acids and
peptides with aromatic side chains. The availability of various rutheniu
radioisotopes makes them attractive for application in diagnostic nuclear medicine [34].
One of the central obstacles in ruthenium arene chemistry is the difficult purification
of these [RuCp]+-complexes, which has limited their use in organic and bioorganic
chemistry.
Ru
Cl
 KOtBu, 18-crown-6, THF, 
    -78°C to 20°C, 15 h
Ru
OOH+Cl [CpRu(NCCH3)3]+
dichloroethane, 
reflux, 4-6 h
Scheme 1: Formation of [RuCp]+-complexed diaryl ethers.
Facing the need to supply bastadin 5 in sufficient quantities for further biological
activity investigation and the perspective of developing ruthenium-labelled peptoids,
the following questions were addressed in this thesis:
• Ruthenium mediated synthesis of diaryl ethers;
• Purification and separation of charged ruthenium sandwich complexes;
• Extension of the application of ruthenium arene chemistry in organic synthesis;
• Use of ruthenium arene chemistry in the synthesis of the bastadin skeleton.
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2 Bromotyrosines from marine sponges
Although seawater contains a much higher concentration of chloride (559 mM) than
bromide (0.86 mM) or iodide (0.45 µM), brominated secondary metabolites
predominate in marine organisms. Bromide is more easily and readily oxidised than
chloride1 and the resulting bromonium ions undergo electrophilic addition to alkenes
and aromatic systems[35]. Haloperoxidases are the enzymes which are able to oxidise
chloride, bromide and iodide in the marine environment. Consequently, various
marine organisms effectively used the available bromonium ions in the biosynthesis
of defensive and other necessary constituents [36]. Out of nearly 3200 known natural
organohalogen compounds, more than 1600 contain bromine. Illustrative are the
bromotyrosine-derived secondary metabolites of marine sponges and certain
tunicates[7].
Marine sponges (phylum Porifera) are a rich source of secondary metabolites with
novel structures and interesting biological activities[7]. Over the past 30 years, an ever
increasing number of bromotyrosine-derived secondary metabolites have been
isolated from marine sponges, mainly from the order Verongida.
2.1 Structures, biogenetic relationship and function
Marine sponges belonging to the order Verongida (Table 1) show a peculiar
biochemistry characterised by the production of sterols with an apysane skeleton and
of bromo compounds biogenetically related to tyrosine. These bromotyrosine-derived
metabolites are considered distinct chemotaxonomic markers for Verongid sponges
and range from simple monomeric metabolites, such as aeroplysinin-1 ( 18), to more
complex structures such as the bastadins (see chapter 2.2)[29].
                                           
1
 Oxidation potentials: Cl--Cl2 = 1.36 E°/V; Br--Br2 = 1.07 E°/V.
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Table 1: Systematic distribution of sponges of the order Verongida (phylum Porifera,
class Demospongiae, subclass Ceractinomorpha)[37].
Order Family Genera
Verongida Aplysinidae Aplysina
Verongula
Aplysinellidae Aplysinella
Psammaplysilla
Porphyria
Pseudoceratina
Suberea
Ianthellidae Anomoianthella
Bajalus
Ianthella
Biosynthetic studies of sponges are very difficult to conduct. Sponges have very slo
growth rates and possess a plethora of symbiotic microorganisms [38]. Therefore, very
few studies have been performed which elucidated the biosynthetic mechanisms
involved in the production of secondary metabolites. The first experiment was
performed by Rinehart and Tymiak [39a], in which they administered 14C-, 15N-
radiolabelled precursors to sponges in solution with sea water [39a]. In 1995, Rinehart
and Carney conducted feeding experiments with Aplysina fistularis using U-14C-
labelled bromine and O-methylated tyrosine derivatives as well as methoxybenzyl
[14C]cyanide[39c]. The results of both biosynthetic studies showed that the metabolic
pathway employed by Verongid sponges (Scheme 2) involves a bromination of the
tyrosine (11) aromatic ring as the first step. It was suggested [39c] that the brominated
tyrosines (12) can follow two different pathways (Scheme 2): I) oxidation of the amine
to an oxime ( 15) or II) O-methylation of the tyrosine followed by oxidation of the
amine to an oxime (13). The first pathway gives phenolic nitriles (19) and amides (22)
or bastadins and psammaplins. The second pathway can follow two different
biosynthetic routes: A) dehydration and decarboxylation to give the O-methylated
nitriles (14), which can be oxidised to arene oxides ( 17) followed by nucleophilic
opening of the epoxide leading to aeroplysinin-1 ( 18); B) direct epoxide formation
(16) which leads to isoxazoline rings giving metabolites like aerothionin, or
homoaerothionin or to oxepins giving the psammaplysins. The O-methylated tyrosine
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epoxide intermediate ( 16) could also be dehydrated and decarboxylated ( 17)
followed by nucleophilic opening of the epoxide also leading to aeroplysinin-1 (18)[39].
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11: L-tyrosine
OH
CO2H
NH2
R1 R2
     
12
R1, R2=H or Br
OCH3
BrBr
O
N
HO
isoxazolines:
aerothionin,
homoaerothionin, etc
OCH3
Br Br
HO
CN
HO
Bromoperoxidase
[O]
OH
CO2H
NOH
R1 R2
15
 
OH-free oximes
R1, R2=H or Br
19 phenolic nitriles
OH
NOH
R1 R2
bastadins, psammaplins     
R1, R2=H or Br
O
1) O-methylation
2) [O]
OCH3
CO2H
NOH
R1 R2
13
 
OMe-oximes
R1, R2=H or Br
OCH3
CN
R1 R2
14
 nitriles
R1, R2=H or Br
-CO2, -H2O
[O]
OCH3
CO2H
NOH
R1 R2
16
 intermediate
R1, R2=H or Br
O
-CO2
-H2O
OCH3
CN
R1 R2
17
 intermediate
R1, R2=H or Br
O
18: aeroplysinin-1O
O
BrH3CO
N
O
HO
O N
H
Br
oxepins:
psammaplysins
-CO2
-H2O
OH
CN
Br Br
[H2O]
OH
Br Br
NH2
O
[O]
O
BrBr
HO
OH2N
OH
OH
Br Br O
NH2
20
21 22
 phenolic amides
Scheme 2: Biotransformation of brominated secondary metabolites of Verongid
marine sponges. Compounds in dashes were not isolated and therefore, their
biosynthetic pathways are proposed.
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A large number of brominated tyrosines containing a novel spirocyclic isoxazoline
ring has been found in several Verongid sponges. The first examples are aerothionin
(23) and homoaerothionin (24) (Figure 4). Aerothionin (23) was isolated from several
species of Aplysina[40], as well as fro Psammaplysilla purpurea[40c] and
Pseudoceratina durissima[40d], and possesses antibacterial activity. Homoaerothionin
(24) was also isolated from Aplysina[40a, b, e] spp. and Pseudoceratina durissima[40d].
Both compounds affect the behaviour and survival of several invertebrates in an
attempt to prevent colonisation of the sponge. Additionally, it was demonstrated that
mechanical injury to the sponge stimulates the release of these compounds at
concentrations 10-100x higher [41] than that normally measured near an intact
organism. Another interesting chemical defence mechanism observed in this order is
the enzymatic conversion of biologically inactive storage compounds into active
defence metabolites following disruption of the sponge’s cells. The spirocyclic
isoxazolines aerophobin-2 (25)[7, 42] from Aplysina spp. and isofistularin-3 (26)[43] from
Aplysina[43a-d]
 and Pseudoceratina[43e] spp. (Figure 4), undergo enzymatic
biotransformation into active metabolites, aeroplysinin-1 ( 18) and dienone ( 27)
(Figure 4), when the sponge is injured [41]. These two metabolites have been found in
all Verongid families[43b,e, 44] and exhibit cytotoxic and antimicrobial activities.
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Figure 4: Bromotyrosine-derived metabolites of Verongid marine sponges.
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The bromotyrosine-derived metabolites, aside from their ecological functions, have
other interesting biological properties. For example, araplysin I (28) from
Psammaplysilla arabica
 (Figure 4) possesses antimicrobial as well as Na + and K +-
ATPase inhibition activities[45].
Among the spirocyclic oxazolines, the psammaplysins A-F ( 29-34)[46] and the
ceratinamides A and B ( 35 and 32, resp.) (Figure 5) are a small family of unique
metabolites which contain an oxepin moiety, possibly formed from epoxidation
followed by electrocyclic opening of the oxirane ring. The psammaplysins are found
in Psammaplysilla purpurea[46a,b], Pseudoceratina purpurea [46e] and Aplysinella
sp.[46c,d] while the ceratinamides are found in Pseudoceratina purpurea[46e]. The
psammaplysins A ( 29) and E ( 33) and the ceratinamides A ( 35) and B ( 32) possess
anti-fouling properties[46e]. Psammaplysin A ( 29) shows antibacterial activity[46a] and
psammaplysins C (31) and E (33) are cytotoxic[46d].
O
Br
H3CO
N
O
HO
O N
H
O
H
N
R2
R1
Br
Br
Br
29: psammaplysin A R1=R2=H 
30: psammaplysin B R1=OH, R2=H 
31: psammaplysin C R1=OH, R2=CH3 
32: psammaplysin D or ceratinamide B R1=H, R2=CO(CH2)11CH(CH3)2 
33: psammaplysin E R1=H, R2=                          
34: psammaplysin F R1=H, R2=CH3
 
35: ceratinamide A R1=H, R2=CHO
O
O
Figure 5: Psammaplysins A-E (29-34, resp.) and ceratinamides A and B ( 35 and 32,
resp.) are spirocyclic oxazolines bearing an oxepin moiety.
Some bromotyrosine metabolites have been isolated from non-Verongid species
such as 36 from the marine sponge Oceanapia sp.[47]. This compound ( 36) which
contains an unprecedented imidazolyl-quinoline substructure inhibits a novel
mycobacterial enzyme, MCA (mycothiol S-conjugate amidase)[47].
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Figure 6: 36, a bromotyrosine-derived metabolite from the non-Verongid species
Oceanapia
 sp.
Examples of Verongid tyrosine oximes are verongamine (37)[44h, 48] and purealidin C
(38)[49] (Figure 7). Verongamine (37) is a histamine-H3 antagonist and inhibits settling
of barnacle larvae[44h, 48]. Purealidin C ( 38) has antifungal, antibacterial and
antineoplastic properties[49].
H3CO
Br
H
N
N
HO
O N
H
N
37: verongamine
OH2N
Br
Br
H
N
NOH
O O NH2
Br
Br38: purealidin C
O
Br
Br
R
NH3
+
39: ceratinamine R=NHCOCN
40: moloka'iamine R=NH3+
Figure 7: Bioactive bromotyrosine-derived metabolites.
The simple bromotyrosine metabolites ceratinamine ( 39)[7, 46e, 50] and moloka’iamine
(40)[7, 46e, 50] (Figure 7), common components in Verongid sponges, are known to be
cytotoxic, antiviral and antifouling agents.
Turbotoxins A (41) and B ( 42) (Figure 8) are novel diiodotyramine-derived
metabolites from the gastropod Turbo marmorata[51] (Figure 8). Investigations about
the structure-toxicity of 41 and 42 revealed that both are acutely toxic when
administered to mice i. p., and that the iodine and the quaternary ammonium groups
are important in causing the observed toxicity. These two metabolites are structurally
similar to ceratinamine ( 39)[7, 46e, 52], moloka’iamine(40) [7, 46e, 50] and other related
dibromotyrosine-derived metabolites[7, 53].
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O
I
I
NR(CH3)2
(H3C)3N 41: turbotoxin A R=CH3
42: turbotoxin B R=H
+
+
2 CF3CO2-
Figure 8: Turbotoxins A (41) and B (42), diiodotyrosine-derived metabolites which are
structurally related to dibromotyrosine derivatives found in Verongid sponges.
The psammaplins and other related compounds comprise a small group of
metabolites possibly biosynthesised via the linear connection of bromotyrosines and
modified cysteines. They were found in Psammaplysilla sp.[54a], P. purpurea[54b] and
in Aplysinella rhax[54c]. Psammaplin A ( 43)[54a], the first metabolite of this series, is a
symmetrical tetrapeptide composed of two units each of bromotyrosines and
cysteines (Figure 9). Bisaprasin (44)[54a] is a biphenylic dimer of psammaplin A. Other
psammaplins ( 45-49) are linear di- and tripeptides containing thiocyanate ( 47) or
sulphonamide ( 48) on a modified cysteine chain (Figure 9) [54]. Psammaplin A ( 43),
bisaprasin (44) and psammaplins A 1 (45) and A 2 (46) exhibit moderate cytotoxicity
and inhibitory activities against farnesyl protein transferase and leucine
aminopeptidase[54c]. Psammaplin D ( 49) showed antimicrobial activity against gram-
positive and gram-negative bacteria, as well as activity against tyrosine kinase[54b].
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Figure 9: Bromotyrosine-cysteine-derived metabolites of Verongid sponges.
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2.2 Biological activity of the bastadins, unique macrocyclic diaryl ethers
from Ianthella basta, Ianthella sp. and Psammaplysilla purpurea.
The bastadins constitute a family of highly modified tetrapeptides, which have been
isolated from the Verongid marine sponges Ianthella sp.[29g, h], I. basta [29a-e, i-n] and
Psammaplysilla purpurea[29f]. They are composed of two tyrosine and two tyramine
units. With four exceptions (bastadins 1 ( 52)[29a, b], 2 (53)[29a, b], 3 (54)[29b] and 10- O-
sulfatobastadin-3 (71)[29n]), they are all macrocyclic. The bastadin macrocycle can be
divided into two hemibastadin units which are the northern and the southern
hemispheres (Figure 10). Almost all bastadins possess the bastarane ( 50) skeleton
(Figure 10), and only four of them (bastadin 13 ( 63)[29e] , bastadin 19 ( 69)[30] ,
bastadin 20 ( 70)[29n] and 34- O-sulfatobastadin 13 ( 73)[29h], figure 11) possess
isobastarane (51) geometry (Figure 10). Both skeletons have different oxidative modi
of cyclisation. In bastarane geometry the oxygen comes from the B-tyramine unit
(Figure 10) while in isobastarane geometry the oxygen is derived from the B’-
tyramine unit (Figure 10).
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14
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19
13
10
9
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11
10
9
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15
16
14
AB
A'B'
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A'B'
Figure 10: Bastarane and isobastarane geometries.
Bastadins 1 (52) and 2 (53) were isolated first[29a], directly followed by the isolation of
bastadins 3 (54) 4 (55), 5 (9), 6 (56) and 7 (57) (Figure 11)[29b]. These 7 bastadins
were shown to have antimicrobial activity against gram-positive bacteria [29b].
Bastadins 8-11 ( 58-61, respectively) have been reported by Podersino and
Schmitz[29c] together with other known bastadins. Bastadins 4 ( 55), 8 (58) and 9 ( 59)
showed cytotoxic activity against P-388 leukaemia cells and inhibited inflammation in
a mouse ear assay[29c].
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66: bastadin 16 R1=R2=Br, R3=H
68: bastadin 18 R1=R2=H, R3=Br
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Figure 11: Structures of all isolated bastadins from the marine sponges Ianthella sp.,
I. basta
 and Psammaplysilla purpurea.
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Bastadin 12 (62) (= bastadin 9 of Miao et al. [29d]) and bastadin 13 (63) (= bastadin 12
of Butler et al.[29e]) have been renamed by Carney et al. (Figure 11) [29f]. Bastadin 13
(63) was the first bastadin isolated with an alternative oxidative cyclisation modus,
the isobastarane geometry. This metabolite showed activity against the gram-positive
bacteriu Bacillus subtilis (Figure 11)[29h]. Bastadin 14 ( 64), isolated from
Psammaplysilla purpurea[29f], and bastadin 15 (65) from Ianthella sp.[29g] were the first
bastadins isolated from sponges other than I. basta (Figure 11). Bastadin 14 ( 64)
exhibited modest cytotoxicity and inhibited the enzymes topoisomerase-II and
dehydrofolate reductase[29f]. 34-O-Sulfatobastadin 13 (73), isolated fro Ianthella sp.,
was the first sulphated compound of the bastadin series (Figure 11) [29h]. This
bastadin did not show the same antibacterial activity as its OH-free analogue,
bastadin 13 (63). The free phenolic group may be required for this activity[29h].
Bastadins 16 (66)[29i, k], 17 (67)[29i, m] and 18 ( 68)[29j] (Figure 11) were isolated fro
Ianthella basta , but no biological tests have been reported about these three
compounds.
Bastadins 19 (69)[30, 29n], 20 ( 70)[29n], 10-O-sulfatobastadin 3 (71)[29n] and 15, 34- O-
dissulfatobastadin 7 (72)[29n] have also been isolated fro Ianthella basta (Figure 11).
The later was the first reported bastadin disulphate ester.
The isolation of the hemibastadins 1 (77), 2 (78) and 3 (79), and the hemibastadinols
1 (80), 2 (81) and 3 (82) from Ianthella basta was also reported[55] (Figure 12). These
compounds provide some information about the biosynthetic routes of the bastadins,
since they represent the northern or southern hemispheres of the bastadin
macrocycle. Except for bastadin 6 ( 56), compounds 77-82 inhibited growth of
Neisseria gonorrhoeae.[55] With the exception of the hemibastadinols 1-3, all other
tested metabolites inhibited the growth of gram-positive Enterococcus faecalis and
Staphylococcus aureus. None of those compounds were active against Escherichia
coli
 or the fungi Candida albicans and Cryptococcus neoformans.
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Figure 12: Hemibastadins and hemibastadinols fro Ianthella basta.
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The bastadins are efficient and novel modulators of the ryanodine receptor type 1
(Ry1R) Ca2+ channels[30]. Dihydropyridine receptors (DHPR) are voltage sensitive
channels which allow the influx of Ca2+ into the sarcoplasm. This influx mediates the
efflux of Ca2+ from the sarcoplasmatic reticulum (SR) through calcium-sensitive
channels, the ryanodine receptors (Figure 13). This activation represents the major
physiological Ca2+-release pathway from the sarcoplasmatic reticulum (SR) during
excitation-contraction coupling in skeletal muscle (Figure 13)[30, 56]. The 12 kDa
protein FKBP12 forms a heterocomplex with Ry 1R (FKBP12-Ry1R), which stabilises
the closed conformation of the Ca 2+ release channel. Nanomolar concentrations of
immunosuppressant drugs, including FK506 and its analogues, promote dissociation
of FKBP12[30, 56, 57]. The dissociated FKBP12 forms a complex with FK506 which
inhibits the activity of calcineurin (a Ca2+/calmodulin-stimulated protein phosphatase,
which plays a key role in T-cell activation)[58]. This inhibition is necessary for the
immunossupressive effect of FK506.
Extracellular
S. R.
exchange
Ryanodine
receptor
DHPR
receptor
Figure 13: Components of the electromechanical coupling (excitation-contraction-
coupling) in the skeletal muscle[59].
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SR membranes possess different leak and channel states (opened or closed) of the
FKBP12-Ry1R complex. The channel-to-leak ratio depends on the kind of interaction
between this complex and proteins.
Some experiments have been performed with bastadins in order to find out and
understand the influence of those metabolites on SR Ca2+ transport[30, 56].
Bastadin 5 (9) alone significantly decreases the steady-state loading capacity of SR
vesicules to 50 %, whereas in combination with ryanodine or ruthenium red, bastadin
5 (9) increases the capacity of the SR vesicules by 2-3-fold[56, 57]. Interestingly, FK506
alone enhances the Ca 2+ loading capacity of SR vesicules by only 23  %, but with
ryanodine, this activity is increased by 2 fold [56]. Bastadin 19 (69), the regioisomer of
bastadin 5 (9), lacks this activity, but effectively diminishes the action of bastadin 5
(9)[30, 56].
In the presence of physiological concentrations of K+ and Na+, bastadins 5 (9), 7 (57)
and 10 (60) interact with the FKBP12-Ry1R channel complex enhancing the channel
leak ratio[56, 57]. This leads to an increase in high affinity sites for ryanodine and
enhances Ca2+-induced Ca2+ release rates. With this result, it was proposed that the
bastadins, through their modulatory action on the FKBP12-Ry 1R complex, convert
ryanodine-insensitive leak states into ryanodine-sensitive channels.
The influence on the SR Ca 2+ transport of bastadin 5 ( 9) and of a mixture of
bastadins 5 (9), 7 (57), 10 (60), 18 (68) and 20 (70) was evaluated. Both are able to
activate high-affinity binding of [ 3H]ryanodine to SR membranes, but the activity of
the mixture is 5 fold lower than that of the bastadin 5 [56]. Unlike bastadin 5 ( 9), the
mixture releases Ca2+ from actively loaded vesicles, even when the extravesicular
Ca2+ concentration is below 1 µM[30]. Further investigation showed that this property
is attributed to bastadin 10 ( 60)[57], which also relieves inhibition caused by
physiological Mg2+. Both actions reported for bastadin 10 ( 60) are rapidly
reversible[57].
The actions of the bastadins are all antagonised by FK506 in a dose-dependent
manner[57]. Bastadin 5 ( 9) alone, unlike FK506, does not dissociate the FKBP12-
Ry1R channel complex [30]. Although, in the presence of FK506, bastadin 5 ( 9)
enhances the ability of FK506 to dissociate FKBP12 from SR membranes.
Since the regulatory actions of the bastadins are all eliminated by FK506, it has been
suggested that the pharmacological actions of the bastadins are mediated by a novel
modulation site which requires integrity of the FKBP12-Ry1R channel complex[57].
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2.3 Bastadin synthesis
The bastadins constitute a new class of biologically active secondary metabolites.
Their modulatory action on the FKBP12-Ry1R channel complex is unique. Therefore,
they are attractive candidates for the investigation of the functional significance of
immunophilin/ryanodine-sensitive Ca2+ channel interactions in skeletal muscle.
Three total syntheses of the bastadins have been reported [31]. Yamamura et al.
reported the total syntheses of bastadins 1 ( 52), 2 (53), 3 (54)[31b] and 6 ( 56)[31a].
They used thallium trinitrate oxidation to construct the diaryl ether moieties and to
achieve the macrocyclisation to bastadin 6 (56) (Scheme 3).
OH
RBr
CO2CH3
NOH
80
 R=Br
81
 R=H
a, b
O
NOH
H3CO2C Br
OH
Br
CO2CH3
NOH
R
82 R=Br
83
 R=H,
OH
Br
CHO
84
+
OCH3
Cl
85
c-e
NH2
O
Br OCH3
86
f
R2O
Br
N
H
O
NOH
R1
O
Br
HO
Br
NOH
O
H
N
R2O
Br
87 R1=H, R2=p-OCH3Bn
88
 R1=Br, R2=p-OCH3Bn
52: bastadin 1 R1=R2=H 
53: bastadin 2 R1=Br, R2=H
g
g
h-l
56: bastadin 6
m, g
OH
Br
OH
Br
NOH
CO2CH3
NOH
H3CO2C
54: bastadin 3
89
Scheme 3: Total synthesis of bastadins 1, 2, 3 and 6 by Yamamura et al. [31a,b]: a)
Tl(NO3)3, CH3OH, -35 °C, 20 h; b) Zn powder, THF, 0  °C, 35 min; c) K2CO3, DMF,
r.t., 14  h, then CH 3NO2, THF, K2CO3, r.t., 18  h; d) Ac2O-pyridine, then NaBH 4,
diglyme, 0 °C, 1 h; e) Zn powder, dioxane, AcOH, 0-5 °C, 40 min; f) 60 °C, 36-41 h;
g) TFA, CH2Cl2, r.t., 20 min; h) BnCl, K2CO3, r.t., 2 days, then TFA, CH2Cl2, r.t.; i) Br2,
CHCl3, r.t.; j) Tl(NO3)3, CH3OH, 4 °C, 3.5 h2; k) Zn powder, AcOH, THF, r.t.; l) H2/Pd,
AcOH, dioxane; m) 60 °C, 4 days.
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 This step gave two macrocyclic dienones in 13  % and 10  % yields, respectively. The former was
reduced affording bastadin 6.
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This synthetic route, however, gave very low yields3, mainly because of the low diaryl
ether regioselectivity achieved with the thallium trinitrate method4.
Sih et al. reported an alternative route for the synthesis of bastadins 2, 3 and 6 [31c].
The required diaryl ethers were produced by enzymatic phenolic coupling using
horseradish (HRP) and soybean (SOP) peroxidase (Scheme 4).
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Scheme 4: Total synthesis of bastadins 2, 3 and 6 by Sih et al.[31c]: a) SPO, H2O2, pH
5, r.t., 46 %; b) CrCl2, r.t., 98 %; c) SPO, H2O2, pH 4, r.t., 47 %; d) DCC, HOBt, r.t.,
72 %, e) NaHSO3, NaOH, r.t., 99 %, f) TFA, 95 %; g) DCC, HOBt, 0 °C-r.t., 64 %; h)
NaHSO3, NaOH, r.t., 98 %; i) 3-bromotyramine, DCC, HOBt, 0 °C-r.t., 68 %; j) HRP,
H2O2, pH 4, r.t., 30 %; k) 3-bromotyramine, HOBt, EDCI, 0  °C, 57 %; l) BBr3, 80 %;
m) Pd/C, EtOH, 74 %; n) 3-bromotyramine, HOBt, EDCI, 0 °C, 73 %.
                                           
3
 Up the diaryl ether conversion step, the bastadins 1, 2, 3 and 6 were obtained in an overall yields of
0.6 %, 9 %, 0.7 % and 1.1 %, respectively.
4
 The thallium trinitrate oxidation gave 3 coupling by-products in 5-10 % yield each[31a,b].
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The overall yields of the bastadins5 were higher than the reported by Yamamura et
al.[31a, b], but the enzymatic diaryl ether formation is neither regioselective nor gives
complete conversion. All the steps involving the diaryl ether coupling afforded at least
2 by-products in 5-10 % yields as well as starting material[31c].
Two other research groups reported alternative routes for the synthesis of the
bastadins. Couladouros and Moutsos presented the synthesis of the bastadin 12
skeleton ( 96, figure 14) using the iodonium salt method for the diaryl ether
coupling[31d, e]. The authors mentioned that the use of the triazene method developed
by Nicolaou et al.[60] would not be appropriate because of the difficulties involved in
the removal of the triazenes in the final reaction steps. With this methodology the
authors achieved the stereosselective construction of the bastadin 12 skeleton (96) in
4 % overall yield, where the diaryl ether products were obtained in 68-78  % yield.
Despite of these higher yields, it is important to note that the phenolic oxidation step
using the iodonium salt methodology does not allow for the presence of sensitive
groups in the molecule, since this reaction requires high temperatures[31d, e].
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Figure 14: Bastadin 12 skeleton ( 96) and tyrosine cyclic peptides 97 and 98 by
Couladouros and Moutsos[31d, e] and by Molinski et. al[31f], respectively.
Molinski et. al synthesised the tyrosine cyclic peptides 97 and 98 as a 1:1 mixture[31f].
The diaryl ethers were obtained via Ullmann coupling of commercially available
                                           
5
 Up to the diaryl ether coupling reaction step, the bastadins 2, 3 and 6 were obtained in 30  %, 13-
16 % and 19 % yield, respectively.
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benzaldehyde derivatives. The synthetic route did not show any macrocyclisation
regioselectivity and the products were obtained in very low yields6.
The efforts towards the synthesis of the bastadins has not yet satisfied the
necessities required for a successful synthetic methodology. A synthetic route which
is highly selective, gives products in higher yields, enables the presence of sensitive
groups, and is flexible must be still found.
3 Ruthenium mediated synthesis of diaryl ethers
3.1 Inert sandwich complexes of aromatic amino acids and peptides
Compared to other research fields in chemistry, bioorganometallic chemistry has only
recently emerged. Known difficulties in the handling of organometallic complexes
including air-instability and toxicity, are the main reasons for the relatively late
development of this particular field. Only when chemists and biologists started to
focus their attention on the potential properties organometallic compounds, ( e. g.
specific binding of biologically interesting molecules such as amino acids and
peptides) did interest in the development of this field start. Needless to say, this was
supported by the discovery of metal stable complexes.
Studies of platinum compounds initiated a new era in cancer therapy. Other group
VIII transition metals were also investigated, specifically those that induced
filamentous growth in Escherichia coli, including some ruthenium complexes[34].
Presently several metal compounds are in clinical use [34, 61]. The platinum complexes
cisplatin and carboplatin play a very important role in the treatment of cancer. The
Pt(IV) complex cis, trans, cis-[PtCl2(OAc)2(NH3)(C6H11NH2)] is in phase II clinical
trials as an orally active anti-cancer agent against a wide range of cancer types and
Pt-resistant cells[61]. The gold complexes myocrisin and auranofin are anthiarthritic
drugs while some silver complexes are used as antimicrobial agents and in the
                                           
6
 The regioisomers were obtained in 30 % yield (referred only to the last step) as a 1:1 mixture from
amide coupling reaction between the two diaryl ethers moieties: tyramine-tyramine and tyrosine-
tyrosine.
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therapy of burn wounds[61]. The iron complex, Na2[Fe(NO)(CN)3] is a vasodilator and
a good example for a drug which carries the reactive ligand to the target site [61]. In
the diagnostic field, X-ray imaging is being replaced by NMR imaging as new imaging
agents are developed and in clinical use including the stable, non-toxic DTPA 7 and
DOTA7 gadolinium complexes[61]. Complexes of the radioisotopes 111In  and
especially 99mTc are used for imaging myocardial and cerebral perfusion and
monitoring kidney function[61, 62].
Some complexes of Ru III have been synthesised and their biological activities have
been evaluated[34, 61, 63]. The interest in ruthenium complexes started with the concept
“activation by reduction”. Ruthenium complexes may be selectively toxic for tumour
cells. The reduction potential of Ru III,II (~0.25 E°/V)8 is biologically accessible when
compared to other metals such as Fe III,II (0.77 E°/V)8 [63]. The high metabolism of
tumour cells requires rapid oxygen and glucose consumption, and therefore these
cells have low pH and low O2 concentrations. These conditions favour the reduction
of RuIII to RuII which is the active, toxic form. Examples of those complexes are trans-
[Ru(Im 2Cl4]ImH] (Im=imidazol), which entered clinical trials[61, 63] and cis-
[Cl2(NH3)4Ru]Cl2[63]. Both complexes preferentially bind at the N-7 of guanine and
inhibit DNA replication, mutagenic activity and induction of the SOS repair modus.
The first demonstrated activity against non-small cell lung, breast and renal cancers
as well as clonogenic cells from freshly explanted human tumours[63].
Ruthenium sulfoxide complexes, in particular, NAMI (Na-trans-Cl4(DMSO)(Im)Ru),
have antimetastatic properties. NAMI is active against various tumours and
dramatically reduces lung metastases with minimal toxic side-effects [34, 63].
Transition metals are also very interesting markers. They are selective and their IR
and UV spectra have intensive characteristic absorptions in ranges which are not
common for bioorganic molecules. Their signals are easily differentiated fro
bioorganic molecules and the complexed substrates can be detected even in
picomolar concentrations[64, 65].
                                           
7
 DTPA: diethylenetriaminepentaacetate; DOTA: 1, 4, 7, 10-tetra (carboxy-methyl)-1, 4, 7, 10-tetraaza-
cyclododecane)
8
 The reduction potential is referred to an acidic environment. The values can differ depending on the
ligands.
Theoretical Section 23
___________________________________________________________________
Ruthenium red, [(NH 3)5RuIIIORuIV(NH3)4ORuIII(NH3)5]6+, is known as a cytological
stain. Other biological properties have been attributed to ruthenium red like
immunosupressant and anti-tumour activity. Ruthenium red can selectively bind to
carboxylic or sulphate groups of acidic polysaccharides. Since tumour cells have a
protective mucopolysaccharide cell wall, ruthenium red concentrates in these sites
inhibiting tumour growth. Furthermore, this characteristic makes ruthenium red useful
for specific tumour scanning agents [34, 63]. Ruthenium polypyridyl complexes (Rubipy
and related ions) have been evaluated as visualising agents due to their fluorescent
properties. Their photo-stability in solution and molecular weight enables studies of
low molecular weight antigens [63].
The potential of rutheniu π-arene complexes studied in this thesis is still under
evaluation[66]. Moriarty et al.[33a] reported the facile introduction of
[RuCp(NCCH3)3]PF6 in amino acids.[33a] Sheldrick et al. extended this methodology to
the selective labelling of peptides [67]. Grotjahn et al. showed the specific π-arene
binding of the [RuCp]+-complexes to amino acids and peptides, even in the presence
of S- and N-donors, and the stability of these complexes in reactions occurring in
water[68]. These results, taken with the characteristics of the ruthenium radioisotopes
[97Ru (τ1/2=2.9 days), 103Ru (τ1/2=39.4 days) and 106Ru(τ1/2=368 days)]9 undoubtedly
make these complexes attractive biomarkers.
Although still very limited (probably due to their difficult purification), some
applications of these complexes have been reported. Radiolabelled
ruthenocenylalanine has been investigated as a pancreatic imaging agent [69], and
[RuCp*]+-labelled estradiol has been used in the analysis and recognition of the
active sites on hormone receptors[70].
The employment of [RuCp]+-complexes has been more widely investigated in
nucleophilic aromatic substitution for the synthesis of important biologically active
compounds (see chapter 3.2).
                                           
9
 Emission energy: 99Ru = EC (orbital electron capture); 103Ru = β-; 106Ru = β-.
Theoretical Section 24
___________________________________________________________________
3.2 Application of [RuCp]+-complexes in the synthesis of natural products
Diaryl ethers are structural components of many naturally occurring biologically
active peptide-derived compounds, such as vancomycin ( 99), K-13 (100) and
OF4949 I-IV ( 101-104) (Figure 15). Vancomycin ( 99) is a natural glycopeptide
antibiotic isolated from the bacteria Nocardia orientalis. It is clinically used in the
treatment of methicillin-resistant Staphylococcus aureus infections or in patients
allergic to β-lactam antibiotics[71]. K-13 (100) and OF4949 I-IV ( 101-104) are
isodityrosine-derived cyclic tripeptides. K-13 was isolated from the bacteria
Micromonospora halophytica
 ssp. exilisia and is a natural potent, noncompetitive
angiotensin I converting enzyme (ACE) inhibitor[72]. OF4949 I-IV were isolated fro
the fungus Penicillium rugulosum, are potent inhibitors of aminopeptidase B and
possess anti-tumour and immunopotentiating activities[73].
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Figure 15: Biologically important natural products bearing diaryl ether moieties:
Vancomycin (99), K-13 (100) and OF4949 I-IV (101-104).
Construction of the diaryl ethers moieties from compounds possessing sensitive
amino acid functionalities in their side chains is an important step in the synthesis of
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this class of natural products. Despite the existence of many methods described for
oxidative couplings, the synthesis of cyclic diaryl ether peptides is still limited.
The most common procedure for the preparation of diaryl ethers is the classical
Ullmann coupling. The disadvantages of this method, including the modified Ullmann
couplings by Boger et al.[74a] and by Smith et al.[74b], are the harsh conditions required
which are incompatible with the sensitive amino acid functionalities. Some research
groups developed and continue developing new methods for the synthesis of diaryl
ethers at lower temperatures. The thallium trinitrate (TTN) method, introduced by
Yamamura et al.[75] and modified by Evans et al.[76], gives diaryl ether products at lo
temperatures, but the thallium salt used is highly toxic and the reaction is not
regioselective giving the desired product in low yields. Zhu reported the reaction of o-
fluoro nitroarenes with phenolates at room temperature and its application to the
synthesis of 14-, 16-, and 17-membered macrocycles found in natural products[77].
Nicolaou et al. employed a similar methodology with o-dihalogenated aromatic
triazenes for the total synthesis of vancomycin [78]. The disadvantage of these
methods is that both require the presence of an electron withdrawing group, (nitro
and triazene for Zhu’s and Nicolaou’s procedures, respectively) whose removal
needs at least two reaction steps. Evans et al. [79] and Chan et al. [80] reported the use
of aryl boronic acids with cooper diacetate for the diaryl ether coupling. This reaction
occurs at room temperature with high yields and is applicable to phenolates and aryl
boronic acids with a wide variety of substituents.
The nucleophilic attack of phenolates at π–arene metal complexes of manganese,
iron, and ruthenium is a very interesting and an efficient alternative for the synthesis
of diaryl ethers[28, 81]. Iron and manganese π–arene complexes give diaryl ether
products in high yields under mild reaction conditions [82]. However the reaction
conditions necessary for the attachment of the [FeCp] +- (AlCl3, Al, high
temperature)[83] and of the Mn(CO)3+-complexes[84], is too harsh for the amino acid
functionalities[85]. Therefore, some groups promote the manganese or iron diaryl
ether coupling before the amino acids are built up [82b, c]. The removal of the metal
occurs very easily, especially of the manganese complex [33c, 82a].
The simple removal of the metal complex is an advantage, but not always desired,
like in the field of peptoid metal labelling (see chapter 3.1). [RuCp] +- complexed
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chloroarenes are easily formed under reaction conditions compatible with the amino
acid functionalities. Moriarty et al. [33a], Sheldrick et al.[67] and Grotjahn et al. [68]
reported the specific π-arene binding of the [RuCp]+-complexes to amino acids and
peptides in the presence of S- and N-donors as well as the stability of these
complexes in water[68]. The high yields obtained from the nucleophilic attack of
phenolates at [RuCp]+-complexed chloroarenes under very mild reaction conditions,
first reported by Nesmeyanov et al. [32a] and Segal[32b], was later used for the
synthesis of natural products[33, 85b, 86], including formal[86a, e] and total[86g] synthesis of
K-13[86a, g] and OF4949 III [86e, g] (Scheme 5), and the synthesis of ring systems of
ristocetin A[33d, 86c, h, i, l] and of teicoplanin[86d, k].
The purification of the charged [RuCp]+-complexes is very difficult and, therefore,
these complexes are only used in the last reaction step (Scheme 5). After conversion
to the metal-labelled diaryl ether, the crude product is directly subjected to
photochemical demetallation followed by purification of the non-complexed product.
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Scheme 5: Total synthesis of K-13[86g]. After ruthenium mediated macrocyclisation,
the product is directly subjected to photochemical demetalation.
Compared to other methodologies, the use of ruthenium arene chemistry for the
synthesis of natural products exhibiting diaryl ether moieties comprise som
advantages, such as high yields obtained under mild reaction conditions, as well as
their ease of handling due to their stability. The [RuCp] +-complexed intermediates,
obtained during the synthesis of a natural product, could be used as labelled amino
acids and peptides. However, these advantages have yet to be exploited. The limited
use of the [RuCp]+-arene complexes is probably a consequence of the lack of
efficient protocols for their purification.
Theoretical Section 27
___________________________________________________________________
4 Building blocks of the bastarane skeleton
Almost all bastadins are macrocyclic and consist of two tyrosine and two tyramine
units linked via diaryl ether and peptide bonds (Figure 16). Presently, three synthetic
routes towards the bastadins have been reported [31] employing I) low yielding phenol
oxidation[31a-c]; II) iodonium salt method[31d,e] and III) Ullmann coupling [31f]. Among the
isolated bastadins, bastadin 5 ( 9) is of especial importance because of its biological
and pharmacological activities. Bastadin 5 ( 9) inhibits the Ca2+ uptake into the
sarcoplasmatic reticulum, which is antagonised by the immunosuppressant natural
product FK506[30, 87].
The application of ruthenium arene chemistry promotes diaryl ether coupling in
moderate to high yields under mild reaction conditions and even enables the
presence of sensitive groups.
These advantages, together with our interest in metal-labelled peptoids, were the
reasons to select ruthenium arene chemistry for skeleton synthesis of the
pharmacologically interesting bastadin 5 (9).
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4.1 Retrosynthetic analysis of the 'ABB'A'-bastarane macrocycle
A detailed retrosynthetic analysis of the bastarane macrocycle is presented in figure
16.
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Figure 16: Retrosynthetic analysis of the bastarane skeleton. The two tyrosine and
tyramine units of the macrocycle have been labelled (AA') and (BB') respectively in
order to facilitate this interpretation.
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The AA'BB' units represent the four tyrosine/tyramine building blocks of the
bastarane skeleton (Figure 16). Considering the required protection of sensitive
functional groups present in those ABA'B'-units during the macrocycle synthesis, the
retrosynthesis presented in figure 16 saves some protection-deprotection steps
compared to other retrosynthetic possibilities.
The first step is the amide coupling reaction between the [RuCp] +-complexed 2-(4-
chlorophenyl)ethylamine (116) B and the DOPA derivative (A) 118, where the amino
group and the free phenols of the amino acid have been protected. The next step is
the ruthenium-promoted diaryl ether coupling between AB ( 115) and the dopamine
derivative (B') 112. To assure that the desired phenol group couples with the
[RuCp]+-complexed chlorobenzene derivative, the protection of all other present
phenols in 118 was promoted. For the additional OBn protection one more reaction
step was necessary.
Another group that could compete in this reaction is the free carboxylic acid, which is
never present in this retrosynthetic pathway. Here, all carboxylic acid moieties have
reacted with the respective amines before the diaryl ether coupling takes place.
Analysing the possibility of first promoting the amide coupling between the B'A'-units,
with a previously phenol-protected B'-unit ( 113), the next step would involve the
introduction of the DOPA derivative (A) 117. This strategy would require extra
protection of the free carboxylic acid of the DOPA derivative 117 requiring two extra
steps (protection and deprotection) and consequently lower overall yields.
The approach, starting with the diaryl ether coupling between the BB'-units would
require two different amine protections. This strategy would involve the same number
of protection steps as the one that started with the construction of the AB-unit.
Investigations comparing amine protection versus phenol protection showed that the
latter was the most convenient. The benzyl protecting group remains intact under the
reaction conditions involved in this strategy and can be easily removed under mild
reductive conditions in high to quantitative yields. The conditions required for the
removal of the benzyl protecting group does not affect the other functional groups
present in the target molecule.
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The introduction of the fourth tyrosine unit again should be an amide coupling
between the free amine of ABB'-unit 111 and the [RuCp]+-complexed
cholorophenylalanine derivative (A') 109. The macrocycle is finally achieved by
intramolecular ruthenium (II) promoted diarylether coupling, after deprotection of the
benzylated phenol. Demetalation and oxidation of the amines should afford the
bastarane skeleton 50.
4.2 Synthesis of all four tyrosine/tyramine bastarane subunits
Following the chosen retrosynthetic route (Figure 16), the synthesis of the
intermediates 109, 112 , 116-118 could be envisaged (Figure 17).
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Figure 17: Bastarane macrocycle split into its four tyrosine/tyramine units.
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4.2.1. Synthesis of the B' unit: N-Boc- (119) and 2-(3-hydroxy-4-
methoxyphenyl)ethylamine (112)[88]
2-(3-hydroxy-4-methoxyphenyl)ethylamine ( 112) was synthesised with an overall
yield of 60 %. The synthesis started from the aldol condensation between
commercially available isovaniline ( 120) and nitromethane under basic conditions,
followed by LiAlH4 reduction of the obtained β-nitrostyrene 121. The already
selectively protected dopamine [88] 112 was then converted into its tert-butoxycarbonyl
(Boc) derivative 119 under standard conditions (Scheme 6). Amine protection with
Boc2O was chosen because this group should remain intact under all reaction
conditions and its removal should occur quantitatively by treatment with 4N HCl in
CH3OH at room temperature.
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Scheme 6: Synthesis of B': a) CH 3NH2⋅HCl, Na2CO3, CH3OH, CH3NO2, dark, r.t.,
50 h, 88 %; b) LiAlH4, Et2O, Soxhlet extraction, 18 h, 68 %; c) Et3N, CH2Cl2-
CH3OH (1:1), Boc2O, r.t., 3 h, 93 %.
Following the retrosynthesis shown in figure 16, the dopamine derivative ( 112)
should couple in the third reaction step with the carboxylic acid moiety of the
[RuCp]+-complex 109, forming the tetrapeptide ABB'A'. This free amine derivative
112 has two nucleophilic sites, the free phenol and the amine moiety, which can
compete in the second reaction step for the nucleophilic aromatic substitution (S NAr).
The behaviour of this ambidental nucleophile will be discussed in detail in chapter 5.2
when diaryl ether couplings involving both the free 112 and the protected 119
dopamine derivatives are reported.
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4.2.2. Synthesis of the A unit: N-Boc--(3-hydroxy-4-methoxy)-
phenylalanine (117)[89], its methyl ester (128) and N-Boc-,-(3-
benzyloxy-4-methoxy)-phenylalanine (118)
The synthesis of the bastarane macrocycle does not require the asymmetric
preparation of the DOPA derivative, since all stereocenters present in the building
blocks will be oxidised to oximes in later steps.
Starting from isovaniline (120), the racemic DOPA derivative 117 can be prepared in
two ways[89] by aldol condensation with either commercially available hippuric acid or
hydantoin. Comparing both pathways, the use of hippuric acid afforded product 124
with an overall yield of 14  % whereas hydantoin led to the N-Boc protected product
117 with an overall yield of 31  %, although this procedure requ ires one additional
step (Scheme 7).
After an aldol condensation of 120 with hydantoin, the product 125 was treated with
NaHg under basic conditions to give the reduction product 126. Hydrolysis with
Ba(OH)2 2O under reflux and Boc 2O protection utilising Jung and Lazarova's
procedure[90] afforded the desired N-Boc protected amino acid 117.
The conversion of 117 to its methyl ester analogue 128 was achieved according to
Hassner and Alexanian[91]. The intention for the preparation of this compound was its
use in a model reaction involving ruthenium mediated SNAr.
On the basis of the synthetic route (Figure 16) outlined above, the free phenol of the
racemic (3-hydroxy-4-methoxy)phenylalanine moiety 117 present in the dipeptoid AB
(114) could compete as a potential nucleophile with the phenol from 2-(3-hydroxy-4-
methoxyphenyl)ethylamine ( 112) in the diaryl ether coupling step. To verify this
proposition, the synthesis of both AB dipeptoids with 115 and without 114 further
phenol protection was necessary and, therefore, the preparation of the precursor
118. Selective benzylation of the phenol of 117 (Scheme 7) was acchived utilising
benzylchloride following Grewe and Fischer's procedure[92]. The reaction conditions
allowed the selective protection of the phenol without conjunctive formation of its
benzylester analogue. This protecting group was chosen because of its stability
under the reaction conditions used in this work and the simple cleavage under mild
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conditions using Pd-C, 1,4-cyclohexadiene. These conditions neither involve
concomitant removal of the methyl protecting groups of the other phenols nor affect
the sensitive functions of the target molecule. Moreover, the benzyl group resembles
the side chains of polystyrene polymers as putative supports for solid phase
syntheses of ruthenium-labelled peptoids.
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Scheme 7: Synthesis of the A Unit: a) hydantoin, NaOAc, Ac2O, reflux, 30 min, 84 %;
b) H2O, NaOH (10 %), NaHg, r.t., 90   %; c) Ba(OH)2 8 H2O, H 2O, reflux, 63 %, d)
Et3N, Boc2O, CH3OH-H2O (1:1), 0 °C (30 min), r.t., 48  h, 66 %; e) EDCI, CH 2Cl2,
CH3OH, 4-pyrrolidine-pyridine, r.t., 96 h, 77 %; f) CH3OH, NaOH, BnCl, reflux, 15 h,
65 %; g) hippuric acid, NaOAc, Ac2O, reflux, 30 min, 38 %; h) aq. NaOH (2 %), reflux,
58 %; i) H2O, NaHg, r.t., 63%.
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4.2.3. Synthesis of tris-(acetonitrile)(η5-cyclopentadienyl)ruthenium hexa-
fluorophosphate (132)[93]
 [RuCpBz]Cl (129) was prepared from RuCl3  3 H2O via the method described by
Zelonka and Baird[93a, b]. After anion exchange using NH 4PF6[93c], the complex 131
was subjected to irradiation (8 hours) in acetonitrile with a mercury medium pressure
lamp to give [RuCp(NCCH3)3]+PF6- (132)[93c] (Scheme 8). This complex is the starting
material of all [RuCp]+-complexed benzene derivatives synthesised in this thesis. The
acetonitrile ligands are very labile and, therefore, can easily be exchanged by the
corresponding η6-arene ligand.
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Scheme 8: Synthesis of [RuCp(NCCH3)3]PF6 (132) a) 1,3-cyclohexadiene, EtOH:H2O
(9:1), reflux, 3 h, 95 %; b) TlCp, CH3CN, r.t. 1  h, 70 %; c) NH4PF6, H2O, r.t., 1  h,
68 %; d) Hg-medium pressure lamp (150 W), CH3CN, r.t., 8 h, quant.
4.2.4. Synthesis of the [RuCp]+-complexes: A' (109)[85b] and B (116)[94] units
After treatment of commercially available 2-(4-chlorophenyl)ethylamine ( 133) with
[RuCp(NCCH3)3]PF6 (132) under reflux[93c] a mixture of unidentified products was
obtained. It is likely that the free amine competes with the benzene for the
complexation with ruthenium (II). To prevent this undesired reaction, 2-(4-
chlorophenyl)ethylamine ( 133) was Boc-protected under standard conditions
(Scheme 9).
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Complexations of arenes possessing a free amine functionality have already been
reported[67a, 68a, 86g, 86j]. Rich and Janetka showed that the ruthenium complex of an
amino acid bearing a free amino group can be formed selectively at the aromatic
ring[86g]. Matassa et al. repeated this procedure and arrived at the same result[86j].
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Scheme 9: Synthesis of the B unit ( 116): a) Boc2O, CH 2Cl2, r.t., 4  h, 98 %; b)
[RuCp(NCCH3)3]PF6 complex, 1,2-dichloroethane, reflux, 4  h, 65 %; c) 4N HCl in
CH3OH, r.t., 3 h, quant.
Grotjahn et al. reported in a series of experiments using free amine and sulphur
compounds that η1-N or η1-S coordination is kinetically favoured but that arene
coordination is thermodynamically preferred (Scheme 10-I) [68a]. Sheldrick et al.
investigated the synthesis of peptides labelled with (η5-Cp*)Ru(II) (Scheme 10-II)[67a].
The authors quantitatively obtained η1-N, O-coordinated complex at low
temperatures and, at reflux, the corresponding η6-peptide complex. However, they
observed that the reaction mixture always contained about 10  % of the η1-N, O-
coordinated complex[67a]. The reaction of the dipeptoids 142 and 143 could be
performed at room temperature (Scheme 10-II), whereas stronger conditions were
required for η6--HPheOH 141 formation (12 hours, reflux). This reflects the fact that
the competitive formation of a η1-N, O-coordinated five-membered chelate ring as for
-phenylalanine will be less favourable for HPhe-PheOH and impossible for cyclo(-
Phe-Phe-)[67a].
Despite of all this available information about free amines during rutheniu
complexation, in this work it was found that it is more convenient and more effective
to prepare the [RuCp]+-complexed 2-(4-chlorophenyl)ethylamine via its N-Boc
analogue (145).
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D,L-4-Chlorophenylalanine ( 144) was converted to its Boc analogue ( 145)[90]. Its
methylester derivative 146[85b] was prepared for a model reaction[91].
Ru N
H2
CH3CN
CH3CN
+
PF6-
137
I)
NH2
136
+
r.t., 10min Ru N
H2
CH3CN
NH2
+
PF6-
138
60oC
1h
Ru
+
PF6-
139
NH2
NH2
II)
CD3NO2
Ru
+
CF3SO3-
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CH3CN
CH3CN
NCCH3
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b
c
141
NH2
RuCp* +
-O2C
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RuCp*
N
HNH2
O CO2H RuCp* +
143
*CpRu RuCp*
N
H
H
N
O
O
Scheme 10-I) η1-N coordination is kinetically favoured, but the arene coordination is
thermodynamically preferred[68a]; 10-II) a) Phenylalanine, CH 3OH, 12 h, reflux; b)
HPhe-PheOH, CH3OH, r.t; b) cyclo(-Phe-Phe-); CH3OH; r.t.
Complexation of the N-Boc protected DL-4-chlorophenylalanine (145), its methylester
analogue 146 (Scheme 11) and 2-(4-chlorophenyl)ethylamine (134) (Scheme 9) were
performed according to Gill and Mann [93c]. Products were isolated from the reaction
mixture by precipitation upon addition of diethyl ether and were analysed without
further purification. The success of those reactions could be confirmed by analysis of
their 1H and 13C NMR spectra, where all aromatic protons and carbons were shifted
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to higher fields compared to the non-complexed analogues. The 1H NMR spectra
showed upfield shifts (∆δ) of 0.5 to 0.9 ppm and the 13C ∆δ of 30-45 ppm.
Removal of the Boc protecting group from [RuCp]+-complex (135) with 4N HCl in
CH3OH quantitatively gave {1-(2-amino)ethyl-4-chloro-η6-benzene}(η5-cyclo-
pentadienyl)ruthenium hexafluorophosphate (116) (Scheme 9).
Cl
NH2
a
144
Cl
NHBoc
145
b Ru
Cl
PF6-
109, 85%
CO2H CO2H
NHBoc
CO2H
Cl
NHBoc
CO2CH3
b Ru
Cl
PF6-
147, 78%
NHBoc
CO2CH3
c
146
Scheme 11: Synthesis of A' unit: a) Boc2O, Et3N, CH3OH-H2O (1:1), 0 °C (30 min), r.t.
42 h, 64 %; b) [RuCp(NCCH3)3]+PF6- complex, 1,2-dichloroethane, reflux, 4  h; c)
EDCI, CH2Cl2, CH3OH, 4-pyrrolidine-pyridine, r.t., 96 h, 85 %.
The ruthenium (II) complexation of the chloroarenes 134, 145 and 146 gave
moderate to high yields, but their purification was a challenge.
Chromatography of charged ruthenium sandwich complexes has rarely been
described[95]. Even simple reaction controls by thin layer chromatography (TLC) are
not reported. The usual work-up of [RuCp] +-complexes combines filtration on
alumina, followed by precipitation upon addition of Et 2O. Of course, mixtures of
different sandwich complexes can not be separated by this procedure. Instead,
separation and purification problems are circumvented by photochemical
demetalation immediately following the diaryl ether coupling. As a consequence, the
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analytical and preparative separation of the charged sandwich complexes from each
other
 is of fundamental importance for the success of [RuCp] +-complexes in both
organic synthesis and bioinorganic chemistry[68b].
On silica gel and on cellulose the ruthenium complexes 109, 116, 135 and 147 did
not move even after using many eluents with different polarities. On several common
stationary phases (DIOL, alumina, LH-20, RP-8 and RP-18) the complexes migrated
from the origin, but with identical Rf values. In this preliminary analysis, the only
phase which showed promising results for the purification and separation of these
charged complexes was aminopropyl-functionalised silica. The next challenge was
the elaboration of an efficient methodology for the preparative separation of those
complexes.
4.3 Chromatography of charged [RuCp]+-sandwich complexes on
aminopropyl silica
Despite more than 20 papers on the application of [( η5-Cp)Ru(η6-arene)]+-complexes
to the synthesis of peptide-like diaryl ethers[33, 86], no general protocol yet exists for
the purification of charged ruthenium sandwich complexes by chromatography. Their
limited use in organic synthesis may be the result of their difficult purification and, if
desired, demetalation.
Model compounds have been prepared in order to investigate this problem and find a
reproducible method for the separation and purification of those sandwich complexes
(Scheme 12).
4.3.1. Synthesis of model complexes for the chromatographic study
The model compounds 149, 151[96], 153[97a] and 155 were obtained by treatment of
their respective commercially available arene derivatives 148, 150, 152 and 154 with
[RuCp(NCCH3)3]PF6 in dichloroethane under reflux[93c] (Scheme 12).
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154
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155, 80%
153, 96%
149, 80%
151, 95%
+
Scheme 12: Synthesis of model ruthenium sandwich complexes. a)
[RuCp(NCCH3)3]PF6, 1,2-dichloroethane, reflux, 4 h.
The phenol complex 153[97a] was obtained fro O-trimethylsilylphenol and did not
form a zwitterion[97b], as concluded from FAB+, FAB-MS and elemental analyses.
The [RuCp]+-complexed diaryl ethers 156 and 157 (Figure 18) represent the western
and eastern halves of the bastarane skeleton ( 50). Figure 19 (chapter 4.3.2)
completes the series of sandwich complexes, sorted by increasing polarity, which
has been synthesised and subjected to a detailed chromatographic study [94].
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Figure 18: Bastadin 5 (9) from the marine sponge Ianthella basta and the ruthenium-
complexes 156 and 157 (anion hexafluorophosphate) representing the western and
eastern partial structures.
The synthesis of the [RuCp]+-complexed diaryl ethers 156-160 (Figures 18 and 19,
chapter 4.3.2) is outlined in scheme 13. The appropriate phenolate generated using
KOtBu/[18]crown-6 in THF, was added to the [RuCp] +-complexed chloroarenes 135,
147, 151 and 155 (Scheme 13 and Figure 19)[94].
The commonly used bases for this coupling reaction, Na-2,6-di- tert-butylphenol and
NaH[86], did not give complete diaryl ether formation (TLC analysis). KO tBu in the
presence of [18]crown-6 proved to be much more efficient.
Ru
R5Cl
R4
1) KOtBu, [18]crown-6, THF, 
    -78°C to 20°C, 15 h Ru
R5O
R4
R1
R2 R3
R2 R3
OHR1
2) HPLC: aminopropyl silica+
55-60 %
Scheme 13: Outline of the synthesis of the [RuCp]+-complexed diaryl ethers 156-160
via SNAr reaction (Figure 19), followed by chromatographic purification on
aminopropyl silica.
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4.3.2. Separation of the ruthenium sandwich complexes by HPLC
The idea to investigate aminopropyl-functionalised silica as a stationary phase for a
true chromatography of the inert, positively charged ruthenium sandwich complexes
resulted from the consideration that ionic interactions should be minimal on basic
stationary phases that cannot be deprotonated. It was expected that the free amino
groups would not attack the [RuCp] +-complexes, because the free amine 116 was
observed to be stable (Scheme 9, chapter 4.2.4).
Ru
OCH3
Cl
Ru
Ru
OH
Ru
OCH3Cl
Ru
OCH3
Ru
Cl
NHBoc
Ru
Cl
NHBoc
H3CO2C
O Ru
NHBoc
O Ru
NHBoc
H3CO
Ru
OCH3O
NHBoc
156, 157
158
149
151
153
131
159
160
155
147 135
Figure 19: Ruthenium sandwich complexes 131, 135, 147, 149, 151, 153, 155-160
(anion hexafluorophosphate), grouped by increasing HPLC retention volumes on
aminopropylsilica as stationary phase. The bold and dotted lines indicate separation
using iPrOH-CH3CN (4:1) and (8:1) as mobile phases, respectively.
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Figure 20 gives retention volumes of the diaryl ethers 156, 158, 159, 160, and
chloroarenes 135, 151, 155, as well as of 131, 149 and 153 obtained by preparative
HPLC. Compound 157 has been omitted because it was obtained as a mixture of
diastereomers showing a double-peaked band ( 157 contains a stereogenic center
and a stereogenic plane). In all cases the products were separable from the
respective starting materials. The mobile phase iPrOH-CH3CN (4:1) allowed the
separation (resolution > 1.5) of the less polar (135, 147, 156, 158-160) from the more
polar compounds (131, 149, 151, 153 and 155), as indicated by the bold line in figure
19. The less polar mobile phase iPrOH-CH3CN (8:1) differentiated between the
diarylethers (156, 158-160) and the chloroarenes 135 and 147 (dotted lines in Figure
19). Using pure iPrOH as eluent the diarylethers 156 and 158 were separated fro
159 and 160.
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Figure 20: Preparative HPLC separation of the [RuCp] +-complexed diaryl ethers
(black lines) from the corresponding chloroarenes (blue lines). Retention volumes
(HPLC) are given for different iPrOH-CH3CN mixtures as mobile phases (stationary
phase aminopropyl silica, column length 25  cm, particle size 25-40  	
 
15 mL·min-1).
Even compounds 135, 155 and 158 were separated completely by preparative HPLC
in one injection employing iPrOH-CH3CN (12:1) as the mobile phase (Figure 21).
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Aminopropyl silica appears to act in the normal-phase mode [98] when using iPrOH-
CH3CN mixtures as mobile phases.
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Figure 21: Chromatogram of a mixture of 135, 155 and 158 employing iPrOH-CH3CN
(12:1) as mobile phase (UV-detection at 254  nm, flow rate 15  mL min-1, colum
diameter 25 mm, length 250 mm, 10 mg of each compound).
The new separation protocol also solves earlier reported problems concerning the
removal of [18]crown-6[86f]. Despite the fact that [18]crown-6 and KO tBu gives
complete ruthenium complexed diarylation products, its use was not yet been
extended because of the impossible separation of the ruthenium complexed products
from [18]crown-6[86f]. It is known that the employment of [18]crown-6 and KO tBu as a
base accelerates diaryl ether formation[99]. This could be confirmed in the synthesis
of 156-160. On aminopropyl-functionalised silica, [18]crown-6 elutes later than the
diarylethers 156-160 when toluene-CH3CN (3:1) or iPrOH-CH3CN (18:1) are used as
mobile phases [94]. Furthermore, the frequently observed impurity10
[RuCp(benzene)]PF6 (131, resulting from incomplete formation of the original tris-
                                           
10
 The [RuCp]+-introducing complex [CpRu(NCCH3)3]PF6 is obtained from [CpRu(benzene)]PF6 and
always somewhat contaminated with starting material. See reference [ 94].
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acetonitrile complex, red triangles in figure 20), is effectively removed on the diaryl
ether level using aminopropyl silica.
The HPLC results are directly reflected by the behaviour of the sandwich complexes
on aminopropyl silica TLC plates. The kinetic stability of the complexes can be
estimated by the fact that the characteristic, reddish staining of the rutheniu
complexes on the TLC treated with 1,10-phenanthroline in ethanol only occurs after
intense heating.
Pure crystals of the diaryl ether complex 160 obtained after this chromatographic
study, followed by recrystallisation fro iPrOH-EtOH, have been submitted to X-ray
crystallographic analysis (Figure 22).
Figure 22: Structure of the [RuCp]+-complex 160 in the crystal.
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5 The ABB'A' System
The synthesis of all building blocks required for all later steps has been discussed in
chapter 4.2. Chromatography, as one of the central obstacles in ruthenium mediated
diaryl ether synthesis, has made substantial progress (chapter 4.3). Throughout the
text, compounds composed of amino acid-analogue building blocks are considered
as di-, tri-, or tetrapeptoids. Although the term "oligopeptoid" was originally proposed
for oligomers of N-substituted glycines,[100] the true meaning of the ending "-oid"
stemming from the Old Greek ειδος ("eidos" = picture) justifies the extension to all
compounds representing peptide-like structures. Similar use is made in the literature,
e. g., of the terms "benzoid" or "metaloid".
5.1 Synthesis of an O-benzylated AB system
Reaction of the free amine [RuCp]+-complex 116 to the DOPA derivative 117 was
promoted using N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride
(EDCI) and hydroxybenzotriazol (HOBt) as coupling reagents to give the dipeptoid
complex 114 in 49 % yield. The O-benzylated DOPA analogue 118 was reacted with
the same complexed amine to give the dipeptoid 115 in 60 % yield (Scheme 14).
The use of carbodiimide derivatives is of crucial importance for amide formation. This
class of reagents reacts with the carboxyl group of the acid, thus activating it towards
nucleophilic substitution.[101]
After work-up, the [RuCp]+-dipeptoid complex 114 was purified by preparative HPLC
on aminopropyl silica ( iPrOH:H2O (9:1), flow rate 15  mL·min-1, 17 mg per injection,
Figure 23). The use of aminopropyl silica for the purification of the simple [RuCp] +-
phenol complex 153 is described in chapter 4.3, but the application of this
methodology for the purification of a more functionalised [RuCp] +-phenol complex
has not yet been explored. The result obtained from the preparative HPLC
purification of the [RuCp]+-complexed dipeptoid 114 was one more advance in the
use of this stationary phase. No interaction between the free phenol and the basic
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stationary phase was observed. This behaviour allows further investigation in the
application of aminopropyl silica in complexes possessing acid functionalities.
OCH3
RO
HO2C
BocHN
Ru
Cl
NH2.HCl
PF6-
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NHBoc
O
OCH3
RO
PF6-
+
+
117 R = H 
118 R = Bn
114 R = H, 49%; 
115 R = Bn, 60 %
a
Scheme 14: Synthesis of the AB system. The dipeptoids AB 115 and 114 were
prepared using O-benzylated and O-free phenol, respectively. a) HOBt, EDCI,
iPr2NEt, 0 °C (4 h), r.t., 30-40 h.
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Figure 23: HPLC chromatogram of the purification of the crude dipeptoid 114
employing iPrOH-H2O (9:1) as mobile phase (UV-detection at 254  nm, flow rate
15 mL·min-1, column diameter 25 mm, length 250 mm, 17 mg per injection).
The O-benzylated dipeptoid analogue 115 was purified by column chromatography
on aminopropyl silica ( iPrOH-CH3CN (4:1)) followed by preparative HPLC ( iPrOH-
CH3CN (4:1), Figure 24). Recrystallisation from H 2O (at 80 °C, where iPrOH was
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slowly added until complete solubilisation) gave the pure ruthenium complex as a
colourless powder.
Dipeptoid 114 was prepared in order to investigate its nucleophilic behaviour in the
ruthenium mediated SNAr. Its metal-free analogue 161 was also synthesised with the
purpose of comparing both NMR spectra.
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Figure 24: HPLC chromatogram of the crude O-benzylated dipeptoid 115 employing
iPrOH-CH3CN (4:1) as mobile phase (UV detection at 254  nm, flow rate 12 mL min-1,
column diameter 25 mm, length 250 mm, 10 mg per injection).
The metal-free dipeptoid 161 has been prepared using HOBt and EDCI as coupling
reagents for amide linkages (Scheme 15). Purification by recrystallisation from TMP
was sufficient to give pure colourless crystals in 79 % yield.
OCH3
HO
HO2C
NHBoc
133
NH
NHBoc
O
OCH3
HO
+
a
117 161
Cl
NH2
Cl
Scheme 15: Preparation of the non-complexed dipeptoid 161. a) HOBt, EDCI,
iPr2NEt, 0 °C (4 h), r.t., 26 h, 79 %.
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Comparison of both 1H and 13C NMR spectra of dipeptoids 114 and 161 are shown in
figure 25. The NMR spectra of the complexed dipeptoid 114 demonstrates that
ruthenium generates an electronic field on the chloroarene aromatic ring, shielding
both protons and carbons. The protons show a high field shift of 0.3-1.2  ppm while
the carbon atoms a high field shift up to 40 ppm.
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Figure 25: NMR spectra of the metal-free and -complexed dipeptoids 161 (1H NMR,
250 MHz, CDCl 3; 13C NMR, 60.9 MHz, CDCl3) and 114 (1H NMR, 500 MHz,
[D6]DMSO; 13C NMR, 125 MHz, [D6]DMSO), respectively.
5.2 Synthesis of the A'B' unit
The dipeptoid corresponding to the bastarane A'B' partial structure (Figure 16,
chapter 4.2) was obtained in 59  % yield from the [RuCp]+-complex 109 and
dopamine derivative 112 using the same reaction conditions previously described for
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the preparation of all AB-dipeptoids (Scheme 16). This complex was not intended to
be used in the synthesis of the bastarane skeleton, since its use would require an
additional protection step (Figure 16, chapter 4.1). Nevertheless, the behaviour of
162 in comparison to the AB dipeptoid 114 in diaryl ether formation conditions was
investigated.
Ru
Cl
PF6-
Ru
Cl
PF6-
109
CO2H
NHBoc
+
OCH3
OH
NH2HCl
a
N
HNHBoc
O OCH3
OH
162112
Scheme 16: Preparation of the A'B' unit 162. a) HOBt, EDCI, iPr2NEt, THF:CH3OH
(1:1), 0 °C (4 h), r.t., 26 h, 59 %.
5.3 Alternative approach towards the AB unit using α-thioxo acids
Oxidation of primary amines into their respective oximes can lead to the formation of
nitro and dinitroso compounds as by-products (Scheme 17). The use of reagents like
the sodium salts of tungstic, molybdic or vanadic acid [102], peroxotungstophosphate
(PCWP [103], sodium perborate [104], titanium silicate molecular sieves (TS-1 and TS-
2)[105] and methyltrioxorhenium (MTO)[106] have been investigated as possible
solutions to this problem. The most promising procedure described involves using
MTO[106] in the presence of hydrogen peroxide. This catalyst allows the oxidation of
primary amines to the respective oximes in 70 to 90  % yields under mild reaction
conditions.
R1R2CHNH2  +  H2O2 O R1R2CHNHOH
O
R1R2CHNO
CR1R2HON
R1R2CHNO2
O
N N
O
R1R2CH CHR1R2
O
Scheme 17: General reaction pathways in the oxidation of primary aliphatic amines
with α-hydrogen atoms in presence of a mono-oxygen atom donor.
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α-Thioxo acids can be converted to the corresponding oximes with no by-products in
moderate to high yields using hydroxylamine, base and heat at 70  °C [107]. In a
synthesis of the bastarane macrocycle, the tyrosine units are to be replaced by the
appropriate thioketo acids. After ruthenium demetalation the keto functionalities
would be transformed into oximes.
The synthesis started with the benzylation of 120 from commercially available
isovaniline using standard conditions followed by aldol condensation with rhodanine
(164). Hydrolysis of the benzylidenerhodanine 165 under reflux did not afford the
respective β-phenylthiopyruvic acid 166 tautomer, but 2-mercaptopropenoic acid 167
in 41 % overall yield (Scheme 18) as concluded from the 1H and 13C NMR spectra.
The reaction conditions used for the preparation of this class of compounds afford
the Z-diastereomer[108].
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Scheme 18: Synthesis of the Z-2-mercaptopropenoic acid 167. a) BnBr, K2CO3,
acetone, reflux, 20  h, 74 %; b) AcOH, NaOAc, reflux, 3 h, 92 %; c) i. NaOH (8 %),
reflux, ii. HCl 3N, 0 °C, 30 min, 60 %.
Unfortunately, amide formation using the 2-mercaptopropenoic acid 167 and the
[RuCp]+-complexed 2-(4-chlorophenyl)ethylamine ( 116) did not provide the product
expected for the continuation of this alternative approach (Scheme 19).
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Scheme 19: Reaction of the 2-mercaptopropenoic acid 167 with the [RuCp]+-complex
116 did not afford the desired [RuCp]+-complexed amide 168. a) HOBt, EDCI,
iPr2NEt, THF:CH3OH (1:1), 0 °C (4 h), r.t., 72 h, no reaction.
This reaction was repeated several times using either EDCI or DCC
(dicyclohexylcarbodiimide) as amide coupling agents in large excess, but after
stirring for many days under reflux no amide coupling reaction could be observed;
however, the degradation of the Z-2-mercaptopropenoic acid 167 was detected.
5.4 Nucleophilic reactivity of phenolic hydroxy and aliphatic amino groups
5.4.1. Synthesis of the [RuCp]+complexed tripeptoid ABB' (169)
With the synthesis of [RuCp] +-complexed AB units 114 and 115 completed,
accompanied by a developed purification methodology it was possible to continue
synthesis of the bastarane skeleton.
The reaction of both the OBn-protected and unprotected, complexed amides 115
resp. 114 with N-Boc-4-O-methyldopamine ( 119) were tested using
KOtBu/[18]crown-6 as a base (Scheme 20). The unprotected amide 114 did not yield
any ABB' product, despite the use of excess of external nucleophile. The NMR
spectra of the isolated reaction mixture could not be analysed because of many
overlapping chemical shifts. Separation of the products was also impossible. TLC
analysis on aminopropyl silica of the products also failed, as they did not move fro
the origin after employing several different mobile phase systems. These
observations indicate that the competition by intermolecular condensation is
overwhelming in this reaction. Intramolecular cyclisation products could not be
observed.
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In contrast, nucleophilic aromatic substitution proceeded smoothly in the case of the
OBn-protected amide 115. Reaction with the Boc-protected dopamine 119 provided
the [RuCp]+-complexed diaryl ether amide ABB' ( 169) in 87 % yield after purification
by column chromatography on aminopropyl silica ( iPrOH-CH3CN (4:1)) and by
preparative HPLC (aminopropyl silica, iPrOH:CH3CN (4:1), Figure 26). The formation
of the diaryl ether linkage can be concluded from the downfield effect in the 13C NMR
spectrum from 105.62 ppm (-CarCl, dipeptoid 115) to 132.57 ppm (169, -CarOPh).
Purification of this more complex system bearing one diaryl ether and one amide
function was a new advance in the application of aminopropyl silica.
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Scheme 20: Formation of the tripeptoid ABB' 169 using both ruthenium-complexed
dipeptoids 114 and 115. The non-protected amide-complex did not give the desired
ABB' product. a) KO tBu, [18]crown-6, THF:CH3CN (1:1), -78 °C (1 h), r.t. 16  h, no
product; b) KOtBu, [18]crown-6, THF, -78 °C (1 h), r.t., 16 h, 87 %.
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Figure 26: HPLC chromatogram of the purification of the crude tripeptoid 169
employing iPrOH-CH3CN (4:1) as mobile phase (UV-detection at 254  nm, flow rate
15 mL·min-1, column diameter 25 mm, length 250 mm, 10 mg per injection).
The next step concerned the introduction of the fourth unit, A', into the tripeptoid ABB'
169, by amide formation.
Upon treatment of the ABB' tripeptoid 169 with 4N HCl, both Boc groups were
cleaved off and the [RuCp]+-complexed tripeptoid 170 possessing both a free amine
and a free amino acid moiety was obtained (Scheme 21). For the first time, a
[RuCp]+-complex possessing these free functions was prepared.
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Scheme 21: Cleavage of the Boc-protecting groups off the complexed tripeptoid 170.
5.4.2. Ambident nucleophiles in the ruthenium mediated SNAr reaction
Ruthenium mediated S NAr reaction of various nucleophiles is well
characterised[33e, 109]. Substitution products were obtained even using
malonate[33e, 85a]. However, those studies did not reveal how compounds possessing
different nucleophiles would behave upon reaction with a chloroarene complex.
Since the [RuCp]+-complexed tripeptoid 170 could not be used in the continuance of
this strategy, the next question was whether an ambidental nucleophile, i.e.
possessing a free amine and a free phenol, would exclusively promote the formation
of the diaryl ether product. A model reaction utilising the commercially available
unprotected tyramine ( 171) with [RuCp]+-complexed o-chloroanisol (155)[94] was
performed. The [RuCp]+-complexed diaryl ether 172 was formed in 81  % yield
without concomitant formation of any by-product (Scheme 22). The product was
purified by column chromatography on aminopropyl silica with CH 3CN to remove
[18]crown-6 and with iPrOH:H2O (6:1), followed by recrystallisation fro iPrOH.
The 13C NMR signals of the aromatic part of the diaryl ethers 159 and 172 are
presented in figure 27. The comparison of the 13C NMR chemical shifts of the
aromatic carbons of the N-free diaryl ether to those of its N-Boc analogue shows that
the chemical shift of δ 125.67 ppm is indicative of the successful diaryl ether bond
formation.
The 1H,15N-HMBC spectrum of 172 did not show any correlation between the
nitrogen and the aromatic hydrogen atoms. This positive result encouraged the
continuation of the chosen strategy.
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Scheme 22: Model reaction involving a molecule containing a free amine and a free
phenol as nucleophiles. a) KO tBu, [18]crown-6, THF:CH3CN (1:1), -78 °C (1 h), r.t.
16 h, 81 %.
172 159
δ 125.67 pp
η-CarOPh
δ 123.75 pp
η-CarOPh
Figure 27: 13C NMR spectra of the diaryl ether complexes 172 (13C NMR, 125 MHz,
CD3OD) and 159 (13C NMR, 125 MHz, CDCl 3). The signal at δ 125.67 reveals the
formation of a diaryl ether linkage.
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5.5 Formation of an open-chain ABB'A' system
As envisaged from the model reaction discussed above, the diaryl ether amide 111
could be prepared in 64  % yield from the dipeptoid 115 and N-free dopamine 112
(Scheme 23). The same procedure was employed using the dipeptoid 115 and the
commercially available N-free tyramine ( 171). The respective tripeptoid 174 was
obtained in 79 % yield (Scheme 23). The diaryl ether substitution product again could
be confirmed by comparison of the 13C NMR spectra of 111 (δ 134.31 ppm, η-
CarOPh) with the spectra of its Boc-analogue 169 (δ 132.57 ppm, η-CarOPh). The 13C
NMR spectra of 174 also revealed diaryl ether formation due to the chemical shift of δ
131.28 ppm.
Compound 115 is the first [RuCp]+-complexed amide which was subjected to a
ruthenium mediated diaryl ether coupling with an ambidental nucleophile. The
selective diaryl ether formation with either 1,2-substituted ( 155) or 1,4-substituted
(115) chloroarene complexes and m- (112) or p-phenolates (171) indicates that this
selective behaviour does not depend on the substitution pattern of both ([RuCp] +-
complexed chloroarene and phenolate) aromatic systems.
The preparation of the [RuCp]+-complexed tripeptoids 111, 169 and 174 was a
further advance in ruthenium arene chemistry. For the first time [RuCp]+-complexes
were carried through more than one reaction step, and further, the resulting tripeptoid
complexes could be isolated, purified and completely characterised.
These results are also of great interest to bioorganic chemistry studies when
rutheniu π arene complexes are used in labelling of amino acids and peptides.
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Scheme 23: a) KO tBu, [18]crown-6, THF:CH3CN (1:1), -78 °C (1 h), r.t. 16  h; b)
HOBt, EDCI, iPr2NEt, THF:CH3OH (1:1), 0 °C (4 h), r.t., 26 h, 38 %.
An ambitious experiment was the introduction of the fourth unit, the [RuCp] +-
chorophenylalanine complex 109, into the tripeptoid 111. The amide coupling was
indeed achieved by treating the chlorophenylalanine complex ( 109) with EDCI and
HOBt (Scheme 23, Figure 28). Analysis of the FABMS (Figure 28) and HRFABMS
spectra of the product revealed the formation of the open-chain ABB'A' system of the
bastarane skeleton. The low yield obtained (38  %) can be attributed to the difficult
work-up and purification of the twice [RuCp] +-complexed tetrapeptide 175. The
purification of this system represents a new challenge to the application of
aminopropyl-functionalised silica.
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Figure 28: FABMS spectra of the open-chain ABB'A' system. The isotope pattern of
the [M+] ion (m/z 1420 to 1436) indicates the formation of this tetrapeptoid bis-
ruthenium complex 175.
The feasibility to form the tetrapeptoid bis-ruthenium complex 175 shows that the
demetalation is not required after diaryl ether coupling and that the reaction between
two [RuCp]+-complexes is possible. These results extend the use of the rutheniu
arene chemistry to natural products which have more than one diaryl ether moiety in
different aromatic rings (e. g. bastadins).
The purification of this bis-ruthenium complex ( 175) has not yet been completed.
However, due to the positive results in separation and purification on aminopropyl
silica stationary phase, it is likely that compound 175 can also be purified via this
technique.
Theoretical Section 59
___________________________________________________________________
6 Summary
The bastadins (9: bastadin 5) have been isolated as natural products from the marine
sponge Ianthella basta  since 1981 [29]. Characteristically, the two tyrosine and two
tyramine units of these tetrapeptoid macrocycles are linked via two diaryl ether
bridges and two amide bonds. The diaryl ether moiety is present in clinically
important peptoids, such as the antibiotic vancomycin, and may serve as a key
structural motif for medicinal application of peptide-like molecules.
The synthesis of ruthenium-labelled peptoids explored in this thesis makes use of the
nucleophilic attack of phenolates on [RuCp] +-complexed chloroarenes to form diaryl
ethers in the preparation of metal-labelled bastadin model compounds. The full
purification and characterisation of [RuCp] +-labelled peptoids has not, until now, been
systematically studied. Earlier work described the cleavage of metal to produce
metal-free products[85, 86]. Despite the attractive properties of ruthenium radioisotopes
(long half-lives, stability and non-toxic) for diagnostic medicine, applications of the air
and water-stable [RuCp]+-labelled amino acids and more advanced peptides are still
very limited.
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Figure 29: [RuCp]+-complexes for the chromatography study using aminopropyl-
functionalised silica as stationary phase.
Theoretical Section 60
___________________________________________________________________
A protocol has been developed to ease the purification problems with [RuCp] +-
complexes. The first analyses were performed with the simple model compounds
131, 135, 147, 149, 151, 153, 155, with three model diaryl ether complexes 158-160
(Figure 29) and finally with the two [RuCp]+-complexed diaryl ethers which represent
the western 156 and eastern 157 halves of the bastarane skeleton (Figure 30).
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Figure 30: Western (156) and eastern (157) halves of the bastarane skeleton.
For the first time, aminopropyl functionalised silica was employed as stationary phase
for the purification and separation of [RuCp] +-complexes from each other, using
gradients of iPrOH-CH3CN as mobile phase. The purification of the [RuCp] +-
complexes also solved other problems which existed in the ruthenium mediated
SNAr: reaction monitoring by TLCs (selectively staining ruthenium-complexes by
heating with 1,10-phenanthroline) and removal of 18-crown-6 used for the diaryl
ether formation[86f]. These results enabled continuation of the strategy for synthesis of
the bastarane skeleton.
The preparation of the northern ( 114 and 115) and southern (162) hemispheres of
the bastarane skeleton (Scheme 24) was an additional step towards the synthesis of
the bastarane skeleton. The purification of the OH-free dipeptide 114 (northern
hemisphere) on aminopropyl silica was successful. This result showed that the
aminopropyl silica is also appropriate for more complex structures bearing an acidic
moiety.
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Scheme 24: Synthesis of the northern ( 114 and 115) and southern ( 162) halves of
the bastarane skeleton.
The introduction of the third unit was only possible when the OBn-protected
dipeptoide 115 was used. The unprotected dipeptoide 114 gave a probable mixture
of intermolecular condensation products which could neither be separated nor
characterised.
The behaviour of ambident nucleophiles simultaneously possessing free amine and
free phenol functionalities has also been investigated in the ruthenium mediated
synthesis of diaryl ethers. The results clearly revealed the preference for the phenol
but not for the amine as a nucleophile.
This information encouraged the continuation of the strategy with the synthesis of the
tripeptoides 111 and 174 (Scheme 25). The [RuCp]+-complexed tripeptoides ( 111
and 174) could also be purified on aminopropyl silica and were thoroughly
characterised.
The tripeptoides 111 and 174 are the first [RuCp]+-complexes possessing one amide
linked by ruthenium mediated SNAr to a free amine. Furthermore, the preparation of
these two complexes extended the use of the ruthenium arene chemistry to an
additional reaction step. Normally, the ruthenium complexes are submitted to photo-
demetallation directly after the diaryl ether coupling reaction step and the [RuCp] +-
complex formed is not isolated from the reaction mixture.
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The synthesis of the open-chain bis-[RuCp]+-complexed ABB'A' system was also
achieved (Scheme 25) as indicated by high resolution mass spectra. The purification
of this product, as well as its macrocyclisation, are challenges that still remain
unsolved.
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Scheme 25: Synthesis of the [RuCp]+-complexed tripeptides 111 and 174 of the
open-chain bis-[RuCp]+-complexed ABB'A' system.
This thesis brought important progress to ruthenium arene chemistry, mainly through:
I) employment of a base which promotes complete diaryl ether formation; II)
monitoring of the reactions with TLC; III) use of the [RuCp] +-complexes in more than
one reaction step, thus extending the use of this methodology to include more
complex natural products’ syntheses and IV) preparation of [RuCp]+-complexes as
metal-labelled peptoids. The results of this thesis may now enable us and other
research groups to further explore and promote ruthenium arene chemistry.
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II Experimental Section
1 General
All reactions were carried out under an argon atmosphere with distilled, non-
anhydrous solvents. Yields refer to purified compounds. Reagents were purchased
from Aldrich, Acros, Alfa, and Fluka at high commercial quality and were used
without further purification. Reactions were controlled by thin-layer chromatography
[0.25 mm E. Merck alumina plates NH 2 F254S (for reactions involving rutheniu
sandwich complexes) and 0.25 mm E. Merck alumina plates Si F 254S]. TLCs were
analysed under UV light (λ = 254 nm), followed by heating after treatment with 1,10-
phenanthroline (dipping solution in EtOH) for ruthenium sandwich complexes and
with ninhydrine for amines and amino acids. A Hereaus TQ 150 mercury mediu
pressure lamp, 150 W, was used for the irradiation of the ruthenium complexes. E.
Merck Al2O3  	
 

 	  	
 
    	 
aminopropyl silica LiChroprep NH2 	
 
     
 	 
	
(particle size 230-400 mesh) were used for preparative column chromatography.
HPLC
The HPLC experiments were performed at 25  °C using a Merck-Hitachi L6200A
Intelligent Pump System. The column was a preparative E. Merck Hibar Pre-Packed
Column RT 250-25, customised packing LiChroprep NH 2 (length 25 cm, diameter
2.5  	
 	   3CN, H2O and iPrOH were HPLC-grade. The
detector used was a KONTRON ultraviolet spectrophotometer Uvitron 730S LC and
the integrator was a Merck-Hitachi D-2500 Chromato-Integrator. The peaks were
detected at λ = 254 nm, each injection contained 10 mg of sample.
Melting Point
Melting points were determined with a Reichert melting point microscope and are
uncorrected.
UV/VIS
The UV/VIS-spectra were recorded using a Hewlett-Packard UV-Spectrophotometer
HP 8452 Diode Array System.
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IR Spectra
All infrared spectra were recorded on a Perkin Elmer 1600 series FT-IR
spectrometer.
NMR Spectra
NMR spectra were recorded on Bruker WM 250, AM 360, and AM 500 and on Varian
INOVA-400 spectrometers. The NMR shifts were calibrated using TMS as internal
reference and assigned on the basis of HSQC and HMBC experiments. The
multiplicities are: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet and br =
broad.
Mass Spectra
Fast atom bombardment (FAB) mass spectra were recorded on a JEOL JMS-700
mass spectrometer. Only the three predominant isotopes are listed. EIMS were
recorded on a Varian MAT-311 mass spectrometer.
Elemental Analyses
Elemental analyses were performed at the automatic microanalysator Foss-Heraeus
Vario EL.
X-Ray Analysis
X-ray structural analysis of 160 was performed at a Nonius MACH 3 4-Circle-
diffractometer (graphite-monochromated Mo-Kα radiation (λ = 0.71073 Å)).
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2 Synthesis of the tris(acetonitrile)(η5-cyclopentadienyl)
ruthenium hexafluorophosphate (132)
2.1 Bis-{(η6-Benzene)-dichloro-ruthenium}
 
(129)[93a]
Ru
Cl
Cl
Cl
Ru
Cl
1,3-Cyclohexadiene (6.8 mL; 72 mmol) is added to a pre-heated solution (50  °C) of
RuCl3 • 3 H2O (1.880 g; 7.2 mmol) in 110 mL 90  % aqueous EtOH. The solution is
heated at 90  °C for 3 hours. The resulting red precipitate is collected, washed with
cold EtOH and dried in vacuum.
Yield:
 1.774 g (95 %)
Melting Point.: up 245 °C starts decomposition without melting
1H NMR
 (250 MHz, [D6]DMSO) δ     Har).
13C NMR
 (90.6 MHz, [D6]DMSO) δ   CarH).
IR (KBr): ν~
 
(cm-1) 3448 (m), 3037 (m), 1432 (s), 1149 (w), 976 (w), 844 (s), 617 (w).
MS (FAB+, NBA): m/z (%) 500/501/502 (93/90/100) [M+].
Elemental Analysis: C12H12Cl4Ru2 (500.178)
Calculated: C: 28.82  H: 2.42
Found:        C: 29.21  H: 2.68
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2.2 (η6-Benzene)(η5-cyclopentadienyl)rutheniumchloride (130)[93b]
Ru
+
Cl-
Thallium cyclopentadienide (1.736 g; 12.9 mmol) is added to a solution of bis-{( η6-
benzene)dichloro-ruthenium} (129) (3.33 g; 6.449 mmol) in 1166 mL CH 3CN to give,
after 1 hour a precipitate of thallium chloride. The precipitate is filtered and the
solvent is removed under vacuum. Residue is recrystallised from CH3CN-Et2O to give
a pale brown powder.
Yield:
 2.525 g (70 %)
Melting Point.: up 160 °C starts decomposition without melting
1H NMR
 (360 MHz, CDCl3) δ      Har), 5.54 (s, 5H,.Cp).
13C NMR
 (90.6 MHz, CDCl3) δ    CarH), 80.81 (Cp).
MS (FAB+, NBA): m/z (%) 244/245/247 (60/100/61) [M+].
2.3 (η6-Benzene)(η5-cyclopentadienyl)ruthenium hexafluorophosphate
(131)[93c]
Ru
+
PF6-
(η6-Benzene)(η5-cyclopentadienyl)rutheniumchloride ( 130) (1155 mg; 4.13 mmol) is
dissolved in H2O and filtered. To the filtrate is added ammoniu
hexafluorophosphate (685 mg; 4.2 mmol) and immediately ( η6-benzene)(η5-
cyclopentadienyl)ruthenium hexafluorophosphate ( 131) precipitates. After 1 hour,
under stirring, the product is collected as a pale brown powder. The impurities are
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removed by dissolving the product in acetone and eluting it through a neutral alumina
column (acetone). The product is recrystallised fro iPrOH yielding light yellow
needles.
Yield:
 1137 mg (68 %)
TLC
 (NH2-Si, CH3CN): Rf = 0.81
HPLC
 
retention volumes: 104 mL (CH 3CN), 105 mL ( iPrOH-CH3CN – (1:1)), 110
mL (iPrOH-CH3CN – (2:1)), 125 mL (iPrOH-CH3CN – (4:1)), 140 mL ( iPrOH-CH3CN –
(8:1)), 168 mL (iPrOH-CH3CN – (12:1)), 179 mL (iPrOH-CH3CN – (18:1)).
Melting Point: up 280 °C starts decomposition
1H NMR
 (360 MHz, [D6]acetone) δ      Har), 5.54 (s, 5H, Cp).
13C NMR
 (90.6 MHz, CD3OD) δ   CarH), 81.46 (Cp).
UV/Vis (CH3OH): λmax (ε) = 264 (630), 222 nm (1900 mol-1dm3cm-1); (CH2Cl2): λmax
(ε) = 316 (240), 230 nm (2100 mol-1dm3cm-1).
MS (FAB+, NBA): m/z (%) 244/245/247 (55/100/56) [M+].
Elemental Analysis: C11H11F6PRu (389.2421)
Calculated: C: 33.94  H: 2.85
Found:        C: 33.77  H: 2.99
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2.4 tris-(Acetonitrile)(η5-cyclopentadienyl)ruthenium hexafluorophosphate
(132)[93c]
+
PF6-
Ru
H3CCN
NCCH3
NCCH3
(η6-Benzene)(η5-cyclopentadienyl)ruthenium hexafluorophosphate ( 131) (600 mg,
1.5 mmol) is dissolved in dry CH 3CN (100 mL) and is transferred to a quartz
waterjacket of an inversion medium pressure mercury UV-lamp. The jacket is
stoppered and the solution is degassed by bubbling with argon for 30 min. The stirred
solution is irradiated with the output of a 150 W mercury medium pressure lamp for 8
hours under argon at room temperature. After irradiation, the solution is kept under
refrigeration for the next step.
Yield: 651 mg (quant., yellow needles)
1H NMR
 (250 MHz, CD3CN) δ = 4.28 (s, 5H, Cp), 2.84 (s, 9H, CH3CN).
13C NMR
 (90.6 MHz, CD3CN) δ   !CCH3), 69.67 (Cp), 67.41 (NCCD3).
Obs.: The instability of the product did not allow further structure analysis.
3 General procedure for the preparation of the ruthenium
sandwich complexes:
At 70 °C, [RuCp(NCCH3)3]PF6 (132)[93] (concentrated from a CH 3CN solution
immediately prior to use) is added to a solution of the respective chlorobenzene
derivative (1 eq.) in 1,2-dichloroethane (20 mL) and the reaction mixture is refluxed
for 4 hours.
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3.1 [1-{2-(tert-Butoxycarbonylamino)ethyl}-4-chloro-η6-benzene](η5-cyclo-
pentadienyl)ruthenium hexafluorophosphate (135)[94]
3.1.1. [2-(4-Chloro-phenyl)ethyl]-carbamic acid tert-butyl ester (134)
Cl
NH
O
O
Boc2O (3.838 g, 17.6 mmol) is added to a solution containing 2-(4-chloro-
phenyl)ethylamine (133) (2.22 mL, 16 mmol) in CH 2Cl2. After stirring for 4 hours at
room temperature the solvent is removed and the product is recrystallised fro
nheptane affording colourless needles.
Yield:
 4.008 g (98 %)
TLC
 (Si, TMP-EtOAc (8:2)): Rf = 0.58
Melting Point : 66-68 °C
1H NMR
 (250 MHz, CDCl 3): δ = 7.26 (d, J = 8.5 Hz, 2H, CHar), 7.11 (d, J = 8.4 Hz,
2H, CHar), 4.57 (brs, 1H, CH2NH), 3.33 (t, J = 6.8 Hz, 2H, CH2NH), 2.76 (t, J = 7.0
Hz, 2H, CH2CH2NH), 1.43 (s, 9H, OC(CH3)3).
13C NMR
 (62.9 MHz; CDCl3): δ = 155.78 ( C=O), 137.46 ( CarCl), 132.18 ( CarCH2),
130.09 (CarH), 128.61 (CarH), 79.28 (OC(CH3)3), 41.64 (CH2NH), 35.59 (CH2CH2NH),
28.33 (OC(CH3)3).
IR (KBr): ν~
 
(cm-1) 3315 (s), 3039 (m), 2981 (s), 2931 (m), 1899 (w), 1694 (s), 1538
(m), 1489 (s), 1446 (m), 1408 (m), 1365 (s), 1283 (s), 1248 (s), 1166 (s), 1086 (s),
1052 (s), 1016 (s), 973 (s), 812 (s), 664 (s), 643 (s).
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UV/Vis  (CH3OH):  λmax  (ε) = 276  (840),  268 (890),  222  (7950),  204 n
(6100 mol-1dm3cm-1).
MS (EI, 70 eV): m/z (%) 255 (4) [M+], 199 (76) [M-C4H8+], 138 (74) [M-C5H11NO2+], 57
(100).
Elemental Analysis: C13H18ClNO2 (255.74)
Calculated: C: 61.05  H: 7.09  N: 5.48
Found:        C: 60.80  H: 6.84  N: 5.26
3.1.2. [1-{2-(tert-Butoxycarbonylamino)ethyl}-4-chloro-η6-benzene](η5-cyclo-
pentadienyl)ruthenium hexafluorophosphate
 
(135)[94]
Ru
+
PF6-
Cl
NH
O
O
Prepared from [2-(4-chloro-phenyl)-ethyl]-carbamic acid tert-butyl ester ( 134)
(1100 mg, 2.4 mmol). After solvent concentration, the residue is dissolved in CH 3CN
and is pre-purified by column filtration (alumina, CH 3CN). The product is purified by
column chromatography on aminopropyl silica ( iPrOH) and is finally recrystallised
from iPrOH giving colourless needles.
Yield:
 910 mg (65 %)
TLC
 (NH2-Si, iPrOH): Rf = 0.46
HPLC
 
retention volumes: 103 mL (CH 3CN), 95 mL ( iPrOH-CH3CN (1:1)), 95 mL
(iPrOH-CH3CN (2:1)), 97 mL ( iPrOH-CH3CN (4:1)), 123 mL ( iPrOH-CH3CN (8:1)),
132 mL (iPrOH-CH3CN (12:1)), 141 mL (iPrOH-CH3CN (18:1)), 230 mL (iPrOH).
Melting Point : 127 °C (decomposes)
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1H NMR
 (360 MHz, CDCl3): δ = 6.47 (d,  J     Har), 6.31 (d, J = 6.3 Hz,
 Har), 5.47 (s, 5H, Cp), 5.20 (brt, 1H, CH 2NH), 3.37 (dt, J = 6.7 Hz, 2H,
CH2NH), 2.73 (t, J = 6.7 Hz, 2H, CH2CH2NH), 1.39 (s, 9H, OC(CH3)3).
13C NMR
 (90.6 MHz; CDCl3): δ = 156.10 (C"  Car
   CarCH2),
 Car  CarH), 82.74 (Cp), 79.60 (OC(CH3)3), 40.80 (CH2NH), 33.90
(CH2CH2NH), 28.32 (OC(CH3)3).
IR (KBr): ν~
 
(cm-1) 3369 (s), 3125 (m), 3096 (w), 2987 (m), 2937 (m), 1684 (s), 1524
(s), 1453 (s), 1369 (m), 1281 (s), 1251 (m), 1176 (s), 1094 (m), 839 (s).
UV/Vis (CH3CN): λmax (ε) = 224 (11000), 200 nm (46000 mol-1dm3cm-1).
MS (FAB+, NBA): m/z (%) 421/422/424 (61/100/78) [M+].
HRMS (FAB): calcd. for C18H2335ClO2N 102Ru [M+]: 422.0463, found 422.0449.
Elemental Analysis: C18H23ClF6NO2PRu (566.87)
Calculated: C: 38.14  H: 4.09  N: 2.47
Found:        C: 37.86  H: 4.30  N: 2.27
3.2 [1-{2-(tert-Butoxycarbonylamino)-2-(carboxy)ethyl}-4-chloro-η6-
benzene](η5-cyclopentadienyl)ruthenium hexafluorophosphate (109)[85b]
3.2.1. 2-tert-Butoxycarbonylamino-3-(4-chloro-phenyl)-propionic acid (145)
Cl
NH O
O
CO2H
Et3N (3.2 ml, 22.8 mmol) is added to a solution of ,-4-chloro-phenylalanine (144)
(3.034 g, 15.2 mmol) in CH3OH-H2O (1:1) (55 mL). The reaction is cooled to 0 °C and
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Boc2O (3.635 g, 17.2 mmol) is added. After 30 min the cold bath is removed and the
mixture is allowed to stir for further 42 hours at room temperature. The mixture is
concentrated and the residue is dissolved in H 2O-EtOAc (1:1). The organic layer is
ignored and the aqueous phase is brought to pH 1 with HCl 1N and is back extracted
with EtOAc. The organic extracts are washed with brine and dried over Na 2SO4. The
solvent is removed and the product is recrystallised from petroleum ether yielding
colourless needles.
Yield: 2.921 g (64 %)
TLC (Si, EtOAc-TMP (7:3)): Rf = 0.64
Melting Point : 149-150 °C
1H NMR (250 MHz, CD3OD): δ = 7.26 (d, J = 8.5 Hz, 2H, CHar), 7.20 (d, J = 8.5 Hz,
2H, CHar), 4.33 (dd, J = 5.4, 8.9 Hz, 1H, CH2CH(CO)NH), 3.15 (dd, J = 5.1, 14.0 Hz,
1H, CHHCH(CO)NH), 2.88 (dd, J = 9.3, 14.1 Hz, 1H, CHHCH(CO)NH), 1.37 (s, 9H,
OC(CH3)3).
13C NMR (62.9 MHz; CD 3OD): δ = 175.11 ( C=O), 157.74 ( C=O), 137.56 ( CarCl),
133.63 ( CarCH2), 132.00 ( CarH), 129.43 ( CarH), 80.60 (O C(CH3)3), 56.12
(CH2CH(CO)NH), 38.14 (CH2CH(CO)NH), 28.68 (OC(CH3)3).
IR (KBr): ν~
 
(cm-1) 3372 (m), 2986 (m), 1708 (s), 1691 (s), 1527 (s), 1491 (w), 1450
(w), 1424 (w), 1367 (w), 1320 (m), 1307 (m), 1269 (m), 1239 (m), 1170 (s), 1056 (m),
1033 (w), 936 (w), 810 (w), 777 (w), 735 (w), 641 (w), 567 (w).
UV/Vis (CH3OH): λmax (ε) = 276 (1500), 222 (11800), 204 nm (11400 mol-1dm3cm-1).
EI (EI, 70 eV): m/z (%): 299 (1) [M +], 243 (11) [M +-C4H4], 182 (67) [M+-C5H11NO2],
125 (26) [M+-C7H12NO4], 57 (100).
Elemental Analysis: C14H18ClNO4 (299.75)
Calculated: C: 56.10  H: 6.05  N: 4.67
Found:        C: 55.68  H: 6.10  N: 4.54
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3.2.2. [1-{2-(tert-Butoxycarbonylamino)-2-(carboxy)ethyl}-4-chloro-η6-
benzene](η5-cyclopentadienyl)ruthenium hexafluorophosphate (109)[85b]
Ru
+
PF6-Cl
CO2H
NH O
O
Prepared from 2-tert-butoxycarbonylamino-3-(4-chloro-phenyl)-propionic acid ( 145)
(596 mg, 1.985 mmol). After solvent concentration, the residue is dissolved in 2 mL
CH3OH-CH2Cl2 (1:1) and 50 mL Et2O is added to promote product precipitation. The
pale brown powder is collected and is purified by column chromatography on
aminopropyl silica (iPrOH-H2O (6:1) to (4:1)) giving a pale brown powder.
Yield: 880 mg (85 %)
TLC (NH2-Si, iPrOH-H2O (6:1)): Rf = 0.53.
1H NMR (250 MHz, CD 3OD): δ = 6.69 (dd, J    	
 	 Har), 6.39 (d, J =
 	
 	 Har), 6.30 (d, J   	
 	 Har), 5.52 (s, 5H, Cp), 4.35 (bq, 1H,
CH2CH(CO)NH), 3.07 (dd, J = 6.9, 13.8 Hz, 1H, CHHCH(CO)NH), 2.75 (dd, J = 8.3,
13.8 Hz, 1H, CHHCH(CO)NH), 1.40 (s, 9H, OC(CH3)3).
13C NMR (90.6 MHz; CD 3OD): δ = 173.55 ( C=O), 157.78 ( C  CarCl),
 CarCH2  Car	  Car	  Car	  CarH),
83.98 (Cp), 81.11 (O C(CH3)3), 55.60 (CH 2CH(CO)NH), 37.28 ( CH2CH(CO)NH),
28.67 (OC(CH3)3).
IR (KBr): ν~
 
(cm-1) 3415 (s), 3065 (m), 2963 (m), 2924 (m), 1701 (s), 1617 (s) 1454
(m), 1384 (m), 1366 (m), 1249 (w), 1166 (m), 1087 (m), 1053 (m), 1024 (w), 854 (w).
UV/Vis (CH3OH): λmax (ε) = 266 (5500), 206 nm (30700 mol-1dm3cm-1).
MS (FAB+, NBA): m/z (%) 465/466/468 (61/100/77) [M+].
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3.3 [1-{2-N-(tert-Butoxycarbonylamino)-2-(methoxycarbonyl)ethyl}-4-chloro-
η6-benzene](η5-cyclopentadienyl)ruthenium hexafluorophosphate
(147)[85b]
3.3.1. 2-tert-Butoxycarbonylamino-3-(4-chloro-phenyl)-propionic acid methyl
ester (146)
Cl
HN
CO2CH3
O
O
2-tert-Butoxycarbonylamino-3-(4-chloro-phenyl)-propionic acid  (145) (581 mg,
1.94 mmol) is dissolved in dry CH 2Cl2 and DCC (440 mg, 2.13 mmol), CH 3OH
(0.86 mL, 2.13 mmol) and 4-pyrrolidine-pyridine (29 mg, 0.194 mmol) are added. The
reaction is allowed to stir at room temperature for 24 hours and then the DCC-urea
formed is filtered. The organic layer is washed well with saturated aqueous solution
of NaHCO3 and with H2O and is finally dried over Na 2SO4. The solvent is removed
and the product is purified by flash chromatography on silica gel (TMP-EtOAc (7:3))
affording colourless needles.
Yield: 427 mg (85 %)
TLC (Si, TMP-EtOAc (7:3)): Rf = 0.70
Meting Point : 78 °C
1H NMR (250 MHz, CDCl 3): δ = 7.26 (d, J = 8.4 Hz, 2H, CHar), 7.06 (d, J = 8.3 Hz,
2H, CHar), 5.90 (d, J = 9.4 Hz, 1H, NH), 4.57 (q, J = 7.0 Hz, 1H, CH2CH(CO)NH),
3.71 (s, 3H, CO2CH3), 3.09 (dd, J = 5.8, 13.8 Hz, 1H, CHHCH(CO)NH), 3.00 (dd, J =
5.9, 14.0 Hz, 1H, CHHCH(CO)NH), 1.53 (s, 9H, OC(CH3)3).
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13C NMR (90.6 MHz; CDCl3): δ = 172.09 ( C=O), 155.02 ( C=O), 134.58 ( CarCl),
132.98 ( CarCH2), 130.66 ( CarH), 128.69 ( CarH), 80.09 (O C(CH3)3), 54.30
(CH2CH(CO)NH), 52.31 (CO2CH3), 37.79 (CH2CH(CO)NH), 28.28 (OC(CH3)3).
IR (KBr): ν~
 
(cm-1) 3356 (s), 2994 (m), 2952 (m), 1735 (s), 1679 (s), 1524 (s), 1494
(m), 1437 (m), 1407 (w), 1370 (m), 1351 (s), 1297 (s), 1274 (s), 1230 (s), 1167 (s),
1091 (m), 1056 (m), 1014 (s), 971 (m), 935 (w), 860 (w), 834 (w), 809 (m), 735 (w),
613 (m), 519 (m), 415 (m).
UV/Vis (CH3OH): λmax (ε) = 276 (3350), 222 (24500), 204 nm (17000 mol-1dm3cm-1).
MS (EI, 70 eV): m/z (%) 313 (1) [M+], 257 (41) [M+-C4H8], 240 (32) [M+-C4H9O], 212
(10) [M+-C5H9O2], 196 (45) [M+-C5H9O2-NH2].
Elemental Analysis: C15H20ClNO4 (313.78)
Calculated: C: 57.42  H: 6.42  N: 4.46
Found:        C: 57.68  H: 6.42  N: 4.21
3.3.2. [1-{2-(tert-Butoxycarbonylamino)-2-(methoxycarbonyl)ethyl}-4-chloro-
η6-benzene](η5-cyclopentadienyl)ruthenium hexafluorophosphate
(147)[85b]
Ru
+
PF6-Cl
CO2CH3
NH O
O
Prepared from 2-tert-butoxycarbonylamino-3-(4-chloro-phenyl)-propionic acid methyl
ester (146) (502 mg, 1.60 mmol). After solvent concentration, the residue is dissolved
in CH3CN and is pre-purified by column filtration on alumina (CH 3CN). The product is
purified by column chromatography on aminopropyl silica ( iPrOH) and is
recrystallised fro iPrOH giving a colourless powder.
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Yield: 780 mg (78 %)
TLC (NH2-Si, iPrOH): Rf = 0.43
HPLC retention volumes: 102 mL (CH3CN), 98 mL ( iPrOH-CH3CN – (1:1)), 98 mL
(iPrOH -CH3CN – (2:1)), 98 mL ( iPrOH -CH3CN – (4:1)), 119 mL ( iPrOH -CH3CN –
(8:1)), 127 mL ( iPrOH -CH3CN – (12:1)), 136 mL ( iPrOH -CH3CN – (18:1)), 236 mL
(iPrOH).
Meting Point : 70-71 °C (decomposes)
1H NMR (250 MHz, CDCl 3): δ = 6.57 (t, J   	
 	 Har), 6.31 (t, J = 6.3 Hz,
	 Har), 5.50 (s, 5H, Cp), 5.43 (d,  J = 4.3 Hz, 1H, CH2NH), 4.47 (m, 1H,
CH2CH(CO)NH), 3.09 (dd, J = 6.5, 14.7 Hz, 1H, CHHCH(CO)NH), 2.83 (dd, J = 7.8,
14.5 Hz, 1H, CHHCH(CO)NH), 1.38 (s, 9H, OC(CH3)3).
13C NMR (62.9 MHz; CDCl3): δ = 170.80 ( C=O), 155.35 ( C  CarCl),
 CarCH2  Car	  Car	  CarH), 83.05 (Cp), 80.53
(OC(CH3)3), 54.31 (CH2CH(CO)NH), 52.96 (CO2CH3), 36.73 (CH2CH(CO)NH), 28.17
(OC(CH3)3).
IR (KBr): ν~
 
(cm-1) 3425 (w), 3121 (w), 2980 (w), 1746 (s), 1711 (s), 1506 (m), 1461
(m), 1417 (w), 1367 (m), 1289 (w), 1256 (w), 1167 (m), 1094 (w), 1056 (w), 1011 (w),
833 (s), 556 (s).
UV/Vis (CH3OH): λmax (ε) = 206 (25700), 2046 nm (26200 mol-1dm3cm-1).
MS (FAB+, NBA): m/z (%) 479/480/482 (62/100/79) [M+].
HRMS (FAB): calcd. for C20H2535ClO4N102Ru [M+]: 480.0520, found 480.0522.
Elemental Analysis: C18H23ClF6NO2PRu (566.87)
Calculated: C: 38.44  H: 4.03  N: 2.24
Found:        C: 38.22  H: 4.27  N: 2.12
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3.4 (η5-Cyclopentadienyl)(1-methoxy-4-methyl-η6-benzene)ruthenium hexa-
fluorophosphate (145)[94]
Ru
+
PF6-
OCH3
Prepared from 4-methylanisol ( 148) (69.0 mg, 0.07 mL, 0.565 mmol). The solvent is
concentrated and the product is dissolved in CH3CN followed by pre-purification on a
neutral alumina column (CH3CN). The solvent is evaporated and the product is finally
purified by column chromatography on aminopropyl silica ( iPrOH) followed by
recrystallisation from iPrOH to yield a colourless powder.
Yield: 197 mg (80 %)
TLC (NH2-Si, iPrOH): Rf = 0.26
HPLC retention volumes: 108 mL (CH3CN), 104 mL ( iPrOH-CH3CN (1:1)), 107 mL
(iPrOH-CH3CN (2:1)), 116 mL ( iPrOH-CH3CN (4:1)), 126 mL ( iPrOH-CH3CN (8:1)),
138 mL (iPrOH-CH3CN (12:1)), 150 mL (iPrOH-CH3CN (18:1)).
Melting Point: 147-148 °C (decomposes)
1H NMR (360 MHz, [D6]acetone): δ = 6.34 (d, J   	
 	 Har), 6.26 (d, J = 6.7
	
 	 Har), 5.48 (s, 5H, Cp), 3.84 (s, 3H, OCH3), 2.35 (s, 3H, CH3).
13C NMR (90.6 MHz; [D6]acetone): δ   CarOCH3  CarCH3), 86.27
Car	    CarH), 57.71 (OCH3  arCH3).
IR (KBr): ν~
 
(cm-1) 118 (m), 1549 (s), 1491 (s), 1446 (s), 1264 (s), 1011 (s), 840 (s).
UV/Vis (CH3CN): λmax (ε) = 280 (10800), 226 (15600), 200 nm (61600 mol-1dm3cm-1).
MS (FAB+, NBA): m/z (%) 288/289/291 (61/100/60) [M+].
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HRMS (FAB): calcd. for C13H15O 102Ru [M+]: 289.0170, found 289.0159.
Elemental Analysis: C13H15F6OPRu (433.30)
Calculated: C: 36.04  H: 3.49
Found:        C: 35.64   H: 3.50
3.5 (1-Chloro-2-methoxy-η6-benzene)(η5-cyclopentadienyl)ruthenium hexa-
fluorophosphate (155)[94]
Ru
+
PF6-
OCH3
Cl
Prepared from 2-chloroanisol (154) (116 mg, 0.10 mL, 0.825 mmol). The solvent is
concentrated and the product is dissolved in CH 3CN and is pre-purified on a neutral
alumina column (CH3CN). The solvent is evaporated and the product is finally
purified by column chromatography on aminopropyl silica ( iPrOH-CH3CN (12:1))
followed by recrystallisation fro iPrOH affording colourless needles.
Yield: 300 mg (80 %)
TLC (NH2-Si, iPrOH): Rf = 0.24
HPLC retention volumes: 109 mL (CH3CN), 100 mL ( iPrOH-CH3CN (1:1)), 114 mL
(iPrOH-CH3CN (2:1)), 126 mL ( iPrOH-CH3CN (4:1)), 143 mL ( iPrOH-CH3CN (8:1)),
167 mL (iPrOH-CH3CN (12:1)), 183 mL (iPrOH-CH3CN (18:1)).
Melting Point : 147-149 °C (decomposes)
1H NMR (360 MHz, [D6]acetone): δ = 6.78 (d, J   	
 	 Har), 6.69 (d, J = 6.0
	
 	 Har), 6.25 (t, J   	
 	 Har), 6.21 (t, J   	
 	 Har), 5.58
(s, 5H, Cp), 4.06 (s, 3H, OCH3).
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13C NMR (90.6 MHz; [D6]acetone): δ   CarOCH3  Car  
Car	  Car	  Car	    CarH), 58.13 (OCH3).
IR (KBr): ν~
 
(cm-1) 3109 (m), 1521 (s), 1465 (s), 1435 (s), 1276 (s), 1011 (s), 841 (s),
823 (s), 557 (s).
UV/Vis (CH3CN): λmax (ε) = 232 (4000), 204 nm (26500 mol-1dm3cm-1).
MS (FAB+, NBA): m/z (%) 308/309/311 (61/100/78) [M+].
HRMS (FAB): calcd. for C12H1235ClO 101Ru [M+]: 308.9620, found = 308.9642.
Elemental Analysis: C12H12ClF6OPRu (454)
Calculated: C: 31.77  H: 2.67
Found:        C: 31.85  H: 2.81
3.6 (1-Chloro-4-methoxy-η6-benzene)(η5-cyclopentadienyl)ruthenium hexa-
fluorophosphate (151)[96]
Ru
+
PF6-
OCH3Cl
Prepared from 4-chloroanisol (150) (46 mg, 0.04 mL, 0.326 mmol). The solvent is
concentrated and the product is dissolved in CH3CN followed by pre-purification on a
neutral alumina column (CH 3CN). The solvent is evaporated and the product is
purified by column chromatography on aminopropyl silica ( iPrOH-CH3CN (8:1)) and is
finally recrystallised fro iPrOH giving colourless needles.
Yield: 140 mg (95 %)
TLC (NH2-Si, iPrOH): Rf = 0.24
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HPLC retention volumes: 110 mL (CH 3CN), 107 mL ( iPrOH-CH3CN – (1:1)), 110
mL (iPrOH-CH3CN – (2:1)), 120 mL (iPrOH-CH3CN – (4:1)), 129 mL ( iPrOH-CH3CN –
(8:1)), 146 mL (iPrOH-CH3CN – (12:1)), 165 mL (iPrOH-CH3CN – (18:1)).
Melting Point : 166-167 °C (decomposes)
1H NMR (250 MHz, CD3OD): δ = 6.60 (d, J   	
 	 Har), 6.39 (d, J = 6.4 Hz,
	 Har), 5.52 (s, 5H, Cp), 3.79 (s, 3H, OCH3).
13C NMR (62.9 MHz; CD 3OD): δ   CarOCH3  Car  
Car	    CarH), 58.01 (OCH3).
IR (KBr): ν~
 
(cm-1) 3126 (s), 2941 (m), 1889 (w), 1528 (s), 1464 (s), 1441 (s), 1418
(s), 1256 (s), 1096 (s), 1005 (s), 905 (s), 848 (s), 640 (s).
UV/Vis (CH3OH): λmax (ε) = 206 (20200), 204 nm (19800 mol-1dm3cm-1).
MS (FAB+, NBA): m/z (%) 308/309/311 (61/100/78) [M+].
HRMS (FAB): calcd. for C12H1235ClO102Ru [M+]: 308.9620, found = 308.9641.
3.7 (η5-Cyclopentadienyl)(hydroxy-η6-benzene)ruthenium hexafluoro-
phosphate (153)[97]
Ru
+
PF6-
OCH3Cl
Prepared from phenoxy-trimethylsilane ( 152) (133 mg, 0.15 mL, 0.8 mmol). The
solvent is concentrated and the product is dissolved in CH 3CN and is pre-purified on
a neutral alumina column (CH 3CN). The solvent is concentrated to 2  mL and after
Et2O addition the precipitate is collected. Recrystallisation fro iPrOH affords a
colourless powder.
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Yield: 310 mg (96 %)
TLC (NH2-Si, iPrOH): Rf = 0.16
Melting Point : at 170 °C starts decomposition without melting
HPLC retention volumes: 109 mL (CH 3CN), 107 mL ( iPrOH-CH3CN – (1:1)), 112
mL (iPrOH-CH3CN – (2:1)), 124 mL (iPrOH-CH3CN – (4:1)), 130 mL ( iPrOH-CH3CN –
(8:1)), 150 mL (iPrOH-CH3CN – (12:1)), 155 mL (iPrOH-CH3CN – (18:1)).
1H NMR (360 MHz, CD3OD): δ = 6.10 (d, J   	
 	 Har), 6.07 (t, J = 5.6 Hz,
	 Har), 5.87 (t, J   	
 	 Har), 5.34 (s, 5H, Cp).
13C NMR (90.6 MHz; CD3OD): δ   Car	  CarH), 80.81 (Cp), 76.39
CarH).
IR (KBr): ν~
 
(cm-1) 3420 (m), 3007 (w), 1623 (w), 1479 (m), 1467 (m), 1409 (w), 1363
(w), 1267 (w), 1176 (m), 1102 (m), 944 (m), 841 (s), 559 (s).
UV/Vis (CH3OH): λmax (ε) = 234 (2200), 210 nm (5800 mol-1dm3cm-1).
MS (FAB+, NBA): m/z (%) 260/261/263 (64/100/59) [M+].
HRMS (FAB): calcd. for C11H11O102Ru [M+]: 260.9856, found = 260.9889.
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4 Synthesis of Tyrosine Sub-Units
4.1 3-(3-Benzyloxy-4-methoxy-phenyl)-2-tert-butoxycarbonylamino-propionic
acid (118)
4.1.1. Acetic acid 2-methoxy-5-(5-oxo-2-phenyl-oxazol-4-ylidenemethyl)-
phenyl ester (122)[89]
H3CO
O
O
N
O
O
Isovaniline (120) (4.50 g, 29.58 mmol), hippuric acid (5.50 g, 30.73 mmol), sodiu
acetate (2.50 mg, 30.49 mmol) and acetic anhydride (9 mL) are allowed to stir under
reflux for 30 min. The mixture is cooled to room temperature and EtOH (9  mL) is
added. The yellow crystals obtained are filtered and recrystallised from EtOH.
Yield: 4.056 g (38 %)
Melting Point: 137-139 °C
1H NMR (250 MHz, CDCl3): δ = 8.15 (d, J = 6.8 Hz, 2H, o-CHar), 8.08 (d, J = 2.1 Hz,
1H, CHar), 7.95 (dd, J = 2.1, 8.7 Hz, 1H, CHar), 7.58 (d, J = 7.1 Hz, 1H, p-CHar), 7.52
(t, J = 6.9 Hz, 2H, m-CHar), 7.16 (s, 1H, CH=(CO2)N), 7.03 (d, J = 8.6 Hz, 1H, CHar),
3.91 (s, 3H, OCH3), 2.37 (s, 3H, OCH3).
13C NMR (90.6 MHz; CDCl3): δ = 168.81 ( C=O), 167.73 ( C=O), 162.96 ( C(O)=N),
153.78 ( CarOCH3), 140.04 ( CarOAc), 133.19 ( CH=C), 132.42 ( p-CarH), 131.93
(CarC=(O)N), 130.81 ( CarH), 128.93 ( o-CarH), 128.29 ( m-CarH), 126.81 ( CarCH=C),
126.42 (CarH), 125.72 (CarCH=C), 112.25 (CarH), 56.08 (OCH3), 20.70 (C=OCH3).
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4.1.2. 2-Benzoylamino-3-(3-hydroxy-4-methoxy-phenyl)-acrylic acid (123)[89]
NH
H3CO
HO
HO2C
O
Acetic acid 2-methoxy-5-(5-oxo-2-phenyl-oxazol-4-ylidenemethyl)-phenyl ester ( 122)
(4.00 g, 11.11 mmol) is dissolved in 400 mL aqueous NaOH 2  % and is stirred under
reflux. The azalactone hydrolyses and dissolves. When everything is dissolved, the
impurities are filtered and the solution is acidified to pH 4-5 with concentrated HCl.
The solution rests for 24 hours on the refrigerator to allow complete precipitation. The
precipitate is filtered and is recrystallised from H2O to afford light yellow crystals.
Yield: 2.30 mg (58 %)
TLC (Si, CH3OH-CHCl3 ((1:10)): Rf = 0.24
Melting Point : 129-130 °C
1H NMR (360 MHz, [D6]DMSO): δ = 9.79 (s, 1H, CO2H), 9.14 (s, 1H, NHBz), 8.00 (d,
J = 7.1 Hz, 2H, o-CHar), 7.60 (d, J = 7.1 Hz, 1H, p-CHar), 7.54 (t, J = 7.0 Hz, 2H, m-
CHar), 7.33 (s, 1H, CHar), 7.20 (s, 1H, CH=(CO2H)NH), 7.11 (d, J = 8.4 Hz, 1H, CHar),
6.93 (d, J = 8.4 Hz, 1H, CHar), 3.77 (s, 3H, OCH3).
13C NMR (90.6 MHz; [D6]DMSO): δ = 166.64 ( C=O), 166.01 ( C=O), 149.07
(CarOCH3), 149.07 ( CarOH), 133.79 ( CarCONH), 133.70 ( CH=C), 131.67 ( p-CarH),
128.41 ( o-CarH), 128.10 ( m-CarH), 126.52 ( CarCH=C), 124.94 (C arCH=C), 122.67
(CarH), 116.58 (CarH), 111.80 (CarH), 55.57 (OCH3).
IR (KBr): ν~
 
(cm-1) ν~
 
 3290 (m), 1709 (m), 1683 (s), 1634 (s), 1579 (m), 1516 (s),
1489 (m), 1435 (m), 1265 (m), 1126 (m), 1018 (w), 723 (m), 613 (m).
UV/Vis (CH3OH): λmax (ε) = 318 (9260), 292 (7450), 220 (20600), 208 n
(18200 mol-1dm3cm-1).
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MS (EI, 70 eV): m/z (%) 313 (96) [M+], 295 (21) [M+–H2O], 265 (12) [M+–CO2], 194
(10) [M+–C7H5NO], 163 (22), 137 (17) [M+–C9H6NO3], 105 (100) [M+–C10H10NO4].
Elemental Analysis: C17H15NO5 (313)
Calculated: C: 65.17  H: 4.83  N = 4.47
Found:        C: 65.19  H: 5.07  N = 4.11
4.1.3. 2-Benzoylamino-3-(3-hydroxy-4-methoxy-phenyl)-propionic acid (124)[89]
NH
H3CO
HO
HO2C
O
2-Benzoylamino-3-(3-hydroxy-4-methoxy-phenyl)-acrylic acid ( 123) (2.30 g,
6.5 mmol) is dissolved in 23 mL H 2O  and 15 g of NaHg divided in 4 portion is added
to the solution at each 15 min under vigorous stirring. After addition, the mixture is
allowed to stir at room temperature until complete decolouration. The mercury is
separated and the solution is brought to pH 4-5 with concentrated HCl. The product
starts to precipitate and, after staying overnight in refrigerator, the product is filtered
and recrystallised from H2O giving pale yellow crystals.
Yield: 1.285 g (63 %)
1H NMR (250 MHz, CD3OD): δ = 7.77 (d, J = 6.4 Hz, 2H, o-CHar), 7.49 (d, J = 6.7 Hz,
1H, p-CHar), 7.42 (t, J = 6.8 Hz, 2H, m-CHar), 6.83 (d, J = 7.9 Hz, 1H, CHar), 6.78 (d,
J = 1.5 Hz, 1H, CHar), 6.71 (dd, J = 1.8, 8.3 Hz, 1H, CHar), 4.66 (dd, J = 5.2, 8.3 Hz,
1H, CH2CH(CO)NH), 3.78 (s, 3H, OC H3), 3.21 (dd, J = 5.3, 13.2 Hz,
CHHCH(CO)NH), 2.99 (dd, J = 8.3, 13.6 Hz, CHHCH(CO)NH).
13C NMR (90.6 MHz; CD3OD): δ = 174.99 (C=O), 170.17 (C=O), 147.98 (CarOCH3),
147.48 ( CarOH), 135.42 ( CarCONH), 132.75 ( p-CarH), 131.46 ( CarCH2), 129.51 ( o-
CarH), 128.59 (m-CarH), 121.50 (CarH), 117.29 (CarH), 112.75 (CarH), 56.41 (OCH3),
55.83 (CH2CH(CO)NH), 37.64 (CH2CH(CO)NH).
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4.1.4. Acetic acid 5-(2,5-dioxo-benzylidene-imidazolidin-4-ylidene-methyl)-2-
methoxy-phenyl ester (125)[89]
NH
H3CO
O
O
N
H
OO
Isovaniline (120) (4.20 g, 27.6 mmol), hydantoin (2.80 g, 28 mmol), sodium acetate
(2.60 g, 31.7 mmol) and acetic anhydride (10 mL) are stirred under reflux for 30 min.
After that period, the mixture is cooled and H 2O is added. The precipitate is filtered
and washed with hot H 2O followed by recrystallisation from EtOAc which affords
yellow needles.
Yield: 6.422 g (84 %)
TLC (Si, EtOAc-nBuOH-AcOH-H2O (1:1:1:1)): Rf = 0.80
Melting Point : 197-199 °C
1H NMR (250 MHz, [D6]DMSO): δ = 11.12 (brs, 1H, NH), 7.54 (dd, J = 2.2, 8.6 Hz,
1H, CHar), 7.50 (d, J = 2.1 Hz, 1H, CHar), 7.17 (d, J = 8.5 Hz, 1H, CHar), 6.54 (s, 1H,
CH=C), 3.82 (s, 3H, OCH3), 2.28 (s, 3H, C=OCH3).
13C NMR (90.6 MHz; [D6]DMSO): δ = 168.27 ( C=O), 168.01 (C=O), 161.83 (C=O),
151.58 ( CarOCH3), 151.43 ( CarOAc), 139.37 (C arCH=C), 129.25 ( CH=C), 125.22
(CarCH=C), 123.54 ( CarH), 112.88 ( CarH), 109.71 ( CarH), 55.91 (O CH3), 26.16
(C=OCH3).
IR (KBr): ν~
 
(cm-1) 3440 (m), 3226 (m), 1795 (m), 1743 (s), 1705 (s), 1656 (s), 1608
(m), 1524 (m), 1455 (m), 1377 (s), 1279 (s), 1203 (s), 1127 (s), 1015 (m), 803 (w),
763 (m).
UV/Vis (CH3OH): λmax (ε) = 334 (3500), 212 (3900 mol-1dm3cm-1).
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MS (EI, 70 eV): m/z (%) 276 (22) [M+], 234 (100) [M+–C2H2O], 219 (10) [M+–CHN2O],
163 (10), 148 (19).
Elemental Analysis: C13H12N2O5 (276)
Calculated: C: 56.52  H: 4.38  N: 10.14
Found:        C: 56.24  H: 4.67  N: 9.80
4.1.5. 5-(3-Hydroxy-4-methoxy-benzyl)-imidazoline-2,4-dione (126)[89]
NH
H3CO
HO
N
H
OO
Acetic acid 5-(2,5-dioxo-benzylidene-imidazolidin-4-ylidene-methyl)-2-methoxy-
phenyl ester ( 125) (6.20 g, 22.46 mmol) is dissolved in 190 mL H 2O and aqueous
NaOH (10 %) is added until everything dissolves. The mixture is treated with three
portions of 20 g of NaHg each, which are added every 15 min under stirring. When
the mixture becomes colourless, the mercury is separated and the solution is
neutralised with concentrated HCl. The product starts to precipitate and after staying
overnight in refrigerator, it is filtered and recrystallised from H 2O yielding colourless
needles.
Yield: 4.755 g (90 %)
TLC (Si, CH3OH-CH3Cl (1:10)): Rf = 0.21
Melting Point : 165-166 °C
1H NMR (360 MHz, [D6]DMSO): δ = 10.41 (brs, 1H, NH), 8.85 (brs, 1H, NH), 7.86 (s,
1H, OH), 6.80 (d, J = 8.0 Hz, 1H, CHar), 6.63 (s, 1H, CHar), 6.57 (d, J = 8.0 Hz, 1H,
CHar), 4.25 (brt, 1H, CH2CH(CO)NH), 3.73 (s, 3H, OCH3), 2.80 (d, J = 4.3 Hz, 2H,
CH2CH(CO)NH).
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13C NMR (90.6 MHz; [D6]DMSO): δ = 175.47 ( C=O), 157.35 ( C=O), 146.61
(CarOCH3), 146.02 ( CarOH), 128.05 ( CarCH2CH), 120.62 ( CarH), 117.30 ( CarH),
111.93 (CarH), 58.72 (CH2CH(CO)NH) 55.66 (OCH3), 35.81 (CH2CH(CO)NH).
IR (KBr): ν~
 
(cm-1) 3413 (s), 3248 (s), 3175 (s), 3068 (s), 1772 (s), 1720 (s), 1591 (m),
1512 (s), 1439 (s), 1415 (s), 1364 (m), 1276 (s), 1247 (s), 1200 (s), 1131 (s), 1019
(s), 948 (w), 888 (w), 791 (m), 762 (m), 673 (m), 642 (m).
UV/Vis (CH3OH): λmax (ε) = 230 (1800), 204 (31600 mol-1dm3cm-1).
MS (EI, 70 eV): m/z (%) 236 (38) [M +], 137 (100) [M +–C3H4N2O2], 122 (23) [M +–
C4H7N2O2].
Elemental Analysis: C11H12N2O4 (236)
Calculated: C: 55.93  H: 5.12  N: 11.86
Found:        C: 55.50  H: 5.25  N: 11.94
4.1.6. 2-Amino-3-(3-hydroxy-4-methoxy-phenyl)-propionic acid (127)[89]
NH2
H3CO
HO
O
OH
5-(3-Hydroxy-4-methoxy-benzyl)-imidazoline-2,4-dione ( 126) (4.00 g, 17.2 mmol) is
dissolved in a solution of barium hydroxide octahydrate (85 g, 270 mmol) in 170  mL
H2O. The mixture is heated to reflux until complete ammonium liberation. Then the
mixture is diluted with hot H 2O and the barium is precipitated with concentrated
H2SO4. The filtrate is concentrated to 100 mL and the impurities are removed by
extraction with Et2O. The solvent is removed affording brown-yellow needles.
Yield: 2.30 g (63 %)
TLC (Si, EtOAc-AcOH-nBuOH-H2O (1:1:1:1)): Rf = 0.15
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Melting Point : 225 °C starts decomposition
1H NMR (250 MHz, [D6]DMSO): δ = 6.81 (d, J = 8.2 Hz, 1H, CHar), 6.71 (d, J = 1.8
Hz, 1H, CHar), 6.62 (dd, J = 1.9, 7.8 Hz, 1H, CHar), 4.25 (brm, 1H, CH2CH(CO)NH),
3.72 (s, 3H, OCH3), 3.01 (dd, J = 4.2, 14.6 Hz, 1H, CHHCH(CO)NH), 2.70 (dd, J =
8.0, 14.1 Hz, 1H, CH2CH(CO)NH).
13C NMR (90.6 MHz; [D6]DMSO): δ = 169.50 ( C=O), 146.40 ( CarOCH3), 146.34
(CarOH), 129.95 ( CarCH2CH), 119.72 ( CarH), 116.59 ( CarH), 112.22 ( CarH), 58.68
(CH2CH(CO)NH), 55.59 (OCH3), 36.22 (CH2CH(CO)NH).
IR (KBr): ν~
 
(cm-1) 3473 (s), 1772 (m), 1675 (s), 1456 (s), 1410 (s), 1213 (m), 1069
(w), 1019 (w), 902 (w), 866 (m), 849 (m), 781 (w), 686 (m), 651 (m), 598 (s).
UV/Vis (CH3OH): λmax (ε) = 208 nm (6600 mol-1dm3cm-1).
4.1.7. 2-tert-Butoxycarbonylamino-3-(3-hydroxy-4-methoxy-phenyl)-propionic
acid (117)
NH
H3CO
HO
OO
O
OH
2-Amino-3-(3-hydroxy-4-methoxy-phenyl)-propionic acid ( 127) (4.50 g, 21.80 mmol)
is dissolved in 80 mL CH 3OH-H2O (1:1) and Et 3N (4.6 mL, 32.70 mmol) is added.
The mixture is brought to 0  °C followed by addition of Boc 2O (5.07 g, 23.30 mmol).
The reaction mixture remains at this temperature for further 30 min and then is
brought to room temperature, where is allowed to stir for further 48 hours. The
solvent is concentrated and H2O-EtOAc (1:1) is added. The aqueous layer is brought
to pH 1 with 1N HCl and is extracted with EtOAc. The organic layer is washed with
brine and dried over Na2SO4. The solvent is removed and a light pink-orange powder
is obtained.
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Yield: 4.45 g (66 %)
Melting Point: 110 °C
TLC (Si, EtOAc-TMP (7:3)): Rf = 0.47
1H NMR (250 MHz, CDCl 3): δ = 6.78 (d, J = 8.3 Hz, 1H, CHar), 6.76 (d, J = 2.2 Hz,
1H, CHar), 6.67 (dd, J = 2.2, 8.2 Hz, 1H, CHar), 4.98 (brd, 1H, NH), 4.54 (m, 1H,
CH2CH(CO)NH), 3.85 (s, 3H, OC H3), 3.05 (m, 1H, CH2CH(CO)NH), 1.42 (s, 9H,
OC(CH3)3).
13C NMR (90.6 MHz; CDCl3): δ = 176.08 ( C=O), 155.48 ( C=O), 145.85 ( CarOCH3),
145.53 ( CarOH), 128.86 ( CarCH2CH), 120.95 ( CarH), 115.63 ( CarH), 110.94 ( CarH),
80.27 (O C(CH3)3), 55.90 (O CH3), 54.28 (CH2CH(CO)NH), 37.04 ( CH2CH(CO)NH),
28.24 (OC(CH3)3).
IR (KBr): ν~
 
(cm-1) 3391 (m), 2978 (m), 2934 (m), 1729 (s), 1703 (s), 1687 (s), 1593
(m), 1520 (s), 1443 (m), 1368 (m), 1278 (s), 1248 (s), 1160 (s), 1132 (s), 1027 (m),
974 (w), 852 (w), 800 (m), 762 (m), 618 (w).
UV/Vis (CH3OH): λmax (ε) = 282 (7800), 224 (13300), 204 nm (47000 mol-1dm3cm-1).
MS (EI, 70 eV): m/z (%) 311 (10) [M+], 255 (26) [M+–C4H8], 238 (12) [M+–C4H9O], 194
(32), 137 (100) [M+–C7H12NO4].
HRMS (EI): calcd. for C22H27NO6 [M+]: 311.1369, found 311.1369.
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4.1.8. 3-(3-Benzyloxy-4-methoxy-phenyl)-2-tert-butoxycarbonylamino-
propionic acid (118)
OCH3
O
CO2H
NH O
O
2-tert-Butoxycarbonylamino-3-(3-hydroxy-4-methoxy-phenyl)-propionic acid ( 117)
(3.23 g, 10 mmol) is dissolved in 30 mL CH 3OH and to this solution is given NaOH
(0.88 g, 22 mmol). The mixture is brought to reflux followed by the addition of
benzylchloride (2.785 g, 2.53 mL, 22 mmol). When the reaction mixture becomes
neutral (after 2.5 hours) further NaOH (0.44 g, 11 mmol) in 0.44  mL H2O is added.
The mixture is allowed to stir for further 12 hours under reflux, and after this period
the solvent is removed. The mixture is dissolved in H 2O and the impurities are
removed by extraction with CHCl 3. The product precipitates after acidification of the
aqueous layer with H 2SO4 5N under vigorous stirring. The precipitate is then
collected and recrystallised from toluene to give a colourless powder.
Yield: 2.60 g (65 %)
TLC (Si, EtOAc-TMP (7:3)): Rf = 0.18
Melting Point: 149-150 °C
1H NMR (400 MHz, CD 3OD): δ = 7.45 (d, J = 7.2 Hz, 2H; o-CHar, Bn), 7.35 (t, J =
7.2 Hz, 2H; m-CHar, Bn), 7.30 (d, J = 7.3 Hz, 1H; p-CHar, Bn), 6.94 (d, J = 1.8 Hz, 1H;
CHar), 6.85 (d, J = 8.1 Hz, 1H; CHar), 6.78 (d, J = 8.1 Hz, 1H; CHar), 5.07 (s, 2H;
OCH2Ph), 4.20 (dd, J = 5.0, 7.0 Hz, 1H; (CH2CH(NH)CO), 3.79 (s, 3H; OCH3), 3.07
(dd, J = 4.8, 13.6 Hz, 1H; CH HCH(CO)NH), 2.83 (dd, J = 7.2, 13.6 Hz, 1H,
CHHCH(CONH)), 1.37 (s, 9H, OC(CH3)3).
13C NMR (100 MHz, CD 3OD): δ = 178.49 ( C=O), 157.37 (C=O), 149.75 (CarOCH3),
149.41 ( CarOCH2Ph), 138.90 ( CarOCH2), 132.60 ( CarCH2CH(NH)CO), 129.45 ( m-
CarH, Bn), 128.89 (o, p-CarH, Bn), 123.78 (CarH), 117.20 (CarH), 113.55 (CarH), 79.99
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(OC(CH3)3), 72.35 (O CH2Ph), 58.25 (CH2CH(NH)CO), 56.72 (OCH3), 39.34
(CH2CH(NH)CO), 28.84 (OC(CH3)3).
IR (KBr): ν~
 
(cm-1) 3534 (m), 3384 (s), 2961 (m), 2928 (m), 2586 (w), 1729 (s), 1684
(s), 1669 (s), 1630 (m), 1606 (m), 1592 (m), 1520 (s), 1444 (m), 1365 (m), 1277 (s),
1242 (s), 1167 (s), 1140 (s), 1044 (w), 1024 (m), 849 (w), 808 (w), 730 (m), 700 (w).
UV/Vis (CH3 max    	
 	 
    -1dm3cm-1).
MS (EI, 70 eV): m/z (%): 401 (12) [M+], 345 (3) [M+-C4H8], 301 (2) [M+-C5H9O2], 284
(4) [M+-C5H10NO2], 227 (68) [M+-C7H12O4], 137 (48) [M+-(C7H12O4 + Bn)], 91 (100).
HRMS (EI): calcd. for C22H27NO6 [M+]: 401.1838, found 401.1838.
Elemental Analysis: C22H27NO6 (401.45)
Calculated: C: 65.79  H: 6.78  N: 3.49
Found:        C: 65.31  H: 7.15  N: 3.04.
4.2 2-tert-Butoxycarbonylamino-3-(3-hydroxy-4-methoxy-phenyl)-propionic
acid methyl ester (128)
OCH3
OH
HN
O
O
CO2CH3
2-tert-Butoxycarbonylamino-3-(3-hydroxy-4-methoxy-phenyl)-propionic acid ( 117)
(1000 mg, 4.656 mmol) is dissolved in dry CH2Cl2. To the reaction mixture are added
EDCI (1003 mg, 5.12 mmol), CH3OH (2.07 ml, 5.12 mmol) and 4-pyrrolidine-pyridine
(69 mg, 0.4656 mmol). The reaction is allowed to stir at room temperature under
argon for 96 hours. After this period the EDCI-urea formed is filtered and the organic
layer is washed with saturated aqueous NaHCO 3 solution, with H2O and is finally
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dried over Na 2SO4. The solvent is removed and the product is purified by flash
chromatography on silica gel (TMP-EtOAc (7:3)) yielding a colourless powder.
Yield:
 1166 mg (77 %)
TLC (Si, TMP-EtOAc (7:3)): Rf = 0.30
Melting Point:
 137-138 °C
1H NMR
 (250 MHz, CDCl 3): δ = 6.77 (d, J = 8.2 Hz, 1H; CHar), 6.68 (d, J = 2.0 Hz,
1H; CHar), 6.59 (dd, J = 2.2, 8.2 Hz, 1H; CHar), 5.61 (s, CarOH), 4.97 (d, J = 7.8 Hz,
1H; NH), 4.53 (brq, J = 7.0 Hz, 1H; (CH2CH(NH)CO), 3.86 (s, 3H; C=OCH3), 3.73 (s,
3H; OCH3), 2.99 (d, J = 5.1 Hz, 1H; CH2CH(CO)NH), 1.42 (s, 9H, OC(CH3)3).
13C NMR
 (90.6 MHz, CDCl3): δ = 172.45 ( C=O), 155.20 ( C=O), 145.79 ( CarOCH3),
145.66 ( CarOCH2Ph), 129.11 ( CarCH2CH(NH)CO), 120.75 ( CarH), 115.62 ( CarH),
110.82 ( CarH), 79.91 (O C(CH3)3), 55.94 (OCH3), 55.52 (CH 2CH(NH)CO), 52.19
(CO2CH3), 37.63 (CH2CH(NH)CO), 28.31 (OC(CH3)3).
IR (KBr): ν~
 
(cm-1) 3508 (s), 3357 (s), 2972 (m), 1747 (s), 1706 (s), 1595 (m), 1516
(s), 1447 (m), 1367 (m), 1280 (s), 1220 (s), 1170 (s), 1062 (m), 1025 (s), 960 (m),
893 (w), 826 (m), 761 (m), 527 (m).
UV/Vis
 (CH3 max    	

  

 
  


 -1dm3cm-1).
MS (EI, 70 eV): m/z (%): 325 (5) [M+], 269 (13) [M+-C4H8], 208 (38), 137 (100) [M+-
C8H14NO4].
HRMS (EI): calcd. for C16H23NO6 [M+]: 325.1525, found 325.1525.
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4.3 3-(3-Benzyloxy, 4-methoxy)-2-thiopropionic acid (167)
4.3.1. 3-Benzyloxy, 4-methoxy-benzaldehyde (163)[92]
OCH3
H
O
O
To a stirred suspension of isovaniline ( 120) (7.608 g, 50 mmol) and K 2CO3 (21.0 g,
150 mmol) in 143 mL dry acetone is added benzylbromide (12.75 ml, 105  mmol) in
one portion. The mixture is refluxed for 20 hours and after this period it is brought to
room temperature. The mixture is filtered followed by solvent removal in vacuum. The
product is purified by flash chromatography on silica gel (TMP-EtOAc (8:2)) and is
finally recrystallised from TMP to yield colourless needles.
Yield:
 9.00 g (74 %)
TLC (Si, TMP-EtOAc (7:3)): Rf = 0.29
Melting Point:
 62-64 °C
1H NMR
 (360 MHz, CDCl3): δ = 9.81 (s, 1H, CHO), 7.47-7.44 (m, 5H; o-, m-, p-CHar,
Bn), 7.39 (d, J = 2.0 Hz, 1H; CHar), 7.34 (dd, J = 2.0, 8.4 Hz, 1H; CHar), 6.98 (d, J =
8.7 Hz, 1H; CHar), 5.18 (s, 2H; PhOCH2Ph), 3.95 (s, 3H; OCH3).
13C NMR
 (90.6 MHz, CDCl3): δ = 190.71 ( CHO), 154.98 ( CarOCH3), 148.63
(CarOCH2Ph), 136.23 (CarCH2OPh), 129.91 (CarCHO), 128.55 ( m-CarH, Bn), 128.03
(p-CarH, Bn), 127.40 (o-CarH, Bn), 126.78 (CarH), 111.33 (CarH), 110.72 (CarH), 70.77
(PhOCH2Ph), 56.08 (OCH3).
UV/Vis
 (CHCl3 max   	
 
	 
 		 	  		 -1dm3cm-1).
MS (EI, 70 eV): m/z (%): 242 (10) [M] +, 91 (100) [M-C8H7O3] +.
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Elemental Analysis: C15H14O3 (242.27)
Calculated: C: 74.36  H: 5.82
Found:        C: 74.19  H: 5.96
4.3.2. 5-(3-Benzyloxy-4-methoxy-benzylidene)-2-thioxo-thiazolidin-4-one
(165)[107]
OCH3
O
S
N
H O
S
3-Benzyloxy, 4-methoxy benzaldehyde ( 163) (5.00 g, 20.66 mmol) and rhodanine
(164) (2.752 g, 20.66 mmol) are dissolved in glacial acetic acid (15.7 mL) and are
refluxed for 3 hours with fused NaOAc (5.462 g, 66.61 mmol). To the mixture is
added H 2O and the product is filtered. The orange powder is recrystallised fro
AcOH yielding orange crystals.
Yield:
 6.90 g (92 %)
TLC (Si, TMP-EtOAc (7:3)): Rf = 0.25
Melting Point: 223-225 °C
1H NMR
 (360 MHz, [D6]DMSO): δ = 7.56 (s, 1H, PhCH=C(CO)S), 7.48 (d, J = 6.9 Hz,
2H; o-CHar, Bn), 7.41 (t, J = 7.0 Hz, 2H; m-CHar, Bn), 7.36 (d, J = 7.1 Hz, 1H, p-CHar,
Bn), 7.21 (s, 1H, CHar), 7.20 (d, J = 7.8 Hz, 1H; CHar), 7.15 (d, J = 8.5 Hz, 1H; CHar),
5.19 (s, 2H; PhOCH2Ph), 3.89 (s, 3H, OCH3).
13C NMR
 (90.6 MHz, [D6]DMSO): δ = 195.49 ( C=S), 169.39 ( C=O), 151.59
(CarOCH3), 147.96 ( CarOCH2Ph), 136.63 ( CarCH2OPh), 132.12 (Ph CH=C(CO)S),
128.48 ( m-CarH, Bn), 128.01 ( p-CarH, Bn), 127.85 ( o-CarH, Bn), 125.53 ( CarCH=C),
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125.08(CarH), 122.46 (PhCH=C(CO)S), 115.03 (CarH), 112.48 ( CarH), 69.96
(PhOCH2Ph), 55.82 (OCH3).
IR (KBr): ν~
 
(cm-1) 3143 (w), 3040 (w), 2933 (w), 2838 (w), 1688 (s), 1587 (s), 1511
(s), 1433 (s), 1386 (m), 1347 (m), 1304 (s), 1258 (s), 1213 (s), 1168 (m), 1136 (s),
1073 (w), 1005 (m), 858 (w), 809 (w), 751 (w), 698 (w), 670 (w), 607 (w).
UV/Vis
 (CHCl3 max   	 
		  		  		 
 
			 

(8040), 210 (8300), 204 nm (8200 mol-1dm3cm-1).
MS (EI, 70 eV): m/z (%): 357 (12) [M +], 266 (1) [M +-C7H7], 179 (2), 91 (100) [M +-
C8H7O3].
Elemental Analysis: C18H15NO3S2 (357.45)
Calculated: C: 60.48  H: 4.23  N: 3.92
Found:        C: 60.21  H: 4.38  N: 3.80
4.3.3. 3-(3-Benzyloxy, 4-methoxy-phenyl)-2-mercapto-acrylic acid (167)[107]
OCH3
O
HS
OHO
5-(3-Benzyloxy-4-methoxy-benzylidene)-2-thioxo-thiazolidin-4-one ( 165) (8.00 g,
31.13 mmol) is cleaved with NaOH (8 %, 78.4 mL) under reflux. The mixture is stirred
well until a clear solution is obtained. The mixture is filtered, cooled to 0  °C and then
is acidified with HCl 3N under vigorous stirring. After stirring for 30 min, the acid is
collected and washed well with H 2O. EtOH is added (only necessary amount to
dissolve the product) and double H 2O amount is added under vigorous stirring. After
1 hour the product is filtered and dried well yielding a light yellow powder.
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Yield:
 5.86 g (60 %)
TLC: decomposes on silica gel
Melting Point: 145-146 °C
1H NMR
 (360 MHz, CDCl 3): δ = 10.21 (brs, 1H, CO2H), 7.79 (s, 1H,
PhCH=C(CO)SH), 7.46 (d, J = 7.1 Hz, 2H; o-CHar, Bn), 7.36 (t, J = 6.7 Hz, 2H; m-
CHar, Bn), 7.32 (d, J = 1.7 Hz, 1H, CHar), 7.30 (d, J = 7.3 Hz, 1H, p-CHar, Bn), 7.24
(dd, J = 1.8, 8.7 Hz, 1H; CHar), 6.91 (d, J = 8.7 Hz, 1H; CHar), 5.19 (s, 2H;
PhOCH2Ph), 4.58 (s, 1H, SH), 3.90 (s, 3H, OCH3).
13C NMR
 (90.6 MHz, [D6]DMSO): δ = 170.67 ( C=O), 150.70 ( CarOCH3), 147.75
(CarOCH2Ph), 137.58 (PhCH=C(CO)SH), 136.57 (CarCH2OPh), 128.53 (m-CarH, Bn),
127.92 (p-CarH, Bn), 127.43 (CarCH=C), 127.34 (o-CarH, Bn), 125.15 (CarH), 119.05
(PhCH=C(CO)SH), 115.31 (CarH), 111.33 (CarH), 70.95 (PhOCH2Ph), 55.89 (OCH3).
IR (KBr): ν~
 
(cm-1) 2933 (m), 2814 (m), 2623 (w), 2560 (m), 2500 (w), 1671 (s), 1589
(s), 1514 (s), 1420 (s), 1390 (m), 1322 (s), 1254 (s), 1136 (s), 1048 (w), 1007 (s), 904
(m), 848 (w), 809 (m), 751 (m), 699 (m), 622 (w).
UV/Vis
 (CHCl3 max    		 	  
		 -1dm3cm-1).
MS (EI, 70 eV): m/z (%): 316 (28) [M+], 270 (8) [M+-CH2O2], 225 (7) [M+-C7H7], 193
(5), 91 (100) [M+-C8H7O3].
Elemental Analysis: C17H16O4S (316.37)
Calculated: C: 64.54  H: 5.10
Found:        C: 64.37  H: 5.04
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5 Synthesis of Tyramine-Subunits
5.1 [2-(3-Hydroxy-4-methoxy-phenyl)-ethyl]-carbamic acid tert-butyl ester
(119)
5.1.1. 2-Methoxy-5-(2-nitro-vinyl)-phenol (121)[88]
OCH3
OH
NO2
A mixture of methylamine hydrochloride (0.146 g, 2.17 mmol), Na 2CO3 (0.209 g,
1.97  mmol) and CH3OH (1.6 mL, 3.94 mmol) are stirred well, filtered and added to a
solution of isovaniline (120) (3.00 g, 19.7 mmol) and nitromethane (1.352 g, 1.2  mL,
22.17 mmol) in 8.5 mL CH 3OH. The solution is allowed to rest for 50 hours in the
dark. After this period the mixture is filtered and washed with cold CH 3OH. The
product is recrystallised from CH3OH yielding a strong yellow powder.
Yield:
 3.386 g (88 %)
Melting Point: 160 °C
1H NMR
 (250 MHz, CDCl 3): δ = 7.95 (d, J = 13.6 Hz, 1H; CH=CHNO2), 7.47 (d, J =
13.6 Hz, 1H; CH=CHNO2), 7.09 (dd, J = 1.9, 7.4 Hz, 1H; CHar), 7.08 (d, J = 2.0 Hz,
1H; CHar), 6.88 (d, J = 7.6 Hz, 1H, CHar), 5.85 (brs, 1H, OH), 3.95 (s, 3H; OCH3).
13C NMR
 (62.9 MHz, CDCl3): δ = 150.18 ( CarOCH3), 146.35 ( CarOH), 139.71
(CH=CHNO2), 135.60 (CH=CHNO2), 123.75 (CarCH=CHNO2), 123.56 (CarH), 113.74
(CarH), 110.94 (CarH), 56.18 (OCH3).
Elemental Analysis: C9H9NO4 (195.17)
Calculated: C 55.39  H 4.65  N 7.18
Found: C 55.70  H 4.79  N 6.93
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5.1.2. 5-(2-Amino-ethyl)-2-methoxy-phenol (112)[88]
OCH3
OH
NH2HCl
2-Methoxy-5-(2-nitro-vinyl)-phenol (121) (3.84 g, 17.6 mmol) is added over a period
of 18 hours to LiAlH4 (3.406 g, 89.75 mmol) in 465 mL dried Et 2O by the soxhlet
extraction technique. The flask is cooled and ice cold H 2SO4 (210 mL, 1.5N) is added
dropwise with vigorous stirring. The H2O layer is separated and its pH is adjusted to 6
with Li2CO3. The solution is heated to boiling and the precipitated Al(OH)3 is removed
from the reaction mixture. The filtrate is mixed with picric acid (4.877 g, 17.6  mmol)
dissolved in minimum amount hot EtOH. The crystals are filtered and dissolved in
120 mL boiling H2O. Concentrated HCl (25 mL) is added and the precipitated picric
acid is removed. The filtrate is extracted with Et 2O and the aqueous layer is
concentrated until crystallisation starts. The product is recrystallised from CH 3OH-
EtOAc affording light yellow needles.
Yield:
 2.428 g (68 %)
TLC (Si, EtOAc-nBuOH-AcOH-H2O (1:1:1:1)): Rf = 0.42
Melting Point:
 207 °C
1H NMR
 (360 MHz, CD3OD): δ = 6.89 (d, J = 8.1 Hz, 1H; CHar), 6.74 (d, J = 2.0 Hz,
1H; CHar), 6.71 (dd, J = 2.0, 8.0 Hz, 1H; CHar), 3.83 (s, 3H; OC H3), 3.12 (t, J =
7.7 Hz, 2H; CH2CH2NH2), 2.84 (t, J = 8.0 Hz, 2H; CH2CH2NH2).
13C NMR
 (62.9 MHz, CD 3OD): δ = 149.85 ( CarOCH3), 149.22 ( CarOH), 130.59
(CarCH2CH2NH2), 120.94 (CarH), 116.71 (CarH), 113.26 (CarH), 56.52 (OCH3), 42.11
(CH2CH2NH2), 33.90 (CH2CH2NH2).
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IR (KBr): ν~
 
(cm-1) 3332 (s), 3010 (s), 2926 (s), 1991 (w), 1591 (m), 1511 (s), 1463
(m), 1443 (m), 1343 (w), 1281 (s), 1230 (s), 1133 (s), 1024 (s), 946 (m), 876 (m), 806
(s), 761 (m), 621 (m).
UV/Vis
 (CH3 max   
 		  	 	  		 -1dm3cm-1).
MS (EI, 70 eV): m/z (%): 167 (21) [M +-HCl], 138 (100) [M +-CH3N], 123 (27) [M +-
C2H6N].
Elemental Analysis: C9H14ClNO2 (203.67)
Calculated: C: 53.08  H: 6.93  N: 6.88
Found:        C: 52.95  H: 6.93  N: 6.65.
5.1.3. [2-(3-Hydroxy-4-methoxy-phenyl)-ethyl]-carbamic acid tert-butyl ester
(119)
OCH3
OH
NH O
O
Et3N (1.5 mL, 10.7 mmol) is added to a solution of 5-(2-amino-ethyl)-2-methoxy-
phenol ( 112) (1.50 g, 7.36 mmol) in CH 2Cl2-CH3OH (1:1) (50 mL). After 15 min
Boc2O (1.71 g, 8.096 mmol) is added and the solution is allowed to stir for further 3
hours. The solvent is removed and the product is purified by flash column
chromatography on silica gel (TMP-EtOAc (8:2)). Recrystallisation fro nheptane
yields colourless needles.
Yield:
 1.834 g (93 %)
TLC (Si, TMP-EtOAc (8:2)): Rf = 0.30
Melting Point:
 98-99 °C
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1H NMR
 (250 MHz, CDCl 3): δ = 6.82 (d, J = 8.4 Hz, 1H; CHar), 6.80 (d, J = 1.9 Hz,
1H; CHar), 6.71 (dd, J = 2.4, 8.0 Hz, 1H; CHar), 5.58 (s, 1H, OH), 4.57 (brs, 1H, NH)
3.86 (s, 3H; OC H3), 3.32 (t, J = 8.0 Hz, 2H; CH2CH2NH), 2.74 (t,  J = 7.7 Hz, 2H;
CH2CH2NH), 1.45 (s, 9H, OC(CH3)3).
13C NMR
 (62.9 MHz, CDCl3): δ = 159.90 (C=O), 145.69 (CarOCH3), 145.23 (CarOH),
132.31 ( CarCH2CH2NH), 120.17 ( CarH), 114.92 ( CarH), 110.83 ( CarH), 79.85
(OC(CH3)3), 56.01 (O CH3), 43.85 (CH2CH2NH), 35.55 ( CH2CH2NH2), 28.40
(OC(CH3)3).
IR (KBr): ν~
 
(cm-1) 3514 (m), 3358 (s), 2983 (m), 2940 (m), 2873 (w), 1681 (s), 1591
(w), 1532 (s), 1443 (m), 1367 (m), 1303 (m), 1279 (s), 1248 (s), 1224 (s), 1171 (s),
1131 (s), 1018 (s), 869 (m), 812 (m), 761 (w), 627 (m).
UV/Vis
 (CH3 max   
 		 	 
		 	  			 -1dm3cm-1).
MS (EI, 70 eV): m/z (%): 267 (14) [M+], 211 (40) [M+-C4H8], 150 (100) [M+-C5H11NO2],
137 (72) [M+-C6H12NO2].
Elemental Analysis: C14H21NO4 (267.32)
Calculated: C: 62.90  H: 7.92  N: 5.24
Found:        C: 62.96  H: 7.96  N: 4.98.
5.2 [2-(4-Hydroxy-phenyl)-ethyl]-carbamic acid tert-butyl ester (176)
OH
NH
O
O
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To a solution of Tyramine ( 171) (5.00 g, 36.45 mmol) in CH 3OH-CH2Cl2 (1:1)
(100 mL) is added Boc 2O (8.706 g, 40.09 mmol). After 2 hours, the solvent is
removed and the product is recrystallised from TMP yielding colourless needles.
Yield:
 8.50 g (98 %)
TLC (Si, TMP-EtOAc (7:3)): Rf = 0.36
Melting Point:
 71 °C
1H NMR
 (360 MHz, CDCl 3): δ = 7.24 (brs, 1H, OH), 6.99 (d, J = 8.4 Hz, 2H; CHar),
6.79 (d, J = 8.5 Hz, 2H; CHar), 4.68 (brs, 1H, NH), 3.32 (q, J = 6.2 Hz, 2H;
CH2CH2NH), 2.69 (t, J = 6.8 Hz, 2H; CH2CH2NH), 1.44 (s, 9H, OC(CH3)3).
13C NMR
 (90.6 MHz, CDCl3): δ = 156.30 ( C=O), 154.92 ( CarOH), 130.02
(CarCH2CH2NH), 129.71 ( CarH), 115.49 ( CarH), 79.63 (O C(CH3)3), 42.01
(CH2CH2NH), 35.15 (CH2CH2NH2), 28.35 (OC(CH3)3).
IR (KBr): ν~
 
(cm-1) 3378 (s), 2981 (m), 2940 (m), 2865 (w), 1890 (w), 1686 (s), 1665
(s), 1615 (s), 1596 (s), 1517 (s), 1454 (s), 1394 (m), 1368 (s), 1292 (s), 1262 (s),
1219 (s), 1159 (s), 1106 (m), 1051 (w), 1025 (w), 962 (m), 834 (s), 785 (m), 646 (m),
556 (m), 520 (m).
UV/Vis
  (CH3 max   
 			  	  		 	 
(9300 mol-1dm3cm-1).
MS (EI, 70 eV): m/z (%): 237 (5) [M+], 181 (42) [M+-C4H8], 164 (13) [M+-C4H9O], 120
(100) [M+-C5H11NO2].
Elemental Analysis: C13H19NO3 (237.29)
Calculated: C: 65.80  H: 8.07  N: 5.90
Found: C: 65.67  H: 8.12  N: 5.76.
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6 General procedure for the preparation of the diarylether
ruthenium sandwich complexes:
The respective phenol (1.0 eq.) is added to a solution of KO tBu (1.0 eq.) and
[18]crown-6 (0.1 eq.) in THF (15 mL). After 30 min the mixture is cooled to 0  °C and is
transferred to a pre-cooled (-78  °C) solution of the respective ruthenium aryl complex
(1.0 eq.) in THF (20 mL). After 1 hour the reaction is slowly brought to 20  °C. After 16
hour, the reaction mixture is filtered and concentrated.
6.1 [1-{2-(tert-Butoxycarbonylamino)ethyl}-4-{(5-(2-(tert-butoxycarbonyl-
amino)ethyl)-2-methoxy)phenoxy}-η6-benzene](η5-cyclopentadienyl)
ruthenium hexafluorophosphate (156)[94]
NH
H3CO
Ru
NH
O
PF6-O
O
O
O
Prepared fro [1-{2-(tert-butoxycarbonylamino)}ethyl-4-chloro-η6-benzene](η5-
cyclopentadienyl)ruthenium hexafluorophosphate (135)[94] (100 mg, 0.17 mmol) and
from [2-(3-hydroxy-4-methoxy-phenyl)-ethyl]-carbamic acid tert-butyl ester (119)
(45.0 mg, 0.17 mmol). After column chromatography on aminopropyl silica (toluene-
CH3CN (3:1)), the product is dissolved in iPrOH at 60 °C, followed by slo
precipitation after addition of trace amounts of Et 2O at room temperature yielding a
colourless powder.
Yield: 81 mg (60 %)
TLC
 (NH2-Si, iPrOH): Rf = 0.49
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HPLC
 
retention volumes: 109 mL (CH 3CN), 95 mL ( iPrOH-CH3CN (1:1)), 95 mL
(iPrOH-CH3CN (2:1)), 96 mL ( iPrOH-CH3CN (4:1)), 101 mL ( iPrOH-CH3CN (8:1)),
102 mL (iPrOH-CH3CN (12:1)), 110 mL (iPrOH-CH3CN (18:1)), 172 mL (iPrOH).
Melting Point: 80-81 °C (decomposes)
1H NMR
 (360 MHz, CDCl 3): δ = 7.13 (d, J = 8.7 Hz, 1H, CHar), 7.00 (d, J = 8.4 Hz,
1H, CHar), 6.88 (s, 1H, η-CHar), 6.12 (d, J = 6.0 Hz, 2H, η-CHar), 6.01 (d, J = 5.7 Hz,
2H, η-CHar), 5.34 (s, 5H, Cp), 4.95 (m, 1H, CH2NH), 4.36 (t, J = 7.1 Hz, 1H, CH2NH),
3.81 (s, 3H, OCH3), 3.34 (brd, 4H, CH2NH), 2.77 (brt, J = 6.7 Hz, 2H, CH2CH2NH),
2.67 (brt, 2H, CH2CH2NH), 1.40 (s, 18H, OC(CH3)3).
13C NMR
 (90.6 MHz; CDCl3): δ = 156.15 ( C=O), 155.99 ( C=O), 149.59 ( CarOCH3),
140.33 ( CarO(η-Ph)), 133.12 (CH 2Car), 132.76 ( η-CarOPh), 128.46 ( CarH), 122.37
(CarH), 113.41 ( CarH), 101.18 ( η-CarCH2), 84.81 ( η-CarH), 82.74 (Cp), 79.43
(OC(CH3)3), 79.19 (OC(CH3)3), 74.77 (η-CarH), 55.98 (OCH3), 41.80 (CH2NH), 41.00
(CH2NH), 35.38 ( CH2CH2NH), 33.70 ( CH2CH2NH), 28.37 (OC(CH3)3), 28.33
(OC(CH3)3).
IR (KBr): ν~
 
(cm-1) 3440 (m), 3354 (m), 2979 (s), 1700 (s), 1512 (s), 1477 (s), 1367
(s), 1274 (s), 1233 (s), 1171 (s), 1122 (s), 841 (s).
UV/Vis  (CH3CN):  λmax  (ε)  =  282   (30400),   222   (43500),   196 nm   (120900
mol-1dm3cm-1).
MS (FAB+, NBA): m/z (%) 652/653/655 (62/100/56) [M +], 596/597/599 (5/7/4) [M +-
C4H8].
HRMS (FAB): calcd. for C32H43O6N2 102Ru [M+]: 653.2174, found = 653.2144.
Elemental Analysis: C32H43F6N2O6PRu (797.74)
Calculated: C: 48.18  H: 5.43  N: 3.51
Found:        C: 47.46  H: 5.68  N: 3.20
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6.2 [1-{2-(tert-Butoxycarbonylamino)-2-(methoxycarbonyl)ethyl}-4-{(5-(2-
(tert-butoxycarbonylamino)-2-(methoxycarbonyl)ethyl)-2-methoxy)-
phenoxy}-η6-benzene](η5-cyclopentadienyl)ruthenium hexafluoro-
phosphate (157)[94]
H3CO2C
OCH3
Ru
NH
NH
H3CO2C
O
O
O
O
O
PF6-
Prepared from [1-{2-(tert-butoxycarbonylamino)-2-(methoxycarbonyl)ethyl}-4-chloro-
η6-benzene](η5-cyclopentadienyl)ruthenium hexafluorophosphate ( 147)[85b] (100 mg,
0.16 mmol) and 2- tert-butoxycarbonylamino-3-(3-hydroxy-4-methoxy-phenyl)-
propionic acid methyl ester (128) (52 mg, 0.16 mmol). After column chromatography
on aminopropyl silica (toluene-CH3CN (3:1)), the product is recrystallised fro iPrOH
yielding colourless needles.
Yield: 87 mg (60 %).
TLC
 (NH2-Si, iPrOH): Rf = 0.51
Melting Point:
 98-100  °C (decomposes)
1H NMR
 (360 MHz, CDCl 3): δ = 7.09 (dd, J = 8.4, 2.3 Hz, 1H, CHar), 7.00 (d, J =
8.4 Hz, 1H, CHar), 6.83 (d, J = 2.3 Hz, 1H, CHar), 6.17 (t, J = 8.7 Hz, 1H, η-CHar),
6.05 (m, 2H, η-CHar), 5.97 (t, J = 6.7 Hz, 1H, η-CHar), 5.43 (m, 1H, CHNH), 5.35 (s,
5H, Cp), 5.09 (m, 1H, CHNH), 4.51 (m, 1H, CH2CH(NH)CO), 4.42 (m, 1H,
CH2CH(NH)CO), 3.83 (s, 3H, COOC H3), 3.81 (s, 3H, COOCH3), 3.74 (s, 3H,
PhOCH3), 3.12 (brdd, 1H, PhCHHCH), 3.00-2.93 (m, 2H, PhCHHCH), 2.82 (dd,  J =
13.4, 8.7 Hz, 1H, PhCHHCH), 1.41 (s, 9H, OC(CH3)3), 1.40 (s, 9H, OC(CH3)3).
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13C NMR
 (90.6 MHz, CDCl3): δ = 172.06 (C=O), 170.89 (C=O), 155.46 (C=O), 155.43
(C=O), 150.21 (CarOCH3), 140.21 (CarO(η-Ph)), 132.93 (CH2Car), 130.21 (η-CarOPh),
129.23 (CarH), 122.96 (CarH), 113.44 (CarH), 98.95 (η-CarCH2), 85.72 (η-CarH), 85.58
(η-CarH), 81.13 (Cp), 80.46 (OC(CH3)3), 80.41 (OC(CH3)3), 74.86 (η-CarH), 74.76 (η-
CarH), 56.04 (PhOCH3), 54.60 ( CH2CH(NH)CO), 53.06 (CO2CH3), 52.55 (CO2CH3),
37.83 ( CH2CH(NH)CO), 36.69 ( CH2CH(NH)CO), 28.30 (OC(CH3)3), 28.26
(OC(CH3)3).
IR (KBr): ν~
 
(cm-1) 3420 (w), 2979 (w), 1743 (s), 1717 (s), 1513 (s), 1477 (s), 1368
(m), 1275 (s), 1235 (s), 1166 (s), 1022 (w), 843 (s), 558 (m).
UV/Vis (CH3CN): λmax (ε) = 278 (11400), 224 (23100), 196 nm (66600 mol-1dm3cm-1).
MS (FAB+, NBA)
 
m/z
 (%) 768/769/771 (61/100/56) [M+].
HRMS (FAB): calcd. for C36H47O10N2102Ru [M+]: 769.2274, found 769.2299.
6.3 [{1-(4-(2-(tert-Butoxycarbonylamino)ethyl))phenoxy-2-methoxy}-η6-
benzene](η5-cyclopentadienyl)ruthenium hexafluorophosphate (159)[94]
O Ru
NH
H3CO
O
O
PF6-
Prepared from (1-chloro-2-methoxy-η6-benzene)(η5-cyclopentadienyl)rutheniu
hexafluorophosphate (155)[94] (110 mg, 0.242 mmol) and from [2-(4-hydroxy-phenyl)-
ethyl]-carbamic acid tert-butyl ester ( 177) (57 mg, 0.242 mmol). After column
chromatography on aminopropyl silica (toluene-CH3CN (3:1)), the product is
dissolved in iPrOH at 60 °C, followed by slow precipitation of a colourless powder
after addition of trace amounts of Et2O at room temperature.
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Yield:
 86 mg (55 %)
TLC (NH2-Si, iPrOH): Rf = 0.36
HPLC
 
retention volumes: 112 mL (CH 3CN), 93 mL ( iPrOH-CH3CN (1:1)), 90 mL
(iPrOH-CH3CN (2:1)), 92 mL ( iPrOH-CH3CN (4:1)), 93 mL ( iPrOH-CH3CN (8:1)), 115
mL (iPrOH-CH3CN (12:1)), 130 mL (iPrOH-CH3CN (18:1)), 273 mL ( iPrOH).
Melting Point: 70 °C (decomposes)
1H NMR
 (360 MHz, CDCl 3): δ = 7.29 (d, J = 8.4 Hz, 2H, CHar), 6.99 (d, J = 8.7 Hz,
2H, CHar), 6.48 (d, J = 6.4 Hz, 1H, η-CHar), 5.95 (t, J = 6.1 Hz, 1H, η-CHar), 5.89 (d, J
= 6.0 Hz, 1H, η-CHar), 5.82 (d, J = 6.0 Hz, 1H, η-CHar), 5.36 (s, 5H, Cp), 4.68 (brm,
1H, CH2NH), 3.95 (s, 3H, OCH3), 3.38 (brq, J = 6.7 Hz, 2H, CH2NH), 2.83 (t, J = 7.0
Hz, 2H, CH2CH2NH), 1.44 (s, 9H, OC(CH3)3).
13C NMR
 (90.6 MHz; CDCl3): δ = 155.91 ( C=O), 152.26 (( η-Ph)OCar), 137.54
(CarCH2), 130.94 ( CarH), 127.01 ( η-CarOCH3), 123.75 ( η-CarOPh), 119.65 ( CarH),
81.69 (η-CarH), 80.70 ((η-CarH), 80.61 (Cp), 79.65 (OC(CH3)3), 75.79 ((η-CarH), 72.30
((η-CarH), 57.87 (OCH3), 41.75 (CH2NH), 35.71 (CH2CH2NH), 28.42 (OC(CH3)3).
IR (KBr): ν~
 
(cm-1) 3438 (m), 2878 (m), 1700 (s), 1528 (s), 1501 (s), 1477 (s), 1277
(s), 1258 (s), 1221 (s), 840 (s).
UV/Vis (CH3CN): λmax  (ε) = 260 (6900), 220 (21600), 196 nm (62200 mol-1dm3cm-1).
MS (FAB+, NBA): m/z (%) 509/510/512 (58/100/54) [M+], 452/453/455 (5/10/5) [M+-
C4H8], 406/407/409 (3/4/5) [M+-C5H8O2].
HRMS (FAB):calcd. for C25H30O4N 102Ru [M+]: 510.1226, found = 510.1221.
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6.4 [1-{2-(tert-Butoxycarbonylamino)ethyl}-4-{(4-(2-(tert-
butoxycarbonylamino)ethyl))phenoxy}-η6-benzene](η5-
cyclopentadienyl)ruthenium hexafluorophosphate (158)[94]
PF6-
O Ru
NH
NH
O
O
O
O
Prepared from [1-{2-(tert-butoxycarbonylamino)}ethyl-4-chloro-η6-benzene](η5-
cyclopentadienyl)ruthenium hexafluorophosphate ( 135)[94] (87 mg, 0.15 mmol) and
from [2-(4-hydroxy-phenyl)-ethyl]-carbamic acid tert-butyl ester (177) (35 mg,
0.15 mmol). After column chromatography on aminopropyl silica (toluene-CH 3CN
(3:1)), the product is recrystallised fro iPrOH yielding colourless needles.
Yield: 70 mg (60 %)
TLC (NH2-Si, iPrOH): Rf = 0.70
Melting Point: 117-118 °C (decomposes)
HPLC
 
retention volumes: 97 mL (CH3CN), 89 mL ( iPrOH-CH3CN (1:1)), 90 mL
(iPrOH-CH3CN (2:1)), 88 mL ( iPrOH-CH3CN (4:1)), 92 mL ( iPrOH-CH3CN (8:1)), 96
mL (iPrOH-CH3CN (12:1)), 100 mL (iPrOH-CH3CN (18:1)), 149 mL ( iPrOH).
1H NMR
 (360 MHz, CDCl 3): δ = 7.32 (d, J = 8.5 Hz, 2H, CHar), 6.95 (d, J = 8.4 Hz,
2H, CHar), 6.16 (d, J = 6.5 Hz, 2H, η-CHar), 6.01 (d, J = 6.4 Hz, 2H, η-CHar), 5.35 (s,
5H, Cp), 5.16 (m, 1H, CH2NH), 4.79 (m, 1H, CH2NH), 3.39 (m, 4H, CH2NH), 2.84 (t, J
= 7.0 Hz, 2H, CH2CH2NH), 2.70 (t,  J = 7.1 Hz, 2H, CH2CH2NH), 1.45 (s, 9H,
OC(CH3)3), 1.41 (s, 9H, OC(CH3)3).
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13C NMR
 (90.6 MHz; CDCl3): δ = 156.13 (C=O), 155.79 (C=O), 150.68 (CarO(η-Ph));
138.32 (CH 2Car), 132.93 ( η-CarOPh), 131.06 ( CarH), 120.21 ( CarH), 101.60 ( η-
CarCH2), 85.12 (η-CarH), 80.79 (Cp), 79.48 (OC(CH3)3), 79.27 (OC(CH3)3), 75.14 (η-
CarH), 41.60 ( CH2NH), 40.87 ( CH2NH), 35.64 ( CH2CH2NH), 33.66 ( CH2CH2NH),
28.29 (OC(CH3)3), 28.25 (OC(CH3)3).
IR (KBr): ν~
 
(cm-1) 3373 (m), 1687 (s), 1366 (s), 1249 (s), 843 (s).
UV/Vis (CH3CN): λmax   (ε) = 266 (8800), 204 (65800), 192 nm (87700 mol-1dm3cm-1).
MS (FAB+, NBA): m/z  (%) 622/623/625 (60/100/54) [M +], 566/567/569 (4/7/4) [M +-
C4H8].
HRMS
 
(FAB): calcd for C31H41O5N2 102Ru [M+]: 623.2044, found = 623.2057.
Elemental Analysis: C31H41F6N2O5PRu (797.74)
Calculated: C: 48.50  H: 5.38  N: 3.65
Found:        C: 48.22  H: 5.59  N: 3.45
6.5 (η5-Cyclopentadienyl)(4-methoxy-1-phenoxy-η6-benzene)ruthenium
hexafluorophosphate (160)[94]
PF6-Ru
OCH3O
Prepared from (1-chloro-4-methoxy-η6-benzene)(η5-cyclopentadienyl)rutheniu
hexafluorophosphate ( 151)[96] (108 mg, 0.24 mmol) and from phenol (23 mg, 0.24
mmol). After column chromatography on aminopropyl silica (toluene-CH 3CN (3:1)),
the product is recrystallised fro iPrOH-EtOH yielding a colourless powder.
Yield: 70 mg (57 %)
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TLC (NH2-Si, iPrOH): Rf = 0.40
HPLC
 
retention volumes: 107 mL (CH3CN), 98 mL ( iPrOH-CH3CN (1:1)), 100 mL
(iPrOH-CH3CN (2:1)), 96 mL ( iPrOH-CH3CN (4:1)), 101 mL ( iPrOH-CH3CN (8:1)),
121 mL (iPrOH-CH3CN (12:1)), 119 mL (iPrOH-CH3CN (18:1)), 220 mL (iPrOH).
Melting Point:
 152-153 °C (decomposes).
1H NMR
 (360 MHz, [D 6]acetone): δ = 7.58 (t, J = 8.2 Hz, 2H, CHar), 7.40 (t, J = 7.5
Hz, 2H, CHar), 7.27 (d, J = 7.7 Hz, 1H, CHar), 6.37 (d, J = 6.6 Hz, 2H, η-CHar), 6.23
(d, J = 6.6 Hz, 2H, η-CHar), 5.59 (s, 5H, Cp), 3.85 (s, 3H, OCH3).
13C NMR
 (90.6 MHz; [D 6]acetone): δ = 154.38 ( CarO(η-Ph)), 133.49 ( η-CarOCH3),
131.85 ( CarH), 131.70 ( η-CarOPh), 127.64 ( CarH), 121.73 ( CarH), 81.63 (Cp), 75.26
(η-CarH), 73.41 (η-CarH), 58.17 (OCH3).
IR (KBr): ν~
 
(cm-1) 3447 (w), 3118 (w), 1482 (s), 1238 (s), 1008 (m), 839 (s), 779 (m),
693 (m).
UV/Vis (CH3CN): λmax (ε) = 264 (5700), 222 (14600), 198 nm (56700 mol-1dm3cm-1).
MS (FAB+, NBA): m/z  (%) 366/367/369 (56/100/56) [M+].
HRMS
 
(FAB): calcd for C18H17O2102Ru [M+]: 367.0263, found = 367.0237.
Elemental Analysis: C18H17F6O2PRu (511.37)
Calculated: C: 42.28  H: 3.35
Found:        C: 42.03  H: 3.48
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6.6 [{1-(4-(2-Amino)ethyl)-phenoxy-2-methoxy}-η6-benzene](η5-
cyclopentadienyl)ruthenium hexafluorophosphate (172)
O Ru
NH2
H3CO PF6
-
Tyramine (171) (15.2 mg, 0.111 mmol) is added to a solution of KOtBu (1.0 eq.) and
[18]crown-6 (0.1 eq.) in THF-CH3CN (1:1) (15 mL). After 30 min the mixture is cooled
to 0  °C and transferred to a pre-cooled (-78  °C) solution of (1-chloro-2-methoxy- η6-
benzene)(η5-cyclopentadienyl)ruthenium hexafluorophosphate ( 155)[94] (50 mg,
0.111 mmol) in THF-CH3CN (1:1) (20 mL). After 1 hour the reaction is slowly brought
to 20  °C. After 16 hours, the reaction mixture is filtered and concentrated. To the
mixture is added Et 2O and the collected precipitate is purified by column
chromatography on aminopropyl silica with CH3CN (removal of [18]crown-6) and with
iPrOH-H2O (6:1), followed by recrystallisation fro iPrOH yielding colourless needles.
Yield: 50 mg (81 %)
TLC (NH2-Si, iPrOH-H2O (6:1)): Rf = 0.33
Melting Point:
 148-150 °C (decomposes)
1H NMR
 (500 MHz, CD 3OD): δ = 7.36 (d, J = 8.4 Hz, 2H; CHar), 7.11 (t, J = 8.5 Hz,
CHar), 6.51 (d, J = 6.1 Hz, η-CHar), 6.06 (d, J = 6.0 Hz, 1H, η-CHar), 5.92 (t, J = 5.7
Hz, 1H, η-CHar), 5.83 (t, J = 5.6 Hz, 1H; η-CHar), 5.42 (s, 5H; Cp), 3.94 (3H, s,
OCH3), 2.93 (t, J = 6.9 Hz, 2H, CH2CH2NH), 2.81 (t, J = 7.1 Hz, 2H, CH2CH2NH).
13C NMR
 (125 MHz, CD 3OD): δ = 153.97 ( CarO(η-Ph)), 138.92 (CH 2Car), 131.93
(CarH), 128.47 (η-CarOCH3), 125.67 (η-CarOPh), 121.14 (CarH), 82.29 (η-CarH), 81.82
(η-CarH), 81.35 (Cp), 77.30 ( η-CarH), 73.28 ( η-CarH), 58.49 (O CH3), 43.86
(CH2CH2NH), 38.74 (CH2CH2NH).
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IR (KBr): ν~
 
(cm-1) 3420 (s), 3094 (m), 2926 (m), 2855 (w), 2363 (w), 1554 (s), 1528
(s), 1499 (s), 1476 (m), 1473 (s), 1437 (m), 1414 (m), 1276 (m), 1260 (m), 1220 (s),
1178 (w), 1103 (w), 1007 (w), 844 (s), 668 (w), 558 (w).
UV/Vis
 (CH3 max    		  			 	  			 -1dm3cm-1).
MS (FAB+, NBA):
 m/z (%): 410/411/412 (92/100/76) [M+].
HRMS (FAB):
 calcd for C20H22NO2102Ru [M+]: 410.0695, found 410.0722.
7 Synthesis of AB-Unit
7.1 [1-{2-(N-(2-(tert-Butoxycarbonylamino)-1-(3-hydroxy-4-
methoxyphenyl)ethyl)carbamoyl)ethyl}-4-chloro-η6-benzene](η5-
cyclopentadienyl)ruthenium hexafluorophosphate (114)
7.1.1. {1-(2-Amino)ethyl-4-chloro-η6-benzene}(η5-cyclopentadienyl) ruthenium
hexafluorophosphate (116)
Ru
Cl PF6-
ClH.H2N
[1-{2-(tert-butoxycarbonylamino)ethyl}-4-chloro-η6-benzene](η5-cyclopentadienyl)
ruthenium hexafluorophosphate (135)[94] (2000 mg, 3.4 mmol) is dissolved in 300 mL
HCl 4N in CH3OH and is allowed to stir at room temperature for 3 hours. The solvent
is removed well in vacuum and the product is purified by recrystallisation fro iPrOH-
CH3OH (3:1) affording colourless needles.
Yield: 1700 mg (quant)
TLC (NH2-Si, iPrOH-H2O (6:1)): Rf = 0.29
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Melting Point:
 at 175 °C starts decomposition without melting
1H NMR
 (360 MHz, CD3OD): δ = 6.75 (d, J = 6.0 Hz, 2H; η-CHar), 6.49 (d, J = 6.1 Hz,
2H; η-CHar), 5.59 (s, 5H; Cp), 3.23 (t, J = 7.5 Hz, 2H; CH2CH2NH), 2.93 (t,  J = 7.3,
Hz, 2H, CH2CH2NH).
13C NMR
 (90.6 MHz, CD 3OD): δ = 106.43 ( η-CarCl), 102.30 ( η-CarCH2), 88.40 ( η-
CarH), 88.10 (η-CarH), 84.15 (Cp), 41.03 (CH2CH2NH2), 32.11 (CH2CH2NH2).
IR (KBr): ν~
 
(cm-1) 3424 (m), 3082 (s), 1617 (w), 1525 (s), 1457 (w), 1420 (s), 1375
(w), 1288 (m), 1053 (s), 995 (s), 861 (m), 734 (w), 658 (w), 493 (w).
UV/Vis
 (CH3 max   	  		 -1dm3cm-1).
MS (FAB+, NBA):
 m/z (%): 321/322/324 (56/91/69) [M+].
HRMS (FAB):
 calcd for C13H1535ClN102Ru [M+]: 321.9937, found 321.9941.
7.1.2. [1-{2-(N-(2-(tert-Butoxycarbonylamino)-1-(3-hydroxy-4-
methoxyphenyl)ethyl)carbamoyl)ethyl}-4-chloro-η6-benzene](η5-
cyclopentadienyl)ruthenium hexafluorophosphate (114)
Ru
Cl PF6-
OCH3
OH
N
HNHO
O
O
2-tert-Butoxycarbonylamino-3-(3-hydroxy-4-methoxy-phenyl)-propionic acid ( 117)
(95 mg, 0.46 mmol) is dissolved in THF-CH3OH ((1:1), 10 mL) and HOBt (93 mg,
0.69 mmol) is added. The mixture is cooled to 0  °C followed by addition of EDCI
(120 mg, 0.506 mmol). The mixture is stirred for 15 min and then {1-(2-amino)ethyl-4-
chloro-η6-benzene}(η5-cyclopentadienyl)ruthenium hexafluorophosphate ( 116)
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(269 mg, 0.46 mmol) dissolved in CH3OH (1.2 ml) and in iPr2Et (0.08 mL, 0.46 mmol)
are given. The mixture is stirred at 0  °C for 4 hours and at room temperature for
further 30 hours. The solvent is concentrated and the mixture is diluted with 10 mL
H2O and is extracted with CH2Cl2. The organic layers are combined and washed with
saturated aqueous solution of NaHCO 3 and brine and is finally dried over Na 2SO4.
The solution is concentrated to 2 mL and after Et 2O (70 mL) addition, a brown
powder precipitates. The product is collected, dried well and purified by preparative
HPLC on aminopropyl silica ( iPrOH-H2O (9:1), 17 mg each injection, flow rate
15 mL cm-1) giving a light brown powder.
Yield: 171 mg (49 %)
TLC (NH2-Si, iPrOH-H2O (6:1)): Rf = 0.53
HPLC
 
retention volumes: 179 mL iPrOH-H2O (9:1)).
1H NMR
 (500 MHz, [D6]DMSO): δ = 6.84 ( d, J = 8.2 Hz, 1H, OH), 6.80 (d, J = 8.2 Hz,
1H CHar), 6.73 (d, J = 5.9 Hz, 1H; η-CHar), 6.69 (d, J = 6.0 Hz, 1H; η-CHar), 6.65 (d, J
= 1.9 Hz, 1H, CHar), 6.59 (dd, J = 1.9, 8.1 Hz, 1H, CHar), 6.30 (d, J = 5.9 Hz, 1H, η-
CarH), 6.11 (d, J = 5.9 Hz, 1H, η-CHar), 5.52 (s, 5H; Cp), 4.57 (t, J = 5.5 Hz, 1H,
CHNHCO), 4.09 (bq, J = 5.1 Hz, 1H, CH2NHBoc), 3.96 (brq , J = 8.7 Hz, 1H,
CH2CH(CO)NH), 3.72 (s, 3H, OCH 3), 3.31 (m, 1H, CH2CHHNH), 3.24 (m, 1H,
CH2CHHNH), 2.75 (dd, J = 5.3, 13.7 Hz, 1H; CH HCH(CO)NH), 2.57 (dd, J = 9.3,
13.6 Hz, 1H; CHHCH(CO)NH), 2.50 (m, 2H, CH2CH2NH), 1.31 (s, 9H, C(CH3)3).
13C NMR
 (125 MHz, [D 6]DMSO): δ = 172.33 ( C=O), 155.55 ( C=O), 146.48
(CarOCH3), 146.23 ( CarOH), 130.69 ( CarCH2CH(CO)NH), 120.21 ( CarH), 116.85
(CarH), 112.23 (CarH), 104.18 (η-CarCl), 103.19 (η-CarCH2), 86.85 (η-CarH), 86.75 (2 x
η-CarH), 86.64 (η-CarH), 82.58 (Cp), 78.58 (C(CH3)3), 56.41 (CH2CH(CO)NH), 55.93
(OCH3), 37.21 (CH 2CH2NH), 36.14 ( CH2CH(CO)NH), 33.22 ( CH2CH2NH), 28.39
(C(CH3)3).
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IR (KBr): ν~
 
(cm-1) 3418 (w), 3087 (w), 2976 (w), 2935 (w), 1700 (s), 1669 (s), 1591
(w), 1512 (s), 1456 (m), 1368 (m), 1275 (m), 1247 (m), 1164 (s), 1132 (m), 1092 (w),
1024 (w), 842 (s), 732 (w), 558 (s).
UV/Vis
 (CH3 max   
	 	  
 	  	 -1dm3cm-1).
MS (FAB+, NBA):
 m/z (%): 614/615/617 (69/100/74) [M +], 558/559/561 (11/13/11)
[M+-C4H8].
HRMS (FAB):
 calcd for C28H3435ClN2O5102Ru [M+]: 615.1205, found 615.1200.
7.2 [1-{2-(N-(1-(3-Benzyloxy-4-methoxyphenyl)-2-(tert-
butoxycarbonylamino)ethyl)carbamoyl)ethyl}-4-chloro-η6-benzene](η5-
cyclopentadienyl)ruthenium hexafluorophosphate (115)
Ru
Cl PF6-
OCH3
O
N
HNHO
O
O
3-(3-Benzyloxy-4-methoxy-phenyl)-2-tert-butoxycarbonylamino-propionic acid  (118)
(239 mg, 0.597 mmol) and HOBt (120 mg, 0.896 mmol) are dissolved in 10 mL THF
and are cooled to 0  °C. EDCI (129 mg, 0.657 mmol) is given and, after stirring for
15 min {1-(2-amino)ethyl-4-chloro-η6-benzene}(η5-cyclopentadienyl)rutheniu
hexafluorophosphate (116) (300 mg, 0.597 mmol) with 0.2 mL iPr2NEt (0.2 mL,
2.2 eq) in CH3OH are added. The mixture is allowed to stir at 0  °C for 4 hours and at
room temperature for further 40 hours. When the reaction finishes, the solvent is
removed and the product is purified by column chromatography on aminopropyl silica
(iPrOH-CH3CN (4:1)) followed by preparative HPLC on aminopropyl silica ( iPrOH-
CH3CN (4:1), 10 mg each injection, flow rate 12 mL min-1). Recrystallisation from H2O
(at 80 °C is added dropwise iPrOH until everything dissolves) yields colourless
crystals.
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Yield: 310 mg (60 %)
TLC (NH2-Si, iPrOH): Rf = 0.22
HPLC
 
retention volumes: 224 mL iPrOH-CH3CN (4:1)).
Melting Point: 174 °C (decomposes)
1H NMR
 (360 MHz, [D6]acetone): δ = 7.50 (d, J = 7.2 Hz, 2H; o-CHar, Bn), 7.38 (t, J =
7.5 Hz, 2H, m-CHar, Bn), 7.34 (d, J = 7.2 Hz, 1H, p-CHar, Bn), 6.99 (d, J = 1.9 Hz, 1H,
CHar), 6.93 (d, J = 8.2 Hz, 1H, CHar), 6.81 (dd, J = 1.9, 8.1 Hz, 1H, CHar), 6.71 (d, J =
6.1 Hz, 1H; η-CHar), 6.68 (d, J = 6.2 Hz, 1H; η-CHar), 6.43 (d, J = 5.2 Hz, 1H; η-CHar),
6.20 (d, J = 5.5 Hz, 1H; η-CHar), 6.08 (brd, 1H, NH), 5.61 (s, 5H; Cp), 5.09 (s, 2H,
OCH2Ph), 4.21 (brq, J = 6.3 Hz, 1H, CH2CH(CO)NH), 3.82 (s, 3H, OCH3), 3.50 (brq,
J =
 5.8 Hz, 1H, CH2CHHNH), 3.40 (brq, J = 5.7 Hz, 1H, CH2CHHNH), 3.02 (dd, J =
6.4, 13.7 Hz, 1H; CHHCH(CO)NH), 2.81 (dd, J = 8.0, 13.9 Hz, 1H; CHHCH(CO)NH),
2.68 (q, J = 7.1 Hz, 2H, CH2CH2NH), 1.36 (s, 9H, C(CH3)3).
13C NMR
 (90.6 MHz, [D 6]acetone): δ = 173.16 ( C=O), 156.54 ( C=O), 149.81
(CarOCH3), 149.33 (CarOCH2Ph), 138.63 (CarCH2O), 131.28 (CarCH2CH(CO)NHBoc),
129.39 (m-CarH, Bn), 128.79 (p-CarH, Bn), 128.71 (o-CarH, Bn), 123.27 (CarH), 116.71
(CarH), 113.44 (CarH), 105.62 (η-CarCl), 104.56 (η-CarCH2), 88.02 (η-CarH), 87.96 (2 x
η-CarH), 87.80 ( η-CarH), 83.65 (Cp), 79.76 (O C(CH3)3), 71.76 (PhCH2O), 57.23
(CH2CH(CO)NHBoc), 56.52 (O CH3), 40.60 (CH2CH2NH), 38.46 ( CH2CH(CO)NH),
34.46 (CH2CH2NH2), 28.70 (OC(CH3)3).
IR (KBr): ν~
 
(cm-1) 3420 (s), 3290 (m), 3065 (m), 2975 (m), 2929 (m), 1706 (s), 1663
(s), 1512 (s), 1457 (m), 1419 (m), 1364 (m), 1259 (s), 1162 (s), 1139 (m), 1090 (w),
1021 (m), 852 (w), 746 (w), 698 (w), 626 (w).
UV/Vis
 (CHCl3 max   
 
		   
			 -1dm3cm-1).
MS (FAB+, NBA):
 m/z (%): 704/705/707 (62/100/76) [M +], 648/649/651 (9/14/11)
[M+-C4H8].
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HRMS (FAB):
 calcd for C35H4035ClN2O5102Ru [M+]: 705.1676, found 705.1685.
Elemental Analysis: C35H40ClF6N2O5PRu (850.20)
Calculated: C: 49.44  H: 4.74  N 3.29
Found:        C: 49.22  H: 4.88  N 3.18
7.3 [1-[2-(4-Chloro-phenyl)-ethylcarbamoyl]-2-(3-hydroxy-4-methoxy-phenyl)-
ethyl]-carbamic acid tert-butyl ester (161)
OCH3
OH
N
HNHO
O
O Cl
HOBt (283 mg, 2.142 mmol) is added to a solution of 2- tert-butoxycarbonylamino-3-
(3-hydroxy-4-methoxy-phenyl)-propionic acid ( 117) (464 mg, 1.428 mmol) in THF-
CH3OH ((1:1), 8 mL). The mixture is cooled to 0  °C and EDCI (372 mg, 1.57 mmol) is
added. After stirring for 15 min 2-(4-chloro-phenyl)ethylamine ( 133) (0.2 mL,
1.428 mmol) with iPr2NEt (0.25 mL, 1.428 mmol) are given, and the reaction mixture
is allowed to stir for further 4 hours at this temperature and for 26 hours at roo
temperature. The solvent is removed and the mixture is dissolved in CH 2Cl2. The
solute is washed successively with NaHSO 4 (1N), saturated aqueous solution of
NaHCO3 and finally with brine. The organic layer is dried over Na 2SO4 and after
solvent removal, the product is recrystallised from TMP yielding transparent crystals.
Yield: 505 mg (79 %)
TLC (Si, TMP-EtOAc (7:3)): Rf = 0.61
Melting Point: 157-158 °C
1H NMR
 (250 MHz, CDCl 3): δ = 7.22 (d, J = 8.7 Hz, 2H; CHar), 6.98 (d, J = 8.3 Hz,
2H, CHar), 6.76 (d, J = 1.5 Hz, 1H, CHar), 6.75 (d, J = 8.3 Hz, 1H, CHar), 6.64 (dd, J =
Experimental Section - 117 -
___________________________________________________________________
1.9, 8.3 Hz, 1H, CHar), 5.87 (brt, 1H, OH), 5.76 (brs, 1H, NH), 5.02 (brs, 1H, NH),
4.19 (q, J = 7.3 Hz, 1H, CH2CH(CO)NH), 3.86 (s, 3H, OCH3), 3.42 (dd, J = 7.3, 13.7
Hz, 1H, CH2CHHNH), 3.37 (brq, J = 7.3, 13.2 Hz, 1H, CH2CHHNH), 2.98 (dd, J = 6.9,
14.2 Hz, 1H; CHHCH(CO)NH), 2.82 (dd, J = 7.8, 13.7 Hz, 1H; CHHCH(CO)NH), 2.63
(q, J = 6.9 Hz, 2H, CH2CH2NH), 1.40 (s, 9H, C(CH3)3).
13C NMR
 (90.6 MHz, CDCl3): δ = 171.27 ( C=O), 155.37 ( C=O), 145.77 ( CarOCH3),
145.71 (CarOCH2Ph), 137.13 (CarCl), 132.31 (CarCH2CH(CO)NHBoc), 130.08 (CarH),
129.79 ( CarCH2CH2NHBoc), 128.77 ( CarH), 120.81 ( CarH), 115.51 ( CarH), 110.83
(CarH), 80.27 (O C(CH3)3), 56.23 (CH 2CH(CO)NHBoc), 55.99 (O CH3), 40.58
(CH2CH2NH), 38.03 (CH2CH(CO)NH), 34.92 (CH2CH2NH2), 28.64 (OC(CH3)3).
IR (KBr): ν~
 
(cm-1) 3369 (m), 3239 (m), 3001 (w), 2944 (w), 1687 (s), 1669 (s), 1588
(w), 1545 (s), 1507 (s), 1489 (m), 1442 (m), 1364 (m), 1311 (s), 1279 (s), 1241 (s),
1163 (s), 1092 (w), 1034 (w), 1016 (m), 955 (w), 864 (w), 799 (w), 761 (w), 711 (w),
623 (w).
UV/Vis
 (CH3 max   
 			  		 	  
		 -1dm3cm-1).
MS (EI, 70 eV):
 m/z (%): 448 (4) [M+], 392 (3) [M+-C4H8], 375 (8) [M +-C4H9O], 331
(78) [M+-C5H11NO2], 210 (12) [M +-C5H11NO2-C7H6O2], 177 (82), 137 (100) [M +-
C5H11NO2-C10H9ClNO].
Elemental Analysis: C23H29ClN2O5 (448.94)
Calculated: C: 61.53  H: 6.51  N 6.24
Found:        C: 61.26  H: 6.58  N 6.11
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8 Synthesis of A’B’-Unit
8.1 [1-{2-(tert-Butoxycarbonylamino)-2-(N-(2-(3-hydroxy-4-
methoxyphenyl)ethyl)carbamoyl)ethyl}-4-chloro-η6-benzene](η5-
cyclopentadienyl)ruthenium hexafluorophosphate
 
(162)
Cl
Ru
O
NHO
O
OCH3
OH
+
PF6-
To a solution of [1-{2-(tert-butoxycarbonylamino)-2-(carboxy)ethyl}-4-chloro-η6-
benzene](η5-cyclopentadienyl)ruthenium hexafluorophosphate ( 109)[85b] (432 mg,
0.826 mmol) and HOBt (149 mg, 1.1 mmol) in CH 2Cl2 (5 mL) and CH3OH (8 mL) at
0 °C is given EDCI (176 mg, 0.903 mmol). The mixture is stirred for 15 min followed
by the addition of a solution of 5-(2-amino-ethyl)-2-methoxy-phenol (112)[88] (138 mg,
0.826 mmol) and  iPr2NEt (0.14 mL, 0.826 mmol) dissolved in CH 3OH (3 mL). After
stirring for 2 hours at this temperature, the mixture is brought to room temperature
where is allowed to stir for further 26 hours. The solvent is removed and the mixture
is diluted with H2O and extracted with CH 2Cl2. The organic layer is washed with
saturated aqueous solution of NaHCO3 and with brine. The organic layer is dried over
Na2SO4, and after concentration to 3 mL, Et 2O (130 mL) is added and the brown
precipitate is filtered and dried well.
Yield: 370 mg (59 %)
TLC (NH2-Si, iPrOH-H2O (6:1)): Rf = 0.51
1H NMR
 (500 MHz, [D6]DMSO): δ = 6.84 (d, J = 6.2 Hz, 1H; η-CHar), 6.82 (d, J = 8.1
Hz, 1H, CHar), 6.81 (d, J = 5.8 Hz, 1H, η-CHar), 6.62 (d, J = 2.0Hz, 1H, CHar), 6.57
(dd, J = 2.0, 8.2 Hz, 1H, CHar), 6.34 (d, J = 6.0 Hz, η-CHar), 6.24 (d, J = 6.1 Hz, 1H;
η-CHar), 5.53 (s, 5H; Cp), 4.56 (m, 1H, NH), 4.12 (brm, 1H, CH2CH(CO)NH), 3.72 (s,
3H, OCH3), 3.13 (brq, J = 5.8 Hz, 1H, CH2CH2NH), 2.72 (m, 1H; CHHCH(CO)NH),
2.68 (m, 1H; CHHCH(CO)NH), 2.55 (m, 2H, CH2CH2NH), 1.29 (s, 9H, C(CH3)3).
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13C NMR
 (125 MHz, [D 6]DMSO): δ = 170.22 ( C=O), 155.32 ( C=O), 146.46
(CarOCH3), 146.35 ( CarOCH2Ph), 131.89 ( CarCH2CH2NH), 119.39 ( CarH), 116.16
(CarH), 112.38 ( CarH), 104.09 ( η-CarCl), 101.71 ( η-CarCH2CH(CO)NH), 86.85 ( η-
CarH), 86.57 ( η-CarH), 82.51 (Cp), 78.62 (O C(CH3)3), 55.76 (O CH3), 53.64
(CH2CH(CO)NHBoc), 40.51 (CH 2CH2NH), 36.20 ( CH2CH(CO)NH), 34.45
(CH2CH2NH2), 28.11 (OC(CH3)3).
IR (KBr): ν~
 
(cm-1) 3372 (s), 3297 (m), 2926 (s), 2850 (s), 1700 (s), 1623 (s), 1589 (s),
1539 (m), 1499 (m), 1465 (m), 1420 (s), 1339 (s), 1238 (s), 1141 (m), 1054 (w), 923
(w), 822 (w), 744 (w), 715 (w).
UV/Vis
 (CH3 max    			 
 		 	  		 -1dm3cm-1);
(DMF): 282 (11400), 268 nm (10750 mol -1dm3cm-1); (CH2Cl2): 282 (8300), 230 n
(15800 mol-1dm3cm-1).
MS (FAB+, NBA):
 m/z (%): 614/615/617 (70/86/82) [M+].
HRMS (FAB):
 calcd for C28H3435ClN2O5102Ru [M] +: 615.1205, found 615.1234.
9 Synthesis of ABB’-Unit
9.1 [1-{2-(N-(1-(3-Benzyloxy-4-methoxyphenyl)-2-(tert-
butoxycarbonylamino)ethyl)carbamoyl)ethyl}-4-{(5-(2-(tert-
butoxycarbonylamino)ethyl)-2-methoxy)phenoxy}-η6-benzene](η5-
cyclopentadienyl)ruthenium hexafluorophosphate (169)
Ru
O
H
N
O
NH
O
OCH3
H3CO
NH
+
PF6-O
O
O
O
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[2-(3-Hydroxy-4-methoxy-phenyl)-ethyl]-carbamic acid tert-butyl ester ( 119) (15 mg,
0.053 mmol) is added to a solution of KO tBu (1.0 eq.) and [18]crown-6 (0.1 eq.) in
THF-CH3CN (1:1) (15 mL). After 30 min the mixture is cooled to 0  °C and is
transferred to a pre-cooled (-78  °C) solution containing [1-{2-( N-(1-(3-Benzyloxy-4-
methoxyphenyl)-2-(tert-butoxycarbonylamino)ethyl)carbamoyl)ethyl}-4-chloro-η6-
benzene](η5-cyclopentadienyl)ruthenium hexafluorophosphate ( 115) (50 mg,
0.053 mmol) in THF-CH3CN (1:1) (20 mL). After 1 hour the reaction is slowly brought
to 20 °C. After 16 hours, the reaction mixture is filtered and concentrated. Purification
by preparative HPLC on aminopropyl silica ( iPrOH-CH3CN (4:1), 10  mg each
injection, flow rate 15  mL min-1) followed by recrystallisation from CH 2Cl2 and Et 2O
gives a colourless powder.
Yield: 50 mg (87 %)
TLC
 (NH2-Si, iPrOH): Rf = 0.37
HPLC
 
retention volumes: 176 mL iPrOH-CH3CN (4:1)).
Melting Point:
 101-102 °C (decomposes)
1H NMR
 (400 MHz, CDCl 3): δ = 7.48 (d, J = 7.3 Hz, 2H, o-CHar, Bn), 7.35 (t, J =
7.2 Hz, 2H, m-CHar, Bn), 7.27 (t, J = 6.9 Hz, 1H, p-CHar, Bn), 7.11 (dd, J = 1.7, 8.3
Hz, 1H, CHar, dopamine), 6.97 (brs, 1H, CHar, DOPA), 6.96 (d, J = 8.4 Hz, 1H, CHar,
dopamine), 6.85 (brd, J = 8.6 Hz, 1H, CHar, DOPA), 6.84 (brs, 1H, CHar, dopamine),
6.79 (d, J = 8.2 Hz, 1H, CHar, DOPA), 6.45 (brs, 1H; η-CHar), 6.36 (brs, 1H; η-CHar),
5.96 (brt, 5.1 Hz, 2H, η-CHar), 5.77 (brd, J = 7.8 Hz, 1H, NH), 5.33 (s, 5H; Cp), 5.13
(s, 2H, OCH2Ph), 4.79 (brt, 1H, NH), 4.45 (brq, J = 4.9 Hz, 1H, CH2CH(CO)NH), 3.82
(3H, s, OC H3), 3.78 (3H, s, OC H3), 3.58 (brm, 1H, CH2CHHNH), 3.46 (brm, 1H,
CH2CHHNH), 3.32 (brq, J = 6.4 Hz, 2H, CH2CH2NH), 3.08 (dd, J = ,4.8, 13.6 Hz, 1H,
CHHCH(CO)NH), 2.94 (m, 1H, CHHCH(CO)NH), 2.84 (m, 2H, CH2CH2NH); 2.73 (t, J
=
 7.1 Hz, 2H, CH2CH2NH); 1.41 (s, 9H, C(CH3)3), 1.33 (s, 9H, C(CH3)3).
13C NMR
 (100 MHz, CDCl3): δ = 172.78 (C=O), 155.94 (C=O), 155.45 (C=O), 149.63
(CarOCH3, dopamine), 148.39 ( CarOCH3, DOPA), 148.05 ( CarOCH2Ph), 140.36 (( η-
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Ph)OCar), 137.36 ( CarCH2O), 133.08 ( CarCH2CH2NH), 132.57 ( η-CarOPh), 130.02
(CarCH2CH(CO)NHBoc), 128.43 (m-CarH, Bn), 128.43 ( CarH, dopamine), 127.93 ( o-
CarH, Bn), 127.72 ( p-CarH, Bn), 122.37 ( CarH, dopamine, 122.37 ( CarH Dopa)),
115.64 ( CarH, DOPA), 113.41 (CarH, dopamine), 112.02 ( CarH, DOPA), 102.12 ( η-
CarCH2), 85.60 ( η-CarH), 85.33 ( η-CarH), 80.75 (Cp), 79.35 (O C(CH3)3), 79.25
(OC(CH3)3), 74.68 ( η-CarH), 71.06 (PhCH2O), 56.43 (CH 2CH(CO)NHBoc), 56.11
(OCH3), 56.07 (O CH3), 41.80 (CH2CH2NH), 39.38 (CH 2CH2NH), 38.48
(CH2CH(CO)NH), 35.44 ( CH2CH2NH2), 32.61 ( CH2CH2NH2), 28.43 (OC(CH3)3),
28.37 (OC(CH3)3).
IR (KBr): ν~
 
(cm-1) 3407 (m), 3066 (w), 2974 (m), 2931 (m), 1700 (s), 1684 (s), 1663
(s), 1507 (s), 1476 (s), 1442 (w), 1364 (w), 1272 (s), 1232 (s), 1167 (s), 1140 (w),
1121 (w), 1022 (m), 845 (w), 773 (w), 698 (w).
UV/Vis
 (CHCl3 max   
	 
		   		 -1dm3cm-1).
MS (FAB+, NBA):
 m/z (%): 935/936/938 (63/100/57) [M+].
HRMS (FAB):
 calcd for C49H60N3O9102Ru [M+]: 936.3387, found 936.3342.
9.2 [1-{2-(N-(2-Amino-1-(3-benzyloxy-4-methoxyphenyl)ethyl)carbamoyl)
ethyl}-4-{(5-(2-amino)ethyl-2-methoxy)phenoxy}-η6-benzene](η5-
cyclopentadienyl)ruthenium hexafluorophosphate (170)
Ru
O
H
N
O
NH2
O
OCH3
H3CO
NH2
+
PF6-
Experimental Section - 122 -
___________________________________________________________________
[1-{2-(N-(1-(3-Benzyloxy-4-methoxyphenyl)-2-(tert-butoxycarbonylamino)ethyl)
carbamoyl)ethyl}-4-{(5-(2-(tert-butoxycarbonylamino)ethyl)-2-methoxy)phenoxy}-η6-
benzene](η5-cyclopentadienyl)ruthenium hexafluorophosphate ( 169) (40 mg,
0.037 mmol) is treated with HCl 4N in CH3OH (15 mL) and is allowed to stir at room
temperature for 3 hours. The solvent is removed and the product is recrystallised
from iPrOH.
Yield: 27 mg (quant.)
TLC
 (NH2-Si, iPrOH:H2O (6:1)): Rf = 0.32
Melting Point:
 174-176 °C (decomposes)
1H NMR
 (360 MHz, CD3OD): δ = 7.48 (d, J = 7.3 Hz, 2H, o-CHar, Bn), 7.36 (t, J = 7.0
Hz, 2H, m-CHar, Bn), 7.33 (t, J = 6.8 Hz, 1H, p-CHar, Bn), 7.94 (dd, J = 2.3, 8.4 Hz,
1H, CHar, dopamine), 6.93 (d, J = 8.8 Hz, 1H, CHar, dopamine), 6.85 (d,  J = 1.8 Hz,
1H, CHar, dopamine), 6.80 (d, J = 8.1 Hz, 1H, CHar, DOPA), 6.64 (d, J = 2.0 Hz, 1H,
CHar, DOPA), 6.57 (dd, J = 2.3, 8.1 Hz, 1H, CHar, DOPA), 5.93 (d, J = 6.7 Hz, 2H; η-
CHar), 5.75 (d, J = 7.0 Hz, 2H; η-CHar), 5.27 (s, 5H; Cp), 5.07 (s, 2H, OCH2Ph), 4.20
(brm, 1H, CH2CH(CO)NH), 3.81 (s, 6H, 2 x OCH3), 3.63 (brm, 1H, CH2CHHNH), 3.58
(brm, 1H, CH2CHHNH), 3.20 (m, 2H, CH2CH2NH), 2.85-2.73 (m, 6H, CH2CH(CO)NH
+ CH2CH2NH + CH2CH2NH).
13C NMR
 (62.9 MHz, CD 3OD): δ = 169.73 ( C=O), 152.00 ( CarOCH3, dopamine),
151.03 ( CarOCH3, DOPA), 149.91 ( CarOCH2Ph), 142.29 (( η-Ph)OCar), 138.56
(CarCH2O), 134.13 (CarCH2CH2NH), 131.69 (η-CarOPh), 129.57 (m-CarH, Bn), 129.12
(p-CarH, Bn), 128.95 ( o-CarH, Bn), 128.34 ( CarCH2CH(CO)NHBoc), 124.05 ( CarH,
dopamine), 123.89 ( CarH, DOPA), 121.96 (CarH, dopamine), 117.68 ( CarH, DOPA),
115.22 (CarH, dopamine), 114.10 ( CarH, DOPA), 101.95 ( η-CarCH2), 86.25 ( η-CarH),
82.11 (Cp), 76.31 ( η-CarH), 72.59 (PhCH2O), 56.72 (O CH3), 56.62
(CH2CH(CO)NHBoc), 55.92 (OCH3), 41.91 (CH2CH2NH), 41.41 (CH2CH2NH), 38.16
(CH2CH(CO)NH), 34.37 (CH2CH2NH2), 33.47 (CH2CH2NH2).
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IR (KBr): ν~
 
(cm-1) 3411 (s), 3237 (s), 3065 (s), 2933 (s), 1678 (s), 1635 (m), 1617
(m), 1595 (w), 1507 (s), 1473 (s), 1442 (w), 1274 (s), 1230 (s), 1125 (m), 1022 (m),
945 (w), 881 (w), 846 (w), 818 (w), 761 (w), 700 (w).
UV/Vis
 (CH3 max   
	 		  		 	  		 -1dm3cm-1).
MS (FAB+, NBA):
 m/z (%): 735/736/738 (96/100/83) [M +], 644/645/646 (47/54/85)
[M+-C7H6].
HRMS (FAB):
 calcd for C39H44N3O5102Ru [M+]: 736.2336, found 736.2314.
9.3 [4-{(5-(2-Amino)ethyl-2-methoxy)phenoxy}-1-{2-(N-(1-(3-Benzyloxy-4-
methoxyphenyl)-2-(tert-butoxycarbonylamino)ethyl)carbamoyl)ethyl}-η6-
benzene](η5-cyclopentadienyl)ruthenium hexafluorophosphate (111)
Ru
O
H
N
O
NH
O
OCH3
H3CO
NH2
+
PF6
-
O
O
KOtBu (13 mg, 0.0954 mmol) and [18]crown-6 (4 mg, 0.1 eq) are dissolved in dry
THF-acetone (1:1) (15 mL) and after 15 min 5-(2-amino-ethyl)-2-methoxy-phenol
(112)[88] (16 mg, 0.0954 mmol) is added. After 30 min the mixture is cooled to 0  °C
and is transferred to a pre-cooled (-78  °C) solution of [1-{2-( N-(1-(3-Benzyloxy-4-
methoxyphenyl)-2-(tert-butoxycarbonylamino)ethyl)carbamoyl)ethyl}-4-chloro-η6-
benzene](η5-cyclopentadienyl)ruthenium hexafluorophosphate ( 115) (90 mg,
0.0954 mmol) in dry THF. The reaction mixture is stirred for 1 hour at this
temperature and at room temperature for further 48 hours. The solvent is
concentrated to 2 mL and Et 2O is given. The precipitate is filtered on aminopropyl
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silica (CH3CN) in order to remove [18]crown-6 and then is purified by column
chromatography on aminopropyl silica ( iPrOH-H2O (6:1)) affording a pale yello
powder.
Yield:
 60 mg (64 %)
TLC (NH2-Si, iPrOH-H2O (6:1)): Rf = 0.43
1H NMR
 (360 MHz, CD3OD): δ = 7.46 (d, J = 6.6 Hz, 2H, o-CHar, Bn), 7.36 (t, J = 7.0
Hz, 2H, m-CHar, Bn), 7.30 (t, J = 7.4 Hz, 1H, p-CHar, Bn), 7.22 (dd, J = 1.5, 8.7 Hz,
1H, CHar), 7.15 (d, J = 8.7 Hz, 1H, CHar), 7.09 (d, J = 1.9 Hz, 1H, CHar), 7.01 (d, J =
2.1 Hz, 1H, CHar), 6.93 (d, J = 7.8 Hz 1H, CHar), 6.84 (dd, J = 1.8, 7.8 Hz, 1H, CHar),
6.11 (brs, 1H; η-CHar), 6.05 (brs, 1H; η-CHar), 6.02 (brd, 6.6 Hz, 1H, η-CHar), 5.72
(brd, 5.7 Hz, 1H, η-CHar), 5.36 (s, 5H; Cp), 5.08 (s, 2H, OC H2Ph), 4.15 (m, 1H,
CH2CH(CO)NH), 3.81 (3H, s, OCH3), 3.80 (3H, s, OC H3), 3.52 (brm, 1H,
CH2CHHNH(CO)), 3.41 (brm, 1H, CH2CHHNH(CO)), 3.25 (m, 2H, CH2CH2NH), 3.00-
2.75 (m, 6H, CH2CH(CO)NH, CH2CH2NH2, CH2CH2NH(CO)), 1.39 (s, 9H, C(CH3)3).
13C NMR
 (90.6 MHz, CDCl3): δ = 174.51 ( C=O), 155.45 ( C=O), 151.30 ( CarOCH3),
150.30 ( CarOCH3), 149.56 ( CarOCH2Ph), 141.91 (( η-Ph)OCar), 138.68 ( CarCH2O),
134.87 (CarCH2CH2NH2), 134.31 (η-CarOPh), 131.36 (CarCH2CH(CO)NHBoc), 129.59
(m-CarH, Bn), 129.11 (o-CarH, Bn), 128.92 (p-CarH, Bn), 123.79 (CarH), 123.61 (CarH),
117.41 (CarH), 116.33 (CarH), 114.84 (CarH), 113.76 (CarH), 102.10 (η-CarCH2), 86.16
(η-CarH), 81.65 (Cp), 80.77 (O C(CH3)3), 80.02 ( η-CarH), 76.09 ( η-CarH), 75.98 ( η-
CarH), 72.52 (PhCH2O), 57.93 (CH 2CH(CO)NHBoc), 56.72 (OCH3), 56.63 (OCH3),
44.06 (CH 2CH2NH), 41.18 (CH 2CH2NH), 38.83 ( CH2CH(CO)NH), 37.71
(CH2CH2NH2), 34.63 (CH2CH2NH2), 28.75 (OC(CH3)3).
MS (FAB+, NBA):
 m/z (%): 835/836/838 (70/100/56) [M+].
HRMS (FAB):
 calcd for C44H52N3O7102Ru [M+]: 836.2851, found 836.2817.
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9.4 [4-{4-(2-Aminoethyl)phenoxy}-1-{2-(N-(1-(3-Benzyloxy-4-methoxyphenyl)-
2-(tert-butoxycarbonylamino)ethyl)carbamoyl)ethyl}-η6-benzene](η5-
cyclopentadienyl)ruthenium hexafluorophosphate (174)
Ru
O
H
N
O
NH
O
OCH3
NH2
+
PF6-
O
O
KOtBu (6 mg, 0.0424 mmol) and [18]crown-6 (0.1 eq) are dissolved in dry THF-
CH3CN (1:1) (15 mL) and after 15 min tyramine ( 171) (5.8 mg, 0.0424 mmol) is
given. After 30 min  the mixture is cooled to 0  °C and is transferred to a pre-
cooled  (-78 °C) solution of [1-{2-(N-(1-(3-Benzyloxy-4-methoxyphenyl)-2-(tert-butoxy-
carbonylamino)ethyl)carbamoyl)ethyl}-4-chloro-η6-benzene](η5-cyclopentadienyl)
ruthenium hexafluorophosphate ( 115) (40 mg, 0.0424 mmol) in dry THF. The
reaction mixture is stirred for 1 hour at this temperature and at room temperature for
further 16 hours. After solvent removal, the product is purified by column
chromatography on aminopropyl silica with iPrOH-CH3CN (6:1) ([18]crown-6
removal) and with iPrOH-H2O (6:1). Recrystallisation fro iPrOH gives a light yellow
powder.
Yield: 35 mg (79 %)
TLC
 (NH2-Si, iPrOH-H2O (6:1) and iPrOH-CH3CN (8:1)): Rf = 0.42 and 0.37,
respectively
Melting Point:
 104 °C (decomposes)
1H NMR
 (360 MHz, CD3OD): δ = 7.45 (d, J = 7.4 Hz, 2H; o-CHar, Bn), 7.36 (d, J = 8.7
Hz, 2H, CHar, tyramine), 7.36 (t, J = 7.0 Hz, 2H, m-CHar, Bn), 7.31 (d, J = 7.0 Hz, 1H,
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p-CHar, Bn), 7.10 (d, J = 8.7 Hz, 2H, CHar, tyramine), 7.02 (d, J = 8.6 Hz, 1H, CHar,
DOPA), 6.93 (d, J = 2.1 Hz, 1H, CHar, DOPA), 6.83 (dd, J = 2.1, 8.2 Hz, 1H, CHar,
DOPA), 6.72 (d, J = 8.6 Hz, 1H, η-CHar), 6.07 (dd, J = 1.7, 7.4 Hz, 1H; η-CHar), 6.04
(dd, J = 1.7, 6.2 Hz, 1H; η-CHar), 5.79 (d, J = 6.2 Hz, 1H, η-CHar), 5.38 (s, 5H; Cp),
5.07 (s, 2H, OCH2Ph), 4.15 (t, J = 7.5 Hz, 1H, CH2CH(CO)NH), 3.91 (3H, s, OCH3),
3.39 (brdd, J = 6.6, 12.8 Hz 1H, CH2CHHNH(CO)), 3.25 (dd,  J = 7.0, 13.6 Hz, 1H,
CH2CHHNH(CO)), 2.91 (m, 2H, CH2CH2NH), 2.87 (m, 1H, CHHCH(CO)NH), 2.79 (m,
1H, CHHCH(CO)NH), 2.67 (t, J = 7.4 Hz, 1H, CH2CH2NH), 2.45 (q, J = 6.6 Hz, 2H,
CH2CH2NH), 1.38 (s, 9H, C(CH3)3).
13C NMR
 (90.6 MHz, CD3OD): δ = 174.52 (C=O), 157.56 (C=O), 152.47 (CarO(η-Ph)),
150.14 (CarOCH3), 149.48 (CarOCH2Ph), 139.73 (CarCH2CH2NH2), 138.62 (CarCH2O),
134.54 (CarCH2CH(CO)NH), 132.21 (CarH, tyramine), 131.28 (η-CarOPh), 129.54 (m-
CarH, Bn), 129.04 ( p-CarH, Bn), 128.88 ( o-CarH, Bn), 123.68 ( CarH), 122.00 ( CarH,
tyramine), 116.43 ( CarH), 113.66 ( CarH), 102.16 ( η-CarCH2), 86.29 ( η-CarH), 81.97
(Cp), 80.71 (OC(CH3)3), 76.53 ( η-CarH), 76.40 ( η-CarH), 71.20 (PhCH2O), 57.85
(CH2CH(CO)NHBoc), 56.66 (OCH3), 41.86 (CH2CH2NH), 43.73 (CH2CH2NH), 41.06
(CH2CH(CO)NH), 38.84 (CH2CH2NH2), 34.52 (CH2CH2NH2), 28.70 (OC(CH3)3).
IR (KBr): ν~
 
(cm-1) 3420 (w), 3336 (m), 3087 (w), 2932 (w), 1684 (s), 1653 (s), 1589
(w), 1559 (m), 1517 (s), 1507 (s), 1476 (s), 1457 (w), 1419 (w), 1368 (w), 1252 (s),
1163 (m), 1137 (m), 1018 (m), 838 (s), 746 (w), 699 (w).
UV/Vis
 (CH3 max   
	 		 	 		 	 

		 	  
		
mol-1dm3cm-1).
MS (FAB+, NBA):
 m/z (%): 805/806/808 (63/100/52) [M+].
HRMS (FAB):
 calcd for C43H50N3O6102Ru [M+]: 806.2755, found 806.2753.
Elemental Analysis: C43H50F6N3O6PRu (950.93)
Calculated: C: 54.31  H: 5.30  N 4.42
Found:        C: 53.74  H: 5.55  N 3.92
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10 Formation of an Open-Chain ABB'A' System (175)
10.1 [1-{2-(N-(2-(3-(4-(2-(N-(1-(3-Benzyloxy-4-methoxyphenyl)-2-(tert-
butoxycarbonylamino)ethyl)carbamoyl)ethyl)(η5-cyclopentadienyl-
ruthenio)-η6-phenoxy-4-methoxyphenyl)ethyl)carbamoyl)-(2-tert-
butoxycarbonylamino)ethyl}-4-chloro-η6-benzene](η5-
cyclopentadienyl)ruthenium di-(hexafluorophosphate) (175)
Ru
O
H
N
O
NH
O
OCH3
H3CO
NH
+
PF6-
O
NH
Ru
Cl
OO
+
PF6-
O
O
[1-{2-[tert-Butoxycarbonylamino)-2-(carboxy)ethyl}-4-chloro-η6-benzene](η5-
cyclopentadienyl)ruthenium hexafluorophosphate ( 109)[85b] (12 mg, 0.02 mmol) and
HOBt (4.02 mg, 0.0335 mmol) are dissolved in THF (15 mL) and are cooled to 0  °C.
To this mixture is added EDCI (2.84 mg, 0.022 mmol) and after stirring for 15 min [4-
{(5-(2-Amino)ethyl-2-methoxy)phenoxy}-1-{2-(N-(1-(3-Benzyloxy-4-methoxyphenyl)-
2-(tert-butoxycarbonylamino)ethyl)carbamoyl)ethyl}-η6-benzene](η5-cyclopentadienyl)
ruthenium hexafluorophosphate (111) (20 mg, 0.02 mmol) with iPr2NEt (0.003 mL,
1eq) in CH3OH-THF (1:1) (10 mL) are added. The mixture is allowed to stir at this
temperature for 4 hours and at room temperature for further 48 hours. To the reaction
is given Et2O and the precipitate is collected. Purification on aminopropyl silica
(iPrOH-H2O (7.5:1)) gives a brown powder.
Yield: 12 mg (38 %)
TLC
 (NH2-Si, iPrOH-H2O 7.5:1): Rf = 0.51
MS (FAB+, NBA):
 m/z (%): 1426/1427/1428/1429/1430/1431 (68/78/91/100/92/81)
[M+].
HRMS (FAB):
 calcd for C63H7337ClF6N4O10P100Ru102Ru [M+]: 1429.2717, found
1429.2708.
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11 Enclosure
Table 2: Crystal data and Structure refinement for compound 160.
Empirical formula: C18H17F6O2PRu
Formula Weight: 511.36
Temperature: 293 (2) K
Wavelength: 0.71073 Å
Crystal system: triclinic
Space group: P1
Unit cell dimensions: a: 7.062 (2) Å
b: 10.3801 (15) Å
c: 14.371 (2) Å
α: 74.165 (13)°
β: 75.39 (2)°
γ: 76.12 (2)°
Volume: 964.1 (3) Å3
Z: 2
Density (calculated): 1.762 g c -3
Absorption coefficient [µ: (Mo-Kα)]: 0.963 mm-1
F(000): 508
Crystal size : 0.57 X 0.33 X 0.10 m
θ
 range for data collection: 2.82 to 23.99°
Index ranges: 0 ≤ h ≤8, -11 ≤ k ≤ 11, -15 ≤ l ≤ 16
Reflections collected: 3296
Independent reflections: 3016 (Rint=0.0133)
Absorption correction: semi-empirical
Max. and Min. transmission: 0.9991 and 0.8952
Refinement method: Full-matrix least-squares on F2
Data/restraints/parameters: 3016/86/292
Goodness-of-fit on F2: 1.124
Final R indices [I > 2σ(I)]: R1=0.0330, wR2=0.0835
R
 indices (all data): R1=0.0397, wR2=0.0884
Largest diff. peak and hole: 0.710 and -0.539 eÅ-3
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Table 3: Atomic coordinates (x 10 4) and equivalent isotropic displacement
parameters (Å2 x 103) for compound 160. Ueq is defined as one third of the trace of
orthogonalised Uij tensor.
X Y Z Ueq
Ru1 10240(1) 6121(1) 6955 (1) 42(1)
P1 6567(3) 11142(1) 7198(1) 76(1)
F1 6294(11) 12506(4) 6441(3) 188(3)
F2 6884(9) 9789(4) 7956(4) 163(2)
F3 8165(27) 11620(11) 7510(14) 172(10)
F4 8235(24) 10503(11) 6440(10) 183(10)
F5 5266(28) 10532(11) 6787(14) 154(8)
F6 4824(34) 11721(14) 7936(12) 187(11)
F3A 5908(21) 11910(8) 8046(5) 131(4)
F4A 8691(15) 11314(14) 7155(12) 206(8)
F5A 7270(27) 10452(7) 6304(5) 156(6)
F6A 4435(14) 10991(16) 7277(10) 210(8)
O1 7554(5) 5058(3) 9150(2) 63(1)
O2 7914(6) 6702 (4) 5135(2) 70(1)
C1 7730(6) 5414(4) 8152(3) 48(1)
C2 7239(6) 6806(4) 7746(3) 50(1)
C3 7283(6) 7288(5) 6727(3) 53(1)
C4 7851(6) 6360(5) 6110(3) 53(1)
C5 8496(7) 4983(5) 6507(3) 54(1)
C6 8437(7) 4498(4) 7531(3) 49(1)
C7 7646(10) 8127(7) 4661(5) 90(2)
C8 8189(8) 3703(5) 9606(3) 56(1)
C9 6818(10) 2869(6) 9987(4) 76(2)
C10 7439(14) 1566(7) 10526(5) 100(2)
C11 9360(16) 1174(7) 10663(5) 104(3)
C12 10692(13) 2024(8) 10264(6) 101(2)
C13 10100(10) 3304(6) 9734(5) 81(2)
C14 13254(7) 5247(7) 7170(6) 84(2)
C15 12582(8) 6344(7) 7590(4) 70(2)
C16 12160(9) 7490(6) 6883(6) 83(2)
C17 12599(10) 7125(12) 5992(5) 112(3)
C18 13256(9) 5700(12) 6170(7) 110(3)
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Table 4: Interatomic distances for compound 160.
Atom-atom Distance (Å) Atom-atom Distance (Å)
Ru1-C18 2.147(6) O1-C1 1.360(5)
Ru1-C16 2.154(5) O1-C8 1.398(6)
Ru1-C17 2.158(5) O2-C4 1.341(6)
Ru1-C15 2.164(5) O2-C7 1.438(7)
Ru1-C14 2.168(5) C1-C2 1.396(6)
Ru1-C2 2.190(4) C1-C6 1.400(6)
Ru1-C5 2.200(4) C2-C3 1.407(7)
Ru1-C3 2.202(4) C3-C4 1.406(7)
Ru1-C6 2.209(4) C4-C5 1.396(7)
Ru1-C1 2.245(4) C5-C6 1.413(6)
Ru1-C4 2.247(4) C8-C13 1.356(8)
P1-F6A 1.524(7) C8-C9 1.365(7)
P1-F6 1.528(8) C9-C10 1.392(9)
P1-F2 1.531(4) C10-C11 1.367(11)
P1-F5 1.533(8) C11-C12 1.357(11)
P1-F1 1.537(4) C12-C13 1.366(9)
P1-F4A 1.537(7) C14-C15 1.363(8)
P1-F3 1.539(8) C14-C18 1.385(1)
P1-F4 1.545(8) C15-C16 1.364(9)
P1-F3A 1.550(6) C16-C17 1.373(11)
P1-F5A 1.556(6) C17-C18 1.412(12)
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Table 5: Angles (°) of compound 160.
Atom-atom-atom Angle (°) Atom-atom-atom Angle (°)
C18-Ru1-C16 63.0(3) C3-Ru1-C6 79.2(2)
C18-Ru1-C17 38.3(3) C18-Ru1-C1 149.1(4)
C16-Ru1-C17 37.1(3) C16-Ru1-C1 130.6(2)
C18-Ru1-C15 62.1(2) C17-Ru1-C1 167.3(3)
C16-Ru1-C15 36.8(2) C15-Ru1-C1 110.3(2)
C17-Ru1-C15 61.7(2) C14-Ru1-C1 117.8(2)
C18-Ru1-C14 37.4(3) C2-Ru1-C1 36.7(2)
C16-Ru1-C14 62.0(3) C5-Ru1-C1 66.2(2)
C17-Ru1-C14 62.5(3) C3-Ru1-C1 66.4(2)
C15-Ru1-C14 36.7(2) C6-Ru1-C1 36.6(2)
C18-Ru1-C2 172.7(3) C18-Ru1-C4 116.2(2)
C16-Ru1-C2 109.9(2) C16-Ru1-C4 130.6(2)
C17-Ru1-C2 134.9(3) C17-Ru1-C4 108.7(2)1
C15-Ru1-C2 113.7(2) C15-Ru1-C4 167.4(2)
C14-Ru1-C2 142.3(2) C14-Ru1-C4 148.6(2)
C18-Ru1-C5 107.4(2) C2-Ru1-C4 66.5(2)
C16-Ru1-C5 161.3(2) C5-Ru1-C4 36.6(2)
C17-Ru1-C5 125.4(3) C3-Ru1-C4 36.8(2)
C15-Ru1-C5 155.2(2) C6-Ru1-C4 66.5(2)
C14-Ru1-C5 121.1(2) C1-Ru1-C4 77.6(2)
C2-Ru1-C5 78.9(2) F6A-P1-F2 89.8(4)
C18-Ru1-C3 141.2(3) F6-P1-F2 90.6(4)
C16-Ru1-C3 109.9(2) F6-P1-F5 94.0(13)
C17-Ru1-C3 111.7(3) F2-P1-F5 88.3(4)
C15-Ru1-C3 136.3(2) F6A-P1-F1 91.5(4)
C14-Ru1-C3 171,9(2) F6-P1-F1 89.8(4)
C2-Ru1-C3 37.4(2) F2-P1-F1 178.6(4)
C5-Ru1-C3 66.7(2) F5-P1-F1 92.9(4)
C18-Ru1-C6 120.6(3) F6A-P1-F4A 177.8(9)
C16-Ru1-C6 161.1(2) F2-P1-F4A 89.8(4)
C17-Ru1-C6 155.9(3) F1-P1-F4A 88.8(4)
C15-Ru1-C6 125.7(2) F6-P1-F3 95.3(14)
C14-Ru1-C6 108.4(2) F2-P1-F3 90.0(4)
C2-Ru1-C6 66.7(2) F5-P1-F3 170.5(11)
C5-Ru1-C6 37.4(2) F1-P1-F3 88.7(4)
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Continuation of table 5:
Atom-atom-atom Angle (°) Atom-atom-atom Angle (°)
F6-P1-F4 176.2(13) C5-C4-Ru1 69.9(2)
F2-P1-F4 88.6(4) C3-C4-Ru1 69.9(2)
F5-P1-F4 82.2(10) C4-C5-C6 120.8(4)
F1-P1-F4 91.1(4) C6-C5-Ru1 71.7(2)
F6A-P1-F3A 91.5(7) C1-C6-C5 119.4(4)
F2-P1-F3A 89.7(3) C1-C6-Ru1 73.1(2)
F1-P1-F3A 89.9(3) C5-C6-Ru1 70.9(2)
F4A-P1-F3A 86.4(8) C13-C8-C9 122.6(5)
F6A-P1-F5A 90.2(8) C13-C8-O1 118.6(5)
F2-P1-F5A 93.5(3) C9-C8-O1 118.6(5)
F1-P1-F5A 86.8(3) C8-C9-C10 117.6(7)
F4A-P1-F5A 92.0(9) C11-C10-C9 119.7(7)
F3A-P1-F5A 176.4(5) C12-C11-C10 121.2(6)
C1-O1-C8 119.3(3) C11-C12-C13 119.6(8)
C4-O2-C7 117.8(4) C8-C13-C12 119.4(7)
O1-C1-C2 115.6(4) C15-C14-C18 108.0(7)
O1-C1-C6 124.6(4) C15-C14-Ru1 71.5(3)
C2-C1-C6 119.7(4) C18-C14-Ru1 70.4(3)
O1-C1-Ru1 130.5(3) C14-C15-C16 109.5(6)
C2-C1-Ru1 69.5(2) C14-C15-Ru1 71.8(3)
C6-C1-Ru1 70.3(2) C16-C15-Ru1 71.2(3)
C1-C2-C3 120.7(4) C15-C16-C17 108.1(7)
C1-C2-Ru1 73.8(2) C15-C16-Ru1 72.0(3)
C3-C2-Ru1 71.8(2) C17-C16-Ru1 71.6(3)
C4-C3-C2 119.6(4) C16-C17-C18 107.6(6)
C4-C3-Ru1 73.3(3) C16-C17-Ru1 71.3(3)
C2-C3-Ru1 70.8(2) C18-C17-Ru1 70.4(4)
O2-C4-C5 115.8(4) C14-C18-C17 106.8(6)
O2-C4-C3 124.7(4) C14-C18-Ru1 72.1(3)
C5-C4-C3 119.4(4) C17-C18-Ru1 71.3(4)
O2-C4-Ru1 130.2(3)
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